Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
05/2012 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions May archived by USPTO category 05/12

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
05/31/2012 > 162 patent applications in 127 patent subcategories. archived by USPTO category

20120135913 - Lysine compounds and their use in site- and chemoselective modification of peptides and proteins: The present invention concerns new thiolysine and selenolysine compounds that can be used as building blocks for peptides and proteins, providing ligation handles for site- and chemoselective modification of said peptides and proteins. In particular, the invention provides. In particular, the invention provides (the use of) the compounds 5-thiolysine (also... Agent:

20120135912 - Polypeptide inhibitors of vla4: The invention provides novel 2D-VCAM-1 variant polypeptides and conjugates thereof that bind human VLA4. The invention also provides related polynucleotides, compositions, vectors, host cells, and methods.... Agent: Perseid Therapeutics LLC

20120135914 - Etoposide and doxorubicin conjugates for drug delivery: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4′-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood... Agent: Angiochem Inc.

20120135915 - Treatment of traumatic or degenerative neurologic, otologic, or ophthalmologic diseases with targeted protease inhibitors: Described herein are compounds and methods for treating or preventing a neurologic, otologic, or ophthalmologic disease in a subject. Also described herein are compounds that can be used as therapeutics.... Agent:

20120135916 - Monomeric and dimeric forms of adiponectin receptor fragments and methods of use: Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain... Agent: Siemens Healthcare Diagnostics Inc.

20120135917 - Anti-gram negative bacteria agent: Provided are: a method for blocking the biosynthesis of an outer membrane protein (OMP) necessary for the survival of Gram-negative bacteria by inhibiting the formation of a YaeT complex in the outer membrane of the bacteria and an agent therefor for the purpose of basically solving a problem of the... Agent:

20120135918 - Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof: The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18, wherein each... Agent: The Administrators Of The Tulane Educational Fund

20120135919 - Polymer-drug conjugates: A conjugate that includes a drug covalently linked to a polymer. Upon administration, the conjugate is digested by an enzyme that is present at the site of administration thereby releasing a therapeutic agent. The conjugate may demonstrate substantially the same pharmacokinetic and pharmacodynamic behavior as the drug itself. A material... Agent: Smartcells, Inc.

20120135920 - Preparation comprising insulin, nicotinamide and an amino acid: Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.... Agent: Novo Nordisk A/s

20120135921 - Tripetide boronic acid or boronic ester, preparative method and use thereof: The present invention discloses proteasome inhibitors of tripeptide boronic acids or boronic esters represented by Formula (I), preparative method and use thereof. The proteasome inhibitors are therapeutical agents for treating malignant tumor, various nervous system degenerative diseases, muscle cachexia or diabetes, wherein the malignant tumor is leukemia, gastric cancer, hepatocarcinoma... Agent:

20120135922 - Modified exendins and exendin agonists: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions... Agent: Amylin Pharmaceuticals, Inc.

20120135923 - Use of melanocortins to treat dyslipidemia: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of dyslipidemia and associated complications such as alcoholic and non-alcoholic fatty liver disease.... Agent: Ipsen Pharma, S.a.s.

20120135925 - Covalent inhibition of bacterial quorum sensing: Inhibitors of bacterial communication, such as quorum sensing, and method of use and manufacture thereof.... Agent:

20120135924 - Prosthesis for joint cartilage repair and method of manufacture: A cartilage prosthesis is made according to a method that includes the steps of collecting animal material from a bovine, ovine or porcine source, the animal material being a cartilage, shaping the animal material to provide a desired shape for the cartilage implant, removing cells from the animal material, crosslinking... Agent: Grandhope Biotech Co., Ltd.

20120135926 - Peptides for inhibiting igf-1: The invention relates to peptides useful for inhibiting IGF-1 activity and their use as agents for inhibition of in vitrocell proliferation and for treatment of various diseases.... Agent: Universite Pierre Et Marie Curie (paris 6)

20120135927 - Bone morphogenetic proteins for the treatment of insulin resistance: The present disclosure relates to compositions and methods for treating insulin resistance and/or obesity in a cell and/or a subject.... Agent: Joslin Diabetes Center, Inc.

20120135928 - Method for purifying recombinant fsh: The present invention relates to a method for purifying a recombinant follicle stimulating hormone (FSH) or re-combinant FSH variant. The method comprises the steps of subjecting a liquid containing a recombinant FSH or recombinant FSH variant to an anion exchange chromatography, to a hydrophobic interaction chromatography, and to a dye... Agent: Biogenerix Ag

20120135929 - Methods of modulating uric acid levels: Described herein are compounds useful in the reduction of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, a compound disclosed herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.... Agent: Ardea Biosciences Inc.

20120135930 - Methods of correcting imbalance between bone resorption and bone formation and kits and compositions therefor: Compounds, methods, uses, compositions, kits and packages for the treatment of imbalance between bone resorption and bone formation, based on uses of 4-phenyl-2-propionamidotetralin (4-P-PDOT) and analogs, derivatives, prodrugs, precursors thereof, and salts thereof, are described.... Agent: Chu Sainte-justine

20120135931 - Method of modifying serine protease inhibitors: The present invention relates to a method of modifying serine protease inhibitors in order to acquire or enhance any one of a variety of desired properties, including extent of inhibition, maintenance of inhibition following cleavage of the serine protease inhibitor by the target serine protease, speed of binding to the... Agent: Natural Environment Research Council

20120135932 - Compositions and methods for treating ischemia and ischemia-reperfusion injury: The present invention relates, in some embodiments, to compositions comprising a substantially pure compound represented by Structural Formula (I) and methods of using such compounds to activate cytoprotective kinases. In additional embodiments, the invention relates to methods for treating an ischemia or an ischemia-reperfusion injury in a subject, comprising administering... Agent:

20120135933 - Soluble tumor necrosis factor receptor treatment of medical disorders: The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNFα by administering a TNFα antagonist, such as recombinant TNFR:Fc.... Agent: Immunex Corporation

20120135934 - Combined preparation for treating joint diseases: An object of the present invention is to enable the repair and regeneration of articular cartilage, which could not be achieved by conventional therapies, and to provide a safe and inexpensive agent that is effective for the treatment of joint diseases such as osteoarthritis. According to the present invention, a... Agent: Riken

20120135935 - Gpr54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities: Use of a GPR54 agonist or antagonist for the treatment of a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, and/or for treatment of depression, and/or for improving cognitive function is disclosed. In particular, the invention relates to the use of kisspeptin or a peptide... Agent:

20120135936 - Inhibition of prion protein propagation by receptor associated protein (rap), its derivatives, mimetics and synthetic peptides: A pharmaceutical formulation and method of treatment of prion disease include a RAP agent with a pharmaceutically acceptable carrier and/or excipient, and the administration of same to a subject suffering from or at risk of a prion disease. The RAP agent is an effective means for the prevention and/or treatment... Agent: American National Red Cross

20120135937 - Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection: The present invention concerns an injectable composition comprising a filler or a botulinum toxin and an adrenergic receptor agonist, and its use for diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation.... Agent: Symatese

20120135938 - Polypeptides that bind trail-r1 and trail-r2: Agonists for TRAIL death receptors including polypeptides having a multimerizing, e.g. trimerizing, domain and a polypeptide sequence that binds to at least one of TRAIL death receptors TRAIL-R1 and TRAIL-R2. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin.... Agent: Anaphore, Inc.

20120135939 - Cyclosporin analogs: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.... Agent: Allergan, Inc.

20120135940 - Pharmaceutical compositions for lipophilic drugs: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms... Agent: Watson Laboratories, Inc.

20120135941 - Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘C terminus of HSP70-Interacting Protein’ (CHIP), in particular, by targeting natural antisense polynucleotides of ‘C terminus of HSP70-Interacting Protein’ (CHIP). The invention also relates to the identification of these antisense oligonucleotides and their use in... Agent:

20120135942 - Beta-hairpin peptidomimetics: β-Hairpin peptidomimetics of the general formula Cyclo(-Xaa1-Xaa2-Xaa3-Cys4-Xaa5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with Xaa1, Xaa2, Xaa3, Xaa5, Xaa6, Xaa7, Xaa8, Xaa12, Xaa13, Xaa14, Xaa15 and Xaa16 being amino acid residues of certain types which are defined in the description and the claims, have CXCR4... Agent: Polyphor Ag

20120135943 - Cell protection in dialysis patients by administration of a creatine compound: The invention relates to a dialysis solution for haemodialysis or peritoneal dialysis, said solution having a theoretical osmolarity within the range of from 250 to 550 mosm/L and a pH value within the range of from 4.9 to 8.0, said solution comprising a creatine compound and one or more electrolytes,... Agent: Crearene Ltd.

20120135944 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20120135945 - Antibacterial aminoglycoside analogs: s

20120135946 - Antibacterial aminoglycoside analogs:

20120135947 - Oil-in-water emulsion composition containing difluprednate and tobramycin: The present invention provides an oil-in-water emulsion composition for topical administration, containing (a) tobramycin, (b) difluprednate, (c) water, (d) oil and (e) an emulsifier. Moreover, it provides a method for stabilizing tobramycin, which includes mixing (a) tobramycin, (b) difluprednate, (c) water, (d) oil and (e) an emulsifier to form an... Agent: Senju Pharmaceutical Co., Ltd.

20120135948 - Antibacterial aminoglycoside analogs: e

20120135949 - Combination therapy for treating hcv infection: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally (c) ribavirin, and methods of using such therapeutic combinations for treating HCV infection or alleviating one... Agent: Boehringer Ingelheim International Gmbh

20120136043 - Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.... Agent:

20120136042 - Carbohydrate conjugates as delivery agents for oligonucleotides: e

20120136044 - Compositions and methods of inhibiting nadph oxidase expression: The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of a NOX gene selected from the group consisting of NOX4, NOX1, NOX2 (gp91phox, CYBB), NOX5, DUOX2, NOXO1, NOXA1 and NOXA2 (p67phox). The invention also relates to a pharmaceutical composition comprising the compound, or a... Agent: Quark Pharmaceuticals, Inc.

20120136040 - Hybrid interfering rna: The invention relates to a hybrid interfering RNA molecule comprising a duplex RNA and a single stranded DNA molecule and its use in the ablation of mRNA and in polymerase chain reactions.... Agent: The University Of York

20120136046 - Method of treating age related disorders: The present invention relates to the use of fujimycin for the treatment of a disorder related to the chronological and/or replicative life-span of a cell, and to methods for increasing the replicative life span of a cell, said method comprising disrupting the function of a polynucleotide or gene encoding a... Agent: Chronos Therapeutics Limited

20120136045 - Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation: The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to the screening of compounds that modulate GPR3 activity and/or beta-arrestin signaling in a mammalian cell and, in particular, compounds... Agent: Katholieke Universiteit Leuven, K.u. Leuven R&d

20120136039 - Single nucleotide polymorphism (snp) targeting therapies for the treatment of huntington's disease: The present invention relates to the discovery of (SNPs) significantly associated with Huntington's disease (HD). The present invention utilizes RNA silencing technology (e.g. RNAi) against such SNPs optimally combined with select additional SNP targeting silencing agents, thereby resulting in an effective treatment of significantly-sized patient populations. Silencing agents having enhanced... Agent: University Of Massachusetts

20120136041 - Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists: The present invention provides novel agents, expression constructs, compositions and methods useful for treating an ocular disease associated with unwanted PPARδ activity through the modulation of PPARδ expression. The PPARδ interference RNA (iRNA) agents, expression constructs encoding such agents, and compositions comprising such agents or constructs are directed against RNA... Agent: Allergan, Inc.

20120135950 - Antiviral treatment of lymphoma and cancer: Compositions and methods to treat lymphoma and cancer are disclosed. In particular, the method teaches treatment of lymphoma and cancer using anti-HERV-K(HML-2) therapies. Further taught are compositions and methods for characterizing patient samples to, for example, select or identify therapeutic options or assess the impact of therapies.... Agent: The Regents Of The University Of Michigan

20120135951 - 3'-azido purine nucleotide prodrugs for treatment of viral infections: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, and HBV, in human patients or other animal hosts. The compounds are 3′-azido-2′,3′-dideoxy purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral... Agent:

20120135953 - Bis-benzimidazole derivatives as hepatitis c virus inhibitors: e

20120135952 - Butyric acid salt of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same: The present invention provides metformin butyric acid salt, a method of preparing the same, and pharmaceutical compositions and combinations containing the same. The metformin butyric acid salt according to the present invention has an excellent pharmacological effect as compared with metformin hydrochloride and is capable of achieving a therapeutic purpose... Agent: Hanall Biopharma Co., Ltd.

20120135954 - Compounds for preventing or treating viral infections and methods of use thereof: Described herein are compounds and methods that prevent the viral infection of cells. The compounds and methods described herein minimize viral resistance and maximize the number of targeted viruses. Additionally, the compounds and methods minimize the toxicity toward uninfected cells.... Agent:

20120135955 - External preparation containing nsaids and method for producing the external preparation: Disclosed is an external preparation containing nonsteroidal anti-inflammatory drugs (NSAIDs), which is suppressed in cytotoxicity induced by the NSAIDs. Also disclosed is a method for producing the external preparation. The present invention is based on the finding that skin disorders induced by nonsteroidal anti-inflammatory drugs (NSAIDs) can be suppressed when... Agent: Next21 K.k.

20120135957 - Compositions containing mixtures of fermentable fibers: The present invention relates to synergistic compositions comprising mixtures of fermentable fibers. The present invention specifically relates to composition comprising inulin and arabinoxylan for use in reducing, preventing and/or treating inflammation, wherein said arabinoxylan is partially hydrolyzed arabinoxylan and wherein the ratio of said inulin to said arabinoxylan and/or partially... Agent: Cosucra-groupe Warcoing Sa

20120135956 - Compositions for preventing and treating an immune system disorder: The present invention relates to methods of treating, preventing, or decreasing the occurrence of a condition characterized by Th2 overactivation or impaired Th1, or mitigating symptoms associated with a condition characterized by Th2 overactivation or impaired Th1, comprising orally administering to a subject in need thereof an effective amount of... Agent: Raisio Nutrition Ltd

20120135958 - Tetrahydroquinoxaline urea derivatives, preparation thereof, and therapeutic use thereof: The invention relates to compounds of formula (I), where: A is a bond, an oxygen, or an —CH2— group; Ar1 is a phenyl or heteroaryl group; Ar2 is a phenyl, heteroaryl, or heterocycloalkyl group; R1a,b,c and R2a,b,c are hydrogen or halogen, or an alkyl, cycloalkyl, or lkyl-cycloalkyl group optionally, substituted... Agent: Sanofi

20120135959 - Metalloprotein inhibitors containing nitrogen based ligands: Provided herein metalloproteinase inhibitors containing nitrogen or mixed nitrogen/oxygen donating zinc binding groups. Also provided are pharmaceutical compositions containing the compounds and methods of treating preventing or ameliorating the diseases associated with metalloproteinase activity using the compounds and compositions.... Agent:

20120135960 - Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs: The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid,... Agent: Bio Modeling Systems Ou Bmsystems

20120135962 - Compositions to combat ectoparasites: The present invention provides a method of pesticidal treatment of vertebrate aquatic animals, in particular fish. The method includes applying to said aquatic animals, typically topically or, more preferably, by administration into water in which said aquatic animals are contained, a topical pesticidal composition comprising a pyrethroid and an organophosphate... Agent: Nettforsk As

20120135963 - Lipidated oxoadenine derivatives: Provided are novel lipidated oxoadenines which are useful as immunostimulators and adjuvants and are shown to be inducers of interferon-a and other immunostimulatory cytokines.... Agent:

20120135961 - Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections: The present invention relates to the use of compounds, in which the pharmacophores of quinolone and oxazolidinone are chemically linked together through a linker that is stable under physiological conditions, for the treatment of anthrax and other infections.... Agent: Morphochem Aktiengesellschaft Fur Kombinatorische Chemie

20120135964 - Certain chemical entities, compositions, and methods: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.... Agent:

20120135965 - Amorphous fosamprenavir calcium: The present invention relates to amorphous Fosamprenavir calcium and processes for its preparation, a pharmaceutical composition comprising it and a method for treating a HIV infection therewith.... Agent: Ranbaxy Laboratories Limited

20120135966 - Use of glyphosate for disease suppression and yield enhancement in soybean: The present invention discloses methods for prevention and prophylactic treatment of plant diseases by application of glyphosate to a plant in need of treatment. In certain embodiments, soybean plants in need of treatment at vegetative and reproductive growth stages prior to or subsequent to infection, may be treated with glyphosate... Agent:

20120135967 - Lpa receptor agonists and antagonists and methods of use: Disclosed are compounds according to formula (I) as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating... Agent:

20120135968 - Tetracycline compounds: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.... Agent:

20120135969 - Novel powdered crystalline medicines for inhalation: The invention relates to manufacturing processes for preparing inhalable powders, and to the stable crystalline inhalable powders prepared by this process. Similarly, the invention relates to the use of these inhalable powders for preparing a medicament for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive... Agent: Boehringer Ingelheim International Gmbh

20120135970 - Compositions for preventing and treating an immune system disorder: The present invention relates to methods of treating, preventing, or decreasing the occurrence of a condition characterized by Th2 overactivation or impaired Th1, or mitigating symptoms associated with a condition characterized by Th2 overactivation or impaired Th1, comprising orally administering to a subject in need thereof an effective amount of... Agent: Raisio Nutrition Ltd.

20120135971 - Estrogen antagonists as treatments for sclerosing disorders: The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.... Agent:

20120135972 - Phthalocyanine derivative consisting of a mixture of 4 isomers: There is described a phthalocyanine derivative of formula (I) consisting of 4 isomers wherein the relative isomer B content is less than or equal to 1% by weight.... Agent:

20120135973 - Method for treating chronic pain: The present invention provides analgesic compounds comprising at least one modified metalloporphyrin compound. Also provided are methods of treating pain by orally administering an analgesic compounds comprising at least one modified metalloporphyrin compound.... Agent: Southern Illinois University Edwardsville

20120135974 - Synergistic antimicrobial composition: A synergistic antimicrobial composition containing 3-iodo-2-propynyl-butylcarbamate and fluometuron.... Agent:

20120135976 - Process for the preparation of a pharmaceutical composition comprising ezetimibe: s

20120135975 - Substituted esters as cannabinoid-1 receptor modulators: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck & Co., Inc.

20120135978 - 6,7-unsaturated-7-carbamoyl substituted morphinan derivative: v

20120135977 - Ether benzotriazole derivatives: The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is... Agent:

20120135980 - Gamma secretase modulators: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (Chemical formula should be inserted here as it appears on abstract in paper form). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula... Agent:

20120135981 - Novel substituted triazole and imidazole derivatives as gamma secretase modulators: wherein R1, R2, A1, A2, A3, A4, X, and Het1 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient... Agent:

20120135979 - Pyrazinooxazepine derivatives: Provided is a compound having a serotonin 5-HT2C receptor activating action, useful for lower urinary tract conditions, obesity and cancer. A compound represented by the formula (I0): wherein each symbol is as defined in the specification, or a salt thereof.... Agent:

20120135982 - 5ht2c receptor modulators: o

20120135983 - Dna damage repair inhibitors for the treatment of cancer: The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which... Agent: Royal Cancer Hospital

20120135984 - Dual-action inhbitors and methods of using same: Provided are compounds, compositions, and methods for treating diseases and conditions wherein an inhibitor of a kinase, such as rho kinase (ROCK), and an inhibitor of one or more of the monoamine transporters, such as NET or SERT, act in concert to improve the condition.... Agent:

20120135985 - Substituted piperidines: The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular diseases and tumour diseases.... Agent: Bayer Pharma Aktiengesellschaft

20120135986 - Bicyclic heteroaryl compounds: e

20120135987 - Novel phenylimidazole derivatives as pde10a enzyme inhibitors: This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present... Agent: H. Lundbeck A/s

20120135988 - Purine pi3k inhibitor compounds and methods of use: Purine compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I... Agent:

20120135989 - Azaindole derivative: The present invention provides a (di)azaindole derivative represented by the formula (I). A compound of the present invention inhibits a Cdc7 protein kinase activity and suppresses cell proliferation.... Agent: Sbi Biotech Co., Ltd.

20120135990 - Iap inhibitors: The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.... Agent: Tetralogic Pharmaceuticals Corp.

20120135991 - Orally rapidly disintegrating tablet that contains two or more types of particles: The present invention provides an orally rapidly-disintegrating tablet comprising at least two particles. Regarding medicaments with unpleasant taste, the present invention provides a tablet comprising such medicament having a suitable hardness so that the tablet can be handled without any difficulty in the period from the formulation of the tablet... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20120135992 - Cyclic triazo sodium channel blockers: The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula (I): in which z is a single bond or an optionally substituted linking group, R1 is a halo-alkyl... Agent: University Of Greenwich

20120135993 - Cyclic triazo sodium channel blockers: The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The triazine compounds are of formula (I) wherein: R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N*... Agent: University Of Greenwich

20120135994 - Inhibitors of human phosphatidylinositol 3-kinase delta: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K... Agent: Icos Corporation

20120135995 - Fungicidal diphenyl-substituted pyridazines: Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.... Agent: E.i. Dupont De Nemours And Company

20120135996 - Cytoprotective agent: Disclosed is a cytoprotective agent for use with respect to ischemic damage, including as an active ingredient a triprenyl phenol compound represented by the following general formula (I), wherein X is —CHY—C(CH3)2Z, Y and Z are each independently —H or —OH, or jointly form a single bond, and R represents... Agent:

20120135997 - Pharmaceutical composition comprising a lactam or benzenesulfonamide compound: s

20120135998 - Compounds for treating respiratory syncytial virus infections: The present invention relates to compounds of formula (I), racemates, isomers and/or salts thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds.... Agent: Biota Scientific Management Pty Ltd

20120135999 - Compounds and methods for antiviral treatment: The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.... Agent: Ptc Therapeutics, Inc.

20120136001 - Substituted oxindole derivatives, medicaments containing the latter and use thereof: The invention relates to novel oxindole derivatives of general formula (I), in which the substituents A, B, R1, R2 and R3 are defined as cited in claim 1, to medicaments containing said derivatives and to the use of the latter for the prophylaxis and/or treatment of vasopressin-dependent and/or oxytocin-dependent diseases.... Agent:

20120136000 - Tri-cyclic pyrazolopyridine kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent:

20120136002 - Protease inhibitors: A compound of formula (I) wherein R1 to R15, P1, P2, A, B and Q are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as matriptase inhibitors and are useful in the treatment of matriptase dependent conditions,... Agent:

20120136003 - Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives: The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set... Agent: Institute For Oneworld Health

20120136004 - New combination therapy in treatment of cancer and fibrotic diseases: The invention relates to new methods for the treatment of oncological and fibrotic diseases comprising the combined administration of a receptor tyrosine kinase inhibitor in conjunction with a thrombin inhibitor.... Agent: Boehringer Ingelheim International Gmbh

20120136005 - Eltoprazine for the treatment of anxiety: The present invention relates to the treatment of an individual afflicted with certain forms of anxiety, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof... Agent: Merz Pharma Gmbh & Co. Kgaa

20120136006 - Cold menthol receptor antagonists: e

20120136007 - Methods and compositions for treating degenerative and ischemic disorders: Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g.,... Agent: The General Hospital Corporation

20120136008 - Pyrido[4,3-b]indoles and methods of use: New heterocyclic compounds that may be used to modulate a histamine receptor in an individual are described. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder... Agent:

20120136009 - Indole derivative modulators of the alpha 7 nachr: w

20120136010 - Synergistic antimicrobial composition: A synergistic antimicrobial composition comprising: (a) 3-iodo-2-propynyl-butylcarbamate; and (b) flumetsulam. A synergistic antimicrobial composition comprising: (a) 3-iodo-2-propynyl-butylcarbamate; (b) diclosulam.... Agent:

20120136011 - Compounds and methods for skin repair: The disclosure provides compositions and methods for treating a skin blemish. The compositions comprise a therapeutically effective amount of a compound useful for treating skin blemishes such as wounds, scars and wrinkles.... Agent: Allergan, Inc.

20120136012 - Amino tetrahydro-pyridopyrimidine pde10 inhibitors: The present invention is directed to amino tetrahydro-pyridopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or... Agent: Merck Sharp & Dohme Corp

20120136013 - Organic compounds: Optionally substituted (5- or 7-amino)-3,4-dihydro-(optionally 4-oxo, 4-thioxo or 4-imino)-1H-pyrrolo[3,4-d]pyrimidin-2(6H)-ones, Compounds of Formula I, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.... Agent:

20120136014 - Dihydrofolate reductase inhibitors: or a pharmaceutically acceptable salt thereof, wherein R5, R6 and Z are as described herein. The disclosure also provides pharmaceutical compositions thereof; and methods for inhibiting DHFR activity; and methods for treating cell proliferative diseases, autoimmune disease, inflammatory disease or bacterial, fungal or parasitic infection by administering a compound of... Agent: Trius Therapeutics, Inc.

20120136016 - 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors: The present invention relates to novel heterocyclic compounds of Formulae (I): (Chemical formula should be inserted here as it appears on abstract in paper form) Formula (I) as disclosed herein, or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and... Agent:

20120136015 - Process for preparation of endothelial receptor antagonist (bosentan): The present invention relates to processes for the preparation of an endothelial receptor antagonist. The present invention particularly relates to synthesis of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzene sulfonamide (bosentan).... Agent: Sandoz Ag

20120136017 - Use of 4'-thio-2'-deoxynucleosides as anti orthopoxvirus agents: wherein each R individually is H or aliphatic acyl or aromatic acyl group; X is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, cyano, aryl and nitro; pharmaceutically acceptable salts thereof, prodrugs thereof and mixtures thereof are used... Agent: Southern Research Institute Office Of Commercialization And Intellectual Property

20120136018 - Quinolines: e

20120136019 - (s)-n-methylnaltrexone: This invention relates to S-MNTX, methods of producing S-MNTX, pharmaceutical preparations comprising S-MNTX and methods for their use.... Agent: Progenics Pharmaceuticals, Inc.

20120136022 - Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic: Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period... Agent: Depomed, Inc.

20120136021 - Oxidation-stabilized tamper-resistant dosage form: m

20120136020 - Treatment of effect of chemicals with their ultradilute stereoisomers: A method of treating an effect of a chemical agent, which agent is characterized by one or more chiral centres, by administering a dilution or an ultra-high dilution or potentised preparation of a stereoisomer of said chemical agent.... Agent: Sempach Pty Ltd

20120136023 - Inhibitors of hiv replication: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.... Agent:

20120136024 - 3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereof: The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is... Agent: Targacept, Inc.

20120136025 - Quinolone derivative or pharmaceutically acceptable salt thereof: Disclosed are quinolone derivatives characterized in that these have lower alkyl, cycloalkyl or the like at the 1-position; —N(R0)C(O)-lower alkylene-CO2R0, lower alkylene-CO2R0, lower alkenylene-CO2R0, —O-lower alkylene-CO2R0, —O-(lower alkylene which may be substituted with —CO2R0)-aryl or —O-lower alkenylene-CO2R0 (wherein R0 is H or lower alkyl) at the 3-position; halogen at the... Agent: Astellas Pharma Inc.

20120136026 - 5-membered heterocyclic compound cyclopenta[c]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof: The invention relates to compounds of the general formula (I) where: R2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, C1-6-alkoxy, or NR8R9 group; m and p have a value of 1; n and o have the same value which is 0 or 1; A is... Agent: Sanofi

20120136027 - Phenyl ethynyl derivatives as hepatitis c virus inhibitors: e

20120136028 - Methods of diminishing co-abuse potential: Methods of diminishing or eliminating the co-abuse of a methylphenidate drug comprising identifying a patient or patient group suspected or likely to abuse said methylphenidate drug in combination with a substance known or suspected to give rise to l-ethylphenidate or psychotropic effect when ingested in the combination and making available... Agent: Celgene Corporation

20120136029 - Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles: A 2-aryl-pyridylazole compound and derivatives useful in slowing the growth of cancer cells are disclosed. Also disclosed are methods of synthesizing the compound, methods of using pharmaceutical compositions containing the compound as an ingredient to slow the growth of cancer cells, and methods of treating cancer patients with pharmaceutical compositions... Agent: The Translational Genomics Research Institute

20120136030 - Combinations of mek inhibitors and raf kinase inhibitors and uses thereof: This invention concerns combinations of inhibitors of MEK, Raf protein kinases, and other kinases including VEGFR1-3 and PDGFR-β. This invention also concerns pharmaceutical compositions comprising the compounds described herein and methods of use of the compounds and compositions described herein, including the use in the treatment and/or prevention of cancer... Agent:

20120136031 - P38map kinase inhibitor: or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment... Agent:

20120136032 - Fungicidal active substance combinations containing trifloxystrobin: What are described are novel active compound combinations comprising a known oxime ether derivative (trifloxystrobin) and imidacloprid, which combinations are highly suitable for controlling phytopathogenic fungi and insects.... Agent: Bayer Cropscience Ag

20120136034 - Fatty acids as anti-inflammatory agents: Compounds of formula I and their metabolites are potent mediators of an inflammatory response: (I) where a, b, c, d, e, f, V, W, X, Y, Ra, Ra′, Rb, Rb′, Rc, and Rc′ are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.... Agent: University Of Pittsburgh -of The Commonwealth Syst

20120136033 - Small molecule antagonists of phosphatidylinositol-3,4,5-triphosphate (pip3) and uses thereof: Disclosed are a new class of non-lipid small molecule inhibitors which interfere with the interaction between PIP3 and pleckstrin homology domains. These molecules target a broad range of PIP3-dependent signaling events in vitro and exert significant anti-tumor activity in vivo. The small molecule inhibitors of the invention can be used... Agent: Tufts University

20120136035 - 4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1h-imidazole-2(3h)-thione: Disclosed herein is 4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1H-imidazole-2(3H)-thione and methods of using the compound to treat chronic pain.... Agent: Allergan, Inc.

20120136036 - Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions: The present invention relates to method for treating skin diseases and skin conditions in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, or enantiomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Allergan, Inc.

20120136037 - Deuterium-enriched ruboxistaurin: The present application describes deuterium-enriched ruboxistaurin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20120136038 - Novel polymorphs of azabicyclohexane: The invention provides polymorphic crystalline forms of acid addition salts of (±)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph... Agent:

20120136049 - Antibacterial agent: The present invention provides an epigallocatechin gallate derivative (EGCG derivative) that has excellent safety and antibacterial properties. An epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is used as an antibacterial agent. In the formula, R1 to R6 are each a... Agent: Osaka University

20120136047 - Neuroprotective compositions and methods: This disclosure concerns novel methods for preventing or treating neurological or neurodegenerative diseases or disorders by using kombo butter acid enriched extracts derived from the seeds of African nutmeg, the main active compounds isolated from the extracts, namely sargaquinoic acid, sargachromenol, and sargahydroquinoic acid, or synthetic analogs or derivatives thereof,... Agent:

20120136048 - Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases: A method for preventing, reducing, ameliorating or treating ophthalmic disorders associated with neurodegenerative diseases or trauma, comprising the topical, periocular, or intraocular application of an ophthalmic formulation comprising a therapeutically effective amount of one or more ophthalmic agents selected from the group consisting of alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, delta-tocotrienol, or esters... Agent:

20120136050 - Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia: Embodiments of the invention include the treatment of a sleep disorder comprising the administration of N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cycloproply]methyl]propanamide or a salt, stereoisomer, solvate, or hydrate thereof, in amorphous or crystalline form.... Agent: Vanda Pharmaceuticals Inc.

20120136051 - Rheology modified low foaming liquid antimicrobial compositions and methods of use thereof: The present disclosure relates to rheology modified, low foaming aqueous antimicrobial compositions. The compositions are phase stable under acidic conditions, and do not need to be rinsed from the surface to which they are applied. The present disclosure further relates to methods of use thereof.... Agent: Ecolab Usa Inc.

20120136052 - Substituted acylanilides and methods of use thereof: This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.... Agent:

20120136053 - Copepod oil composition, formulations comprising the oil composition, and the use thereof to reduce accumulation of visceral fat, improve glucose tolerance, and prevent or treat obesity related diseases and disorders: This invention relates to an oil composition, preferably obtained from a copepod, and the use thereof to reduce accumulation of visceral fat and counteract impairment of heart function caused by obesity inducing Western diets. The oil composition of the present invention can thus be used to reduce abdominal obesity and... Agent: Calanus As

20120136054 - Materials and methods for measuring nitric oxide levels in biological fluids: The subject invention presides novel devices and methods for the measurement of nitric oxide in biological samples, including wound fluid samples. These advantageous devices and methods can be used for clinicians to monitor the wound's nitric oxide metabolism and/or response to treatment.... Agent:

20120136055 - Semi-solid compositions and pharmaceutical products: This invention relates to semi-solid compositions and semi-solid pharmaceutical products for use in the photodynamic treatment (PDT) of cancer, pre-cancerous conditions and non-cancerous conditions in the female reproductive system, the anus and the penis, preferably for use in PDT of endometrial, cervical, vulvar, vaginal, anal and penile dysplasia and HPV... Agent: Photocure Asa

20120136056 - Pesticidal compositions for insects and arthropods: The present invention provides an insect or arthropod pesticidal composition. The composition includes active ingredients having a mixture of fatty acids, each of the fatty acids having a straight carbon chain from 6 to 12 carbon atoms long. The fatty acid mixture includes a first fatty acid molecule having a... Agent: Stratacor, Inc.

20120136057 - Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis: A compound of formula (I): wherein R represents a hydroxy substituted C24-C40 straight chain aliphatic group containing at least one double bond in the carbon chain; and at least one carbon in the chain is substituted with a hydroxy group. Such compounds are useful for detecting inflammation, inflammatory disorders and... Agent: Phenomenome Discoveries Inc.

20120136058 - Method for increasing the solubility of methionine by mineral addition and acid treatment: The present invention relates to a method for enhancing the solubility of methionine. More particularly, the present invention relates to a method for increasing the solubility of methionine, in which mineral and sulfuric acid are added at an appropriate ratio to enhance the methionine solubility, thereby overcoming the problem of... Agent: Cj Cheiljedang Corporation

20120136059 - Combinations of adapalene and benzoyl peroxide for treating acne lesions: Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by... Agent: Galderma Research & Development

20120136060 - Immediate release and sustained release ibuprofen dosing regimen: A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, is provided. The inventive dosage forms provide an initial release of the NSAID and a second sustained release of NSAID, preferably in a single dosing step.... Agent:

20120136061 - Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect: A carotenoid and a terpenoid in therapeutically-effective amounts is disclosed such that, upon ingestion in one preparation, or in two separated preparations, simultaneous or sequentially, and upon metabolism, the activity of natural killer (NK) cells is elevated. Specifically, the composition comprises lycopene and resveratrol in the range of 1:10 to... Agent: Hsiehs Biotech (singapore) Pte Ltd

20120136062 - Novel complex for treatment and/or prophylaxis of parasitic infections: Disclosed are complexes of an antipneumocystic compound and an antimalarial compound, processes for their preparation, pharmaceutical compositions and methods of using said complexes or compositions for the treatment and/or prophylaxis of parasitic infections.... Agent: Ipca Laboratories Ltd.

20120136063 - Fty720-derived anticancer agents: wherein R1 is independently selected from the group consisting of hydrogen, methyl. methoxy, and hydroxyl; R2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; R3 is independently selected from the group consisting of alkyl and cyclo-alkyl; and n is independently selected from 0 to 6. The... Agent: The Ohio State University Research Foundation

20120136064 - Methods for screening to identify therapeutic agents for alzheimer's disease and use thereof: Methods for treating Alzheimer's Disease (AD) using modulators of lysosomal activity are described herein. More particularly, methods described herein relate to the use and application of compounds or agents that enhance lysosomal activity for the treatment of AD. In a particular aspect, the method relates to the use and application... Agent:

20120136065 - Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.... Agent: Sunovion Pharmaceuticals Inc.

20120136066 - Glomerulonephritis treatment: A compound of formula (I) R-L-CO—X (I) (wherein R is a C10-24 unsaturated hydrocarbon group optionally interrupted by one or more heteroatoms or groups of heteroatoms selected from S, O, N, SO, SO2, said hydrocarbon group comprising at least 4 non-conjugated double bonds; L is a linking group forming a... Agent: Avexxin As

20120136067 - Oil/water active ingredient emulsion containing uv filter: A cosmetic oil/water emulsion comprising a) 2-ethylhexyl-2-cyano-3,3-diphenylacrylate (INCI: Octocrylene), b) 4-(tert.-butyl)-4′-methoxydibenzoyl methane (INCI: Butylmethoxydibenzoyl methane), c) licorice extract or licochalcone A.... Agent: Beiersdorf Ag

20120136068 - Ameliorant for renal insufficiency: c

20120136069 - Alcoholic pump foam: An alcoholic foam composition, which can be dispensed as a foam via a pump-foam system contains a) at least 52 to ≦99 wt % of an alcohol or mixture of alcohols, b) a surfactant or a surfactant mixture, c) at least one polyalkylene glycol, d) optionally, at least one foam... Agent: DebIPLimited

20120136070 - Ketal esters of anhydropentitols and uses thereof: The present disclosure relates to the preparation of ketal compounds from anhydropentitols and oxocarboxylates; derivatives, homopolymers, and copolymers thereof; and various compositions, formulations, and articles derived therefrom.... Agent: Xl Terra, Inc.

20120136071 - Medicinal cream for diaper rash and a process to make it: The present invention relates to a composition for treating diaper rash along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and an anti diaper rash active ingredient. It discloses a composition for treating diaper rash along with skin rejuvenation containing a) a... Agent: Apex Laboratories Private Limited

20120136072 - Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAE-CD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of... Agent: Cydex Pharmaceuticals, Inc.

20120136073 - Amine-containing transfection reagents and methods for making and using same: There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as... Agent: Life Technologies Corporation

  
05/24/2012 > 201 patent applications in 155 patent subcategories. archived by USPTO category

20120129757 - Compositions and methods for promoting vascular barrier function and treating pulonary fibrosis: Active agents and compositions that promote barrier function or that inhibit permeability of the vascular endothelium associated with pulmonary inflammation are described.... Agent:

20120129758 - Muscle function enhancing peptide: The present invention relates to a peptide comprising a muscle function enhancing amino acid sequence which is derived from the S100 calcium binding protein family. Furthermore, the present invention provides said peptide for medical use, in particular, for treating or preventing disorders associated with muscular malfunction, such as skeletal muscle... Agent: Universitatsklinikum Heidelberg

20120129759 - Protein surface remodeling: Aggregation is a major cause of the misbehavior of proteins. A system for modifying a protein to create a more stable variant is provided. The method involves identifying non-conserved hydrophobic amino acid residues on the surface of a protein, suitable for mutating to more hydrophilic residues (e.g., charged amino acids).... Agent: President And Fellows Of Harvard College

20120129760 - Modified peptides with antiviral properties and methods for obtaining them: An assembly of modified oligopeptides based on a quasi-life, dynamic, self-organizing system that is effective in the treatment of viral infections such as influenza, herpes, and animal viruses at all stages of the development of the infectious process where other drugs are ineffective. This drug has a wide spectrum of... Agent:

20120129761 - Preparation of bone cement compositions: surprisingly shortens the setting times for the cement comprising the additive that retard the setting process to the level observed in the absence of the additive and enables a complete hydration of calcium sulfate hemihydrate to calcium sulfate dihydrate, even when using additives else preventing the hardening.... Agent: Bone Support Ab

20120129762 - Motilin-like peptide compound having transmucosal absorbability imparted thereto: Motilin derivatives were designed and synthesized in consideration of the pathway for the degradation of motilin at a site of its transmucosal absorption and the maintenance of motilin's physiological activity and compounds characterized by substitutions for the amino acid at position 21 of native motilin have been found to show... Agent: Daiichi Sankyo Company, Limited

20120129763 - Novel semi-synthetic glycopeptides as antibacterial agents: Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopeptides described herein are made by chemical modification of a glycopeptide (Compound A, Compound B, Compound H or Compound C) or monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium... Agent: Biomarin Pharmaceutical Inc.

20120129764 - Influenza a and b virus replication-inhibiting peptides: A synthesized or isolated influenza virus replication-inhibiting peptide that competitively inhibits protein-protein interaction of the PA and PB1 of both influenza Virus Types A and B and novel in vitro binding screen to identify peptides with antiviral activity against influenza viruses of both type A and B is disclosed. In... Agent: Pike Pharma Gmbh

20120129765 - Novel specific hcv ns3 protease inhibitors: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HCV in human patients or other animal hosts.... Agent: Rfs Pharma, LLC

20120129766 - Methods of treating fgf21-associated disorders: The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.... Agent: Novartis Ag

20120129768 - Glp-1 analogues and their pharmaceutical salts and uses: e

20120129767 - Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment: A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib2, Glu3(NH-hexyl)]hGhrelin(1-28)-NH2 (SEQ ID NO:2) or other suitable ghrelin agonist, to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.... Agent:

20120129769 - Orally administerable pharmaceutical preparation containing insulin: The subject of the invention is an orally administerable pharmaceutical preparation containing a combination of biotechnologically produced human recombinant insulin and/or modified insulin or an analogue and/or derivative thereof, a protease inhibitor and a high molecular weight (natural) protein. The invention relates to a method for the production of the... Agent:

20120129770 - Novel polynucleotide molecules for enhanced gene expression: Disclosed herein is an isolated polynucleotide molecule encoding protein such as erythropoietin or structural variants, comprising an expression regulating nucleotide sequence operatively linked to a nucleotide sequence(s) encoding said proteins. The said expression regulatory region comprises of Exon A and at least proximal region of Intron A of Major Immediate... Agent:

20120129771 - Peptides and related molecules that modulate nerve growth factor activity: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are... Agent: Amgen Inc.

20120129772 - Soluble igf receptors as anti-angiogenic agents: There is disclosed a method of inhibiting angiogenesis in a patient having an angiogenic associated disorder comprising administering to said patient a therapeutically effective amount of a soluble IGF-IR protein. The use of such soluble IGF-IR protein for inhibiting angiogenesis in a patient is also disclosed.... Agent: The Royal Institution For The Advancement Of Learning/mcgill University

20120129773 - Methods of treating autism and autism spectrum disorders: The present invention relates to methods of treating a subject diagnosed with autism or an autism spectrum disorder, lowering the level of mercury in a subject determined to contain a high level of mercury, methods of lowering the level of mercury in a child diagnosed with autism, lowering the level... Agent:

20120129774 - Kinin b1 receptor peptide agonists and uses thereof: e

20120129775 - Antiangiogenic small molecules and methods of use: Methods of inhibiting undesired angiogenesis are provided, which methods include administering to a subject a therapeutically effective amount of at least one of the compounds described herein, or a pharmaceutically acceptable salt thereof.... Agent:

20120129776 - Bioactive peptides and method of using same: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.... Agent:

20120129777 - Methods for treating bleeding disorders using sulfated polysaccharides: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or, with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of... Agent:

20120129778 - Ligand that bind tgf-beta receptor rii: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. The disclosure also provides a polypeptide, ligand or pharmaceutical composition for treating a disease associated with TGFbeta signaling and a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis, liver fibrosis, including cirrhosis and... Agent: Glaxo Group Limited

20120129779 - Tubulysine derivatives: The present invention relates to novel cytotoxic molecules and their use for the treatment of cancer and other diseases.... Agent: R&d-biopharmaceuticals Gmbh

20120129780 - Lactoferrin and brain health and protection in adults: The present invention relates generally to the field of brain health, brain protection, maintenance of cognitive function, prevention of cognitive decline and cognitive disorders. Neuronal cells in the brain can be protected. Also cognitive performance can be increased.... Agent: Nestec S.a.

20120129781 - Composition comprising alpha-lipoic acid and carnosine for treating the phantom limb syndrome: The present invention relates to a composition comprising an effective amount of α-lipoic and carnosine, or pharmaceutically acceptable derivatives thereof for treating the phantom limb syndrome. The present invention also relates to the use of such a composition for treating the phantom limb syndrome.... Agent: Difass International S.r.l.

20120129782 - Inhibition of apoe cleavage activity in the treatment of apoe-related disorders: The present invention provides methods for treating apoE-related disorders. The methods generally involve administering an effective amount of an agent that inhibits activity of an enzyme that cleaves apoE.... Agent:

20120129783 - Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders: The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, Type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen... Agent:

20120129784 - Oligopeptides and cosmetic compositions containing the oligopeptides: Oligopeptides according to formula (I) and/or (II), R1-Tyr-Pro-Trp-Phe-NH2 (I, SEQ ID NO:1); R1-Tyr-Pro-PhePhe-NH2 (II, SEQ ID NO:2), wherein R1 is linked to the NH2-group of the amino-terminal part of Tyr and is selected from the group consisting of —H; a linear saturated or unsaturated or branched saturated or unsaturated acyl... Agent: CognisIPManagement Gmbh

20120129785 - Companion animal nutrition system: The invention encompasses a nutrition system for a companion animal that includes a plurality of pet food packets, wherein an amount of pet food corresponding to a single meal for a companion animal may be selected and wherein the amount of pet food is formulated to alleviate or manage a... Agent: Hill's Pet Nutrition, Inc.

20120129786 - Novel composition: The present invention relates to compositions comprising a peptide with 2-12 amino acids substituted with a lipophilic moiety and a water soluble salt of an alkali, earth alkaline metal or transition metal. Furthermore, the invention relates to a container comprising such compositions. Additionally, the invention relates to the use of... Agent: DsmIPAssets B.v.

20120129787 - Modified oligopeptides with anticancer properties and methods of obtaining them: An assembly of modified oligopeptides based on a quasi-life, dynamic, self-organizing system that is effective in the treatment of oncological illnesses at all stages of the development of the cancer process where other drugs are ineffective. This drug has a wide spectrum of activity and a low level of toxicity;... Agent:

20120129788 - Phosphodiesterase 4d7 as marker for malignant, hormone-sensitive prostate cancer: The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for malignant, hormone-sensitive prostate cancer, wherein the expression of the marker is increased when comparing the expression in malignant, hormone-sensitive prostate cancer tissue, to the expression in normal tissue or benign prostate tumor tissue, and the use... Agent: Koninklijke Philips Electronics N.v.

20120129789 - Compositions and methods for hair growth: The present invention is directed to compositions and methods comprising the use of bimatoprost and cyclosporine, used concurrently and in combination, to grow hair and for the treatment of all types of hair loss conditions such as but not limited to alopecia areata. The present invention is also directed to... Agent:

20120129790 - Methods of use of epsilon inhibitor compounds for the attenuation of pain: The disclosure herein relates to modified εPKC inhibitory peptides, methods of generating such peptides, and method for using εPKC inhibitory peptides for the treatment of pain.... Agent: Kai Pharmaceuticals, Inc.

20120129791 - Stimulator of genital, sexual and reproductive function: The invention relates to a novel agent having an influence on the genital, sexual and reproductive function of mammals and human beings. More specifically, the invention relates to the use of a heptapeptide of the general formula (I) Thr-Lys-Pro-Arg-Pro-Gly-Pro as a stimulator of the genital, sexual and reproductive function of... Agent: &#x3c &#x3c Bio Peptid&#x3e &#x3e Company Limited

20120129792 - Agent for eliminating multidrug resistance: The invention belongs to medicine, namely to pharmacology, and may be used to overcome multiple drug resistance in oncological and infectious patients undergoing long-term chemotherapy. Essence of the invention: proposed herein as a therapeutic agent intended to overcome multiple drug resistance is a hexapeptide with the following structural formula: lysyl-histidyl-glycyl-lysyl-histidyl-glycine.... Agent:

20120129793 - Antimicrobial polyether and polyol compounds: The present application describes compounds of Formula I and Formula IA and as disclosed herein, that are useful as anti-microbial agents, including as antibacterial, disinfectant, antifungal, germicidal or antiviral agents.... Agent: Novabay Pharmaceuticals, Inc.

20120129794 - Apparati, methods, and compositions for universal microbial diagnosis, detection, quantification, and specimen-targeted therapy: Microbial ecology of a specimen is evaluated using an approach (Level I) that utilizes nucleic acid amplification with specific gene primers that will identify panels of microorganisms and antibiotic-resistance factors generating a diagnostic report (optionally with quantification of each microorganism or antibiotic-resistance factor) and an approach (Level II) that utilizes... Agent:

20120129795 - Antiviral compounds: Herein are disclosed novel compounds according to Formula (I) and aggregates comprising such compounds. These aggregates are useful to treat and prevent ocular infections caused by a vims, which virus binds to terminal sialic residues present on the cell surface of the cell to be infected by the virus.... Agent: Adenovir Pharma Ab

20120129796 - Pest controlling composition: A pest controlling composition comprising spinetoram and a cyclic keto-enol compound having an acetyl CoA carboxylase-inhibiting activity as active ingredients.... Agent: Sumitomo Chemical Company, Limited

20120129797 - Biodegradable stealth polymeric particles fabricated using the macromonomer approach by free radical dispersion polymerization: The present invention is directed to a crosslinked or non-crosslinked polymer particle, wherein the crosslinked polymer particle comprises a copolymer of poly(alklyene glycol-graft-lactate) that is crosslinked by at least one hydrolysable monmer. Another embodiment of the present invention is a polymer particle comprising a crosslinked polymer particle that is a... Agent:

20120129798 - Stealth polymeric particles for delivery of bioactive or diagnostic agents: The present invention is directed to a crosslinked or non-crosslinked polymer particle, wherein the crosslinked polymer particle comprises a copolymer of poly(alklyene glycol-graft-acrylate) that is crosslinked by at least one hydrolysable monomer or crosslinking agent. The present invention is also directed to a polymer particle comprising a crosslinked polymer particle... Agent:

20120129916 - Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof: A method of generating a particle is disclosed, the particle being for delivery of a polynucleotide to a target cell. The method comprises (a) contacting the polynucleotide with a composition comprising cationic molecules, wherein the cationic molecules condense the polynucleotide by electrostatic interactions to generate a complex, wherein the cationic... Agent: Ramot At Tel-aviv University Ltd.

20120129911 - Compositions and methods of targeting apolipoprotein b for the reduction of apolipoprotein c-iii: Disclosed herein are compositions and methods for lowering Apolipoprotein C-III (ApoC-III) in a subject in need thereof. Subjects in need of ApoC-III reduction include subjects with elevated ApoC-III levels, subjects with a condition associated with ApoC-III, subjects with diabetes, obese subjects and subjects with cardiovascular disease. Compositions to lower ApoC-III... Agent:

20120129913 - Dsrna for treating viral infection: The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each... Agent: Novartis Ag

20120129910 - Inhibition of apoptosis-specific eif-5a(elf-5a1\") with antisense oligonucleotides and sirna as anti-inflammatory therapeutics: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or... Agent: Senesco Technologies Inc.

20120129914 - Organic compositions to treat hsf1-related diseases: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.... Agent: Novartis Ag

20120129915 - Organic compositions to treat hsf1-related diseases: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.... Agent: Novartis Ag

20120129912 - Rna targeting in alpha-synucleinopathies: Therapies and assays to screen for small molecules that can have therapeutic use in the control of neurodegenerative diseases such as Parkinson's and other alpha-synucleinopathies.... Agent: University Of Medicine And Dentistry Of New Jersey

20120129917 - Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq): The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Adiponectin (ADIPOQ), in particular, by targeting natural antisense polynucleotides of an Adiponectin (ADIPOQ). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with... Agent: Opko Curna, LLC

20120129921 - Method and device for producing and/or purifying polynucleotides and products obtainable thereof: An apparatus and a method for obtaining a (poly) nucleotide sequence of interest include steps of cultivating hosts cells to produce a nucleotide sequence of interest and harvesting these cells, introducing these cells in a passageway and disintegrating them in a continuous process. In the continuous process, performing in the... Agent:

20120129920 - Mir-31 in duchenne muscular dystrophy therapy: The invention relates to the therapy of Duchenne Muscular Dystrophy (DMD) by means of modulating the amount of a specific miRNA (miR-31).... Agent: Universit&#xc0 Degli Studi Di Roma "la Sapienza"

20120129918 - Modified oligonucleotides for telomerase inhibition: Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.... Agent: Geron Corporation

20120129919 - Polycationic amphiphilic cyclooligosaccharides and the use thereof as molecular transporters: The present invention relates to a group of polycationic amphiphilic cyclooligosaccharides which, due to their molecular structure, may be used as molecular transporters to the interior of cells. Furthermore, the present invention also relates to the use of said compounds in the preparation of a medicament, to the use of... Agent:

20120129799 - stable composition of ready-to-use gemcitabine injection: The present invention relates to non aqueous pharmaceutical preparations containing gemcitabine or its pharmaceutically, acceptable salts in the form of ready-to-use solutions wherein the concentration of Gemcitabine is in the range of about 16 mg/ml to about 200 mg/ml and a pH of about 3.5 to 10.0. Further, a method... Agent: Astron Research Limited

20120129800 - Agent for preventing and treating pityriasis versicolor: The agent according to the present invention comprises at least one transaminase inhibitor effectively inhibiting the transamination process which is of pathogenetic relevance for the disease, prevents a recurrence of the disease and which protects the human skin flora. Upon release into the environment, no resistances are induced in other... Agent: Justus-liebig-universitat Giessen

20120129801 - Blood parasiticide: This application relates to compositions and methods of treating tick-born parasitic diseases in livestock with the compositions. The compositions include imidocarb dipropionate, cyanocobalamin vitamin B12, and pharmaceutically acceptable carriers.... Agent: Wyeth LLC

20120129802 - Process for the production of ultrapure galacto-oligosaccharides: The present invention describes a process for preparing ultrapure (≧95%) galacto-oligosaccharides (GOS), starting from GOS at lower purities by using sequential microbiological purifications involving Saccharomyces cerevisiae and Streptococcus thermophilics.... Agent:

20120129803 - Composition containing chitooligosaccharide for recovering from fatigue: Disclosed is an anti-fatigue composition containing chitooligosaccharide as an active ingredient. The composition exhibits a fatigue recovery effect, and thus can be widely used in the health food or medical field.... Agent: Amorepacific Corporation

20120129804 - Methods of reducing absorption of trans fatty acids using water-insoluble cellulose derivatives: Provided are food products comprising at least 0.5 g of trans fatty acid per serving and one or more water-insoluble cellulose derivatives in an amount sufficient to reduce absorption of the trans fatty acid by a mammal consuming the food product, methods of ameliorating the harmful effects of trans fatty... Agent:

20120129805 - Barley and uses thereof: The invention provides barley gain comprising a reduced level or activity of starch synthase IIa protein and a starch content of at least 41% (w/w) and methods of producing, identifying and using same. The grain may comprise an amylase content of at least 50%, a β-glucan content of 5-9% (w/w)... Agent:

20120129806 - Arginase inhibitors as therapeutics: e

20120129807 - Methods of treatment, improvement and prevention using haloaryl substituted aminopurines:

20120129808 - Blood coagulation reaction inhibitor: The present invention is a blood coagulation reaction inhibitor comprising phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. The present invention is also a thrombin generation inhibitor comprising phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. The blood coagulation reaction inhibitor and the thrombin generation inhibitor of the present invention are useful as an antithrombotic agent, a clinical... Agent: Shino-test Corporation

20120129810 - Combination antineoplastic therapy: The present invention is directed to methods of using a sirolimus drug and chloroquine or a quinoline derivative in combination. Methods of use are also described.... Agent: The Trustees Of The University Of Pennsylvania

20120129809 - Lung cancer treatment: The invention provides a method for treating NSCLC, especially in cases of KRAS mutation, involving the administration of deforolimus.... Agent: Merck & Co.,

20120129811 - Tricyclic inhibitors of pro-matrix metalloproteinase activation: This invention relates to tricycle I and its therapeutic and prophylactic uses, wherein the variables C1, C2, Z1, Z2, Q, J, R1, and R3 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.... Agent:

20120129813 - Novel compounds as receptor modulators with therapeutic utility: The present invention relates to novel derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent:

20120129812 - Novel thyroid hormone beta receptor agonist: e

20120129814 - Novel phosphonic acids as s1p receptor modulators: The present invention relates to novel phosphonic acids derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120129815 - Fungicidal composition: A fungicidal composition comprising tolclofos-methyl, polyoxyethylene polyarylphenol phosphate, polyoxylethylene polyoxypropylene block copolymer, polyoxyethylene fatty alcohol ether and water has good stability of the formulation at high temperature.... Agent: Sumitomo Chemical Company, Limited

20120129816 - Aryl sulfonamide amine compounds and their use as 5-ht6 ligands: The present invention relates to novel aryl sulfonamide amine compounds of the formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates described herein and pharmaceutically acceptable compositions containing them.... Agent: Suven Life Sciences Limited

20120129817 - Combination treatment for diabetes mellitus: The subject matter of this application is directed to combinations of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-ol with other active compounds for the treatment of diabetes mellitus type 2 and/or type 1.... Agent: Nycomed Gmbh

20120129818 - Compositions and methods for treatment of cardiovascular disease: Ortho methoxy phenolic compounds are provided that include methylenedioxyphenyl ferulate and ferulylproline and derivatives thereof. Pharmaceutical compositions comprising the compounds and methods of using the compounds for treating cardiovascular diseases, including hypertension, atherosclerosis, coronary heart disease, angina, stroke, and myocardial infarction, are further provided. The compounds are also useful in... Agent:

20120129819 - Gel compositions for administration of pharmaceutically active compounds: The present invention provides a pharmaceutical composition in the form of a water-based gel comprising: at least one pharmaceutically active compound; at least one gelling agent; a solubilising agent; and water, wherein said composition is free or substantially free of unsubstituted monohydric alcohols having between 1 and 6 carbon atoms.... Agent: Medortus (uk) Ltd

20120129821 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20120129820 - New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders: The present invention provides pharmaceutical compositions comprising one or more CRTH2 antagonists 1 and one or more further active compounds 2.... Agent: Boehringer Ingelheim International Gmbh

20120129822 - Composition containing diosgenin and use thereof to improve at least one of cognitive deficits associated with menopausal syndrome: Disclosed herein is a composition for improving at least one of cognitive deficits associated with menopausal syndrome, which includes diosgenin. Also disclosed herein is a method for improving at least one of cognitive deficits associated with menopausal syndrome in a subject via administering the aforesaid composition.... Agent: Chung Shan Medical University

20120129823 - Contraception process and administration form for the same: A method for hormonal contraception comprising administering at least one contraceptive hormone in a plurality of linked taking periods optionally having a sequence lasting several years. Each taking period comprises at least one taking cycle. Each taking cycle comprises a duration-constant taking phase lasting several days and a taking pause... Agent:

20120129824 - Pharmaceutical formulations containing corticosteroids for topical administration: The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester.... Agent:

20120129825 - Method for on-demand contraception using levonorgestrel or norgestrel: The invention relates to a method for contraception, which method comprises on-demand administering levonorgestrel or norgestrel in a woman, within 24 hours before an intercourse.... Agent:

20120129826 - Method of treating depression: Methods for treatment of depression-related mood disorders in mammals, particularly humans are disclosed. The methods of the invention include administration of compounds capable of enhancing glutamate transporter activity in the brain of mammals suffering from depression. ATP-sensitive K+ channel openers and β-lactam antibiotics are used to enhance glutamate transport and... Agent: Brookhaven Science Associates, LLC

20120129830 - 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof and therapeutic use thereof: The invention relates to compounds of the general formula (I) where: R2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, C1-6-alkoxy, or NR8R9 group; m, n, o and p independently are a number from 0 to 3, provided that m+n≦7 and that o+p≦7; A is a... Agent: Sanofi

20120129832 - Amide derivative: Provided are a compound having an excellent hypoglycemic action, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause an increase in the blood sugar level due to abnormal sugar... Agent: Daiichi Sankyo Company, Limited

20120129827 - Novel derivatives of 1-alkyl-6-oxo-piperidine-3-carboxylic acids and 1-alkyl-5-oxo-pyrrolidine-3-carboxylic acids and their uses as cooling compounds: o

20120129829 - Novel indole modulators of s1p receptors: The present invention relates to novel indole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120129828 - S1p1 receptor agonists and use thereof: The present invention relates to compounds of Formula (I) that are have activity as S1P1 receptor modulating agents, more specifically to specifically compounds that are S1P1 receptor agonists. The invention also related to the use of such compounds to treat diseases associated with inappropriate S1P1 receptor activity such as autoimmune... Agent:

20120129831 - Substituted 3-(1,2,4-oxadiazol-5-yl)-5-phenylpiperidines: The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and tumour disorders.... Agent: Bayer Pharma Aktiengesellschaft

20120129833 - Cyclic ketoenols for therapy: The invention relates to 5′-biphenyl-substituted cyclic ketoenols for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of diabetes, obesity, hyperlipidaemia, fatty livers and of disorders of the cardiovascular system.... Agent: Bayer Pharma Aktiengesellschaft

20120129836 - Imidazole derivatives as pde10a enzyme inhibitors: This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present... Agent: H. Lundbeck A/s

20120129835 - Schizophrenia methods and compositions: Methods of preparing and using neural cells derived from human induced pluripotent stem cell (hiPSCs), particularly hiPSCs derived from subjects with schizophrenia are provided. The hiPSC-derived neural cells can be used to screen test compounds and to identify schizophrenia marker functions. The hiPSC-derived neural cells can be used to diagnose... Agent: Salk Institute For Biological Studies

20120129834 - Serotonin receptor antagonists for use in the treatment of huntington's disease: Methods are provided for the treatment and/or prophylaxis of Huntington's disease. In various embodiments the methods involve administration of one or more serotonin receptor antagonists. In certain embodiments the serotonin receptor antagonists include, but are not limited to loxapine, and/or a loxapine analogue, and/or cyproheptadine, and/or a cyproheptadine analogue (e.g.,... Agent: Buck Institute For Research On Aging

20120129837 - Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/β-catenin signaling pathway, and serve to reduce β-catenin levels present in cells, such... Agent:

20120129838 - Composition for preventing and treating alopecia disorder containing morgalanthamine compounds as an active ingredient: Provided are a pharmaceutical composition, a cosmetic composition and health foods for preventing and treating alopecia disorder, which include a norgalanthamine compound as an active ingredient. Since the norgalanthamine compound has an effect on growth and proliferation of dermal papilla cells that play an important role in hair growth, the... Agent: The Industry & Academic Cooperation In Chungnam National University

20120129839 - Methods of treating disorders associated with protein polymerization: The present invention relates to methods of treatment of clinical disorders associated with protein polymerization comprising administering, to a subject, an effective amount of carbamazepine, oxcarbazepine or another carbamazepine-like compound. It is based, at least in part, on the discovery that, in cells having a genetic defect in α1-antitrypsin, carbamazepine... Agent:

20120129840 - Novel viral replication inhibitors: The present invention relates to a series of novel compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The... Agent: Katholieke Universiteit Leuven

20120129842 - Bisthiazole inhibitors of pro-matrix metalloproteinase activation: This invention relates to bisthiazole I and its therapeutic and prophylactic uses, wherein the variables A, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.... Agent:

20120129841 - Carboline derivatives useful in the treatment of cancer and other diseases: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and compositions, and methods for the administration and use of those compounds. provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor... Agent: Ptc Therapeutics, Inc.

20120129844 - N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof:

20120129843 - Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation: This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables Rz, Q, J, R1, R3, R5, and R6 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.... Agent:

20120129845 - Inhibitors of bruton's tyrosine kinase: wherein, variables R, X, Y1, Y2, Y2′, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto... Agent:

20120129846 - Gamma secretase modulators: In its many embodiments, the present invention provides a novel class of heterocyclic compounds of the formula: as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment,... Agent:

20120129848 - Benzo [e] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors: Compounds of formula (I): wherein: W is O, N—H, N-alkyl, N-alkenyl, N-alkynyl, N-aryl, N-heteroaryl or S; each X is independently CH or N; R1 is formula (b) or R3 is H, alkyl, NH2, OH, =0 or halogen; each A and B are independently CH or N; D is NHR4;... Agent: Karus Therapeutics Limited

20120129847 - Compositions and methods for treating ocular edema, neovascularization and related diseases: Disclosed are methods for the treatment of diseases or conditions of the eye, especially retinopathies, ocular edema and ocular neovascularization. Non-limiting examples of these diseases or conditions include diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced... Agent:

20120129849 - Deuterated serine-threonine protein kinase modulators: The present invention provides deuterated compounds having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. The deuterated compounds of the invention can modulate casein kinase (CK) activity and/or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part... Agent: Cylene Pharmaceuticals, Inc.

20120129850 - Imidazolothiazole compounds for the treatment of disease: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.... Agent: Ambit Biosciences Corporation

20120129852 - Azaindazoles as kinase inhibitors and use thereof: Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, (I) are useful as kinase modulators, including Btk modulation, wherein A1, A2, A3, R4 are as defined herein.... Agent: Bristol-myers Squibb Company

20120129851 - Substituted quinazoline and pyrido-pyrimidine derivatives: The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By... Agent: Endo Pharmaceuticals Inc.

20120129853 - Methods of treatment using selective bcl-2 inhibitors: This invention pertains to methods of treating systemic lupus erythematosus, lupus nephritis or Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting... Agent: Abbott Laboratories

20120129854 - Pesticidal arylpyrrolidines: The invention is directed to arylpyrrolidines compounds which exhibit excellent insecticidal efficacy and which may be used as in the agrochemical field or in the yield of veterinary medicine. The compounds are represented by formula (I): wherein the respective substituents are defined in the specification.... Agent: Bayer Cropscience Ag

20120129855 - Phthalazinone derivatives: A and B together represent an optionally substituted, fused aromatic ring; X and Y are selected from CH and CH, CF and CH, CH and CF and N and CH respectively; RC is selected from H, C1-4 alkyl; and R1 is selected from C1-7 alkyl, C3-20 heterocyclyl and C5-20 aryl,... Agent:

20120129856 - Compounds, compositions and methods useful for cholesterol mobilisation: The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein.... Agent: Cerenis Therapeutics Sa

20120129857 - Substituted sodium 1h-pyrazol-5-olate: The present application relates to sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1 H-pyrazol-5-olate, to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for... Agent: Bayer Pharma Aktiengesellschaft

20120129858 - Compounds, compositions and methods comprising pyridazine sulfonamide derivatives: The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set... Agent: Institute For Oneworld Health

20120129859 - Preparation of 1-(substituted benzyl)-5-trifluoromethyl-2(1h)pyridone compounds and salts thereof and their applications: 1-(substituted benzyl)-5-trifluoromethyl-2(1H)pyridone compounds and their pharmaceutical acceptable salts are disclosed. The preparation methods of the compounds and their salts and the use of the same for preparing the medicaments for treating fibrosis are also disclosed. New pyridine compounds and their salts are obtained from trifluoromethyl pyridone as starting material.... Agent:

20120129860 - Styrenyl derivative compounds for treating ophthalmic diseases and disorders: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders,... Agent: Acucela, Inc.

20120129861 - Compositions of dibromomalonamide and their use as biocides: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.... Agent:

20120129862 - Prokineticin 1 receptor antagonists: b

20120129863 - Chymase inhibitors:

20120129865 - Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt: Provided herein are (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt forms, including crystalline forms, and methods of their preparation. Pharmaceutical compositions comprising a (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt are also provided, as are methods of using (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt to treat a disease or condition, such as a cancer.... Agent: Biomarin Pharmaceutical Inc.

20120129864 - Substituted 1-alkylcinnolin-4(1h)-one derivatives, preparation thereof and therapeutic application of same: The subject of the present invention is compounds corresponding to the formula (I) in which: X represents a divalent (C2-C5)alkylene radical which is unsubstituted or substituted one or more times by an Alk group; R1 represents a phenyl, a naphthyl, a pyridyl, a 1-benzothienyl or a 1,3-benzodioxolyl; R2 represents a... Agent: Sanofi

20120129866 - Methods for preventing or treating metabolic diseases, inflammatory diseases, autoimmune diseases, allergic diseases, central nervous system diseases, cardiovascular diseases, homeostasis-related diseases or glaucoma: e

20120129867 - Inhibitors of protein kinases: The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a... Agent: Portola Pharmaceuticals, Inc.

20120129868 - Poly (adp-ribose) polymerase (parp) inhibitors: e

20120129869 - Phosphorylation and mutations of anaplastic lymphoma kinase as a diagnostic and therapeutic target in lung cancer: The invention related to the use of high-density loss of heterozygosity (LOH) mapping in lung adenocarcinoma to identify intragenic LOH and driver mutations in different domains of ALK resulted in enhanced tumor growth in xenografted mouse. Mutant (H694R and E1384K) ALKs showed activation of Y1604 ALK and downstream AKT, STAT3... Agent: Academia Sinica

20120129870 - Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor: The present invention is directed to piperidinyl and piperazinyl derivatives of formula (II) useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds for the treatment and/or prevention of disorders, diseases and conditions mediated... Agent:

20120129871 - Crystalline form of an inhibitor of mdm2/4 and p53 interaction: A crystalline form of (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, which is useful in the treatment of a disease or disorder associated with the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively,... Agent: Novartis Ag

20120129872 - Fused heteroaryl inhibitors of pro-matrix metalloproteinase activation: This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables A, Q, J, R1, R3, and R5 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.... Agent:

20120129873 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20120129874 - Salt forms of organic compound: The present invention relates to novel salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, a DPP-4 inhibitor and their use in pharmaceutical compositions useful in the treatment of type 2, diabetes, as well as their production.... Agent: Boehringer Ingelheim International Gmbh

20120129875 - Substituted quinazolines as fungicides: The present invention relates to a compound of formula (I) wherein the substituents have the definitions as defined in claim 1 or a salt or a N-oxide thereof, their use and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the... Agent: Syngenta Crop Protection, LLC

20120129876 - [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto: and polymorph forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing... Agent: Portola Pharmaceuticals, Inc.

20120129877 - Use of quinazoline derivatives for neurodegenerative diseases: The present invention relates to the use of a series of quinazoline-derived compounds to produce a medicament for the treatment and/or prevention of neurological and/or neurodegenerative diseases, such as Parkinson's disease or Alzheimer's disease. The present invention also relates to a method for the treatment and/prevention of neurological and/neurodegenerative diseases... Agent: Consejo Superior De Investigaciones Cientificas

20120129878 - Tablet: Provided is a tablet having a high content of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile (compound (A)) or a salt thereof as a pharmaceutically active component. A tablet containing compound (A) or a salt thereof, and a fluidizer, which has a compound (A) content of 35-50 weight %.... Agent: Takeda Pharmaceutical Company Limited

20120129879 - Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers: The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity... Agent:

20120129881 - Combinations of therapeutic agents for treating cancer: A combination of an mTOR inhibitor compound with one or more pharmaceutically active agents, for simultaneous, concurrent, separate or sequential use for preventing or treating a proliferative disease.... Agent:

20120129880 - Method for determining sensitivity to irinotecan and use thereof: The method for determining the sensitivity of a subject to irinotecan, SN-38, and/or a salt thereof includes measuring the expression levels of AMD1 gene, CTSC gene, EIF1AX gene, C12orf30 gene, DDX54 gene, PTPN2 gene, and TBX3 gene in a specimen, and calculating the best tumor response rate (%), overall survival... Agent: Saitama Medical University

20120129882 - Method for producing benzazoloquinolium (bqs) salts, using the composition as cellular markers, and using the biological activity of the composition: A synthesis procedure for benzazolo[3,2-a]quinolinium chloride salts and the inclusion of chloro-substituent, amino-substituent, and nitro-substituent resulting in several compounds wherein said procedures provides an increment in the compounds biological activity. The compounds are further used for intra cellular binding, cytotoxicity on malignant cells through apoptosis activation mediated by mitochondrial damage,... Agent:

20120129883 - Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation ofthe serotonin 5-ht6 receptor: s

20120129884 - Photochemotherapeutic heterocyclic agents having antiproliferative and antineoplastic activity: The present invention concerns the synthesis of new analogs of angelicins, pyrrolo [3,2-h]quinoline, for the treatment of pathologies having hyperproliferative character included those having neoplastic nature. The treatment is based on the combined action of pyrrolo [3,2-h]quinolines and UV-A light, through a clinical approach defined as PUVA (psoralen-UVA light). The... Agent: Universita Degli Studi Di Padova

20120129885 - (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofurn-2-carboxamide, novel salt forms, and methods of use thereof: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.... Agent: Targacept, Inc.

20120129886 - Metalloenzyme inhibitor compounds: The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.... Agent: Viamet Pharmaceuticals, Inc.

20120129887 - Compounds derived from artesunate, preparation process, pharmaceutical composition and use of the respective medicine: The present invention refers to new compounds represented by the general formula (I) where X is represented by the general formula (II) and Y is represented by the general formula (III). The relation X to Y may vary from 1:1 to 1:7. The radicals R1, R2, R3, R4, R5, and... Agent: Fundacao Oswaldo Cruz - Fiocruz

20120129888 - Libraries of n-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides for drug discovery: Novel compounds are continually sought after to treat and prevent disorders. The invention relates to N-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides useful for contributing to the search and identification of new lead compounds which can modulate the functional activity of a biological target.... Agent:

20120129889 - Non-competitive nmda receptor antagonists: Disclosed herein are non-competitive NMDA receptor antagonists having chemical structures similar to that of phencyclidine (PCP). These antagonists contain a polycyclic ring structure in place of the cycloalkyl ring of PCP. The antagonists also differ from PCP in that they include an electron withdrawing group, a hydroxyl group, or an... Agent:

20120129890 - Indole derivative or pharmaceutically acceptable salt thereof: [wherein A represents a benzene ring or the like; Y1 represents a C1-6 alkylene group; Y2 represents a single bond or the like; R1 represents a hydrogen atom, a C1-6 alkyl group or the like; R2 represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic ring... Agent: Kissei Pharmaceutical Co., Ltd.

20120129891 - Sulfone derivative: Provided are a compound having an excellent hypoglycemic action, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause an increase in the blood sugar level due to abnormal sugar... Agent: Daiichi Sankyo Company, Limited

20120129893 - Inhibition of raf kinase using substituted heterocyclic ureas: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.... Agent:

20120129892 - Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl)pyridine and their therapeutical uses: The present invention concerns novel pharmaceutical compositions of immethridine, in particular of novel pharmaceutically acceptable salts thereof, such as the dioxalate salt of immethridine, as well as its therapeutical uses and novel process of preparation.... Agent: Bioprojet

20120129894 - Alkoxy compounds for disease treatment: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD)... Agent: Acucela Inc.

20120129895 - Methods of treatment: The invention relates to combinations comprising a vascular disrupting agent (VDA) with IAP antagonists, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases.... Agent:

20120129896 - Thiazolidinedione analogues for the treatment of metabolic diseases: The present invention relates to thiazolidinedione analogues that are useful for treating hypertension, diabetes, and inflammatory diseases.... Agent: Metabolic Solutions Development Company

20120129897 - Bis heteroaryl inhibitors of pro-matrix metalloproteinase activation: This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables A, Q, J, R1, R3, and R5 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.... Agent:

20120129898 - Pharmaceutical compositions for poorly soluble drugs: The invention relates to solid dispersions of poorly soluble compounds formed by co-precipitation and hot melt extrusion, resulting in improved stability and bioavailability. The invention also relates to hot melt extrusion processes used to prepare such solid dispersions.... Agent:

20120129899 - Synergistic antimicrobial composition of 1,2-benzisothiazolin-3-one and tris(hydroxymethyl)nitromethane: A synergistic antimicrobial composition containing 1,2-benzisothiazolin-3-one and tris(hydroxymethyl)nitromethane.... Agent:

20120129900 - Dual-acting antihypertensive agents: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a... Agent: Theravance, Inc.

20120129901 - Triterpenoid derivatives useful as antiproliferative agents: Formula (I) and (II). The present invention relates to the use of a new lupane derivative of general formula (I) or (II), or a pharmaceutically acceptable salt, crystal form, complex, hydrate, or hydrolysable ester thereof, for preventing and/or inhibiting tumor growth and for treating cancer and other proliferative diseases, more... Agent:

20120129902 - 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists: r

20120129903 - Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetate, and uses thereof: Crystalline polymorphs and solid mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate are described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are provided.... Agent: Ardea Biosciences, Inc.

20120129904 - Liquid formulations of bendamustine: Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.... Agent: Cephalon, Inc.

20120129905 - Pharmaceutical composition: a

20120129906 - Modulators of s1p receptors: The present invention relates to novel diphenylethyne derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120129908 - Agent for the prophylaxis and treatment of highly pathogenic infectious diseases: The invention relates to an agent for the treatment and/or prophylaxis of highly pathogenic infectious diseases, such as highly pathogenic influenza A (in particular, subtypes H5 and H7) and severe acute respirator syndrome caused by the genotype IV coronavirus. The agent is in the form of glutaryl histamine or a... Agent:

20120129907 - Histidinol dehydrogenase inhibitors, and use thereof as medicaments: e

20120129909 - 2-amino-2-phenyl-alkanol derivatives, preparation thereof, and pharmaceutical compositions containing same: Ester derivatives of 2-amino-2-phenyl-alkanol of general formula (I) in which: R1 forms with R3 and the nitrogen and carbon atoms to which they are respectively attached, a heterocycle with 4 to 7 members, optionally substituted in the α position of the nitrogen atom by one or two Ra and Rb... Agent: Oroxcell

20120129922 - Docetaxel formulations with lipoic acid: Pharmaceutical formulations comprising docetaxel or a pharmaceutically acceptable salt thereof, one or more solubilizers, α-lipoic acid, TPGS, one or more hydrotropes, and optionally one or more agents having a pKa of about 3 to about 6. The pharmaceutical formulations are stable and substantially free of excipients that can cause severe... Agent:

20120129923 - Pharmaceutical co-crystals of quercetin: Disclosed herein is synergistic pharmaceutical co-crystals composition comprising Quercetin and an antidiabetic agent(s) as combination drug that have unique physical properties and biological activity which differ from the active agent in pure form. The invention further discloses process for preparation of the same and pharmaceutical compositions comprising these synergistic co-crystals.... Agent: Nutracryst Therapeutics Private Limited

20120129924 - Uses of sesquiterpene derivatives: The present invention relates to a pharmaceutical composition for preventing or treating hyperlipidemia, fatty liver, diabetes and obesity comprising a sesquiterpene derivative as an active ingredient. The sesquiterpene derivatives of the present invention leads to decrease in body fat weight, visceral fat weight and total cholesterol levels, triglyceride of plasma... Agent: Kwang Dong Pharm. Co., Ltd.

20120129927 - New anthraquinone derivatives: e

20120129926 - Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof: The invention relates to novel calcium-sensing receptor (CaSR) modulating trifluoromethylphenylene cyclopentylene compounds represented in formula (I) and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to... Agent: Leo Pharma A/s

20120129925 - Ship 1 modulators: The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.... Agent: The University Of British Columbia

20120129928 - Chlorine-free liquid microbicide treatment: The combination of the surfactant SDS with levulinic acid produces a synergistic effect in relation to the antimicrobial effectiveness of the individual compounds. Accordingly, this surprising synergy allows the formulation of compositions wherein the active agents are present at concentrations effective to reduce bacterial counts in liquids, including, but not... Agent: University Of Georgia Research Foundation, Inc.

20120129929 - Compound used to prevent diseases caused by aquaporin deficiency: A compound used to prevent diseases caused by aquaporin deficiency, which is 18β-Glycyrrhetinic acid derivative. Said compound can not only prevent diseases caused aquaporin deficiency, but be able to prevent aquaporin (AQP) production and enhance skin function. Since AQPs have many advantages in skin cells, e.g. promoting water and glycerine... Agent: Fu-jen Catholic University

20120129930 - Ketone compounds and compositions for cholesterol management and related uses: The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing... Agent: Esperion Therapeutics, Inc.

20120129931 - Caffeic acid derivatives and their use in improving neuronal cell viability: This invention relates to caffeic acid derivatives and improving viability of neuronal cells by contacting neuronal cells by caffeic acid derivatives as shown in the specification.... Agent: Chemigen

20120129932 - Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof: The invention concerns compositions comprising substituted 1,3-diphenylprop-2-en-1-one derivatives designed for therapeutic use. The inventive compositions are useful in particular for preventing or treating cardiovascular diseases, syndrome X, Ia restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative, dermatological diseases and disorders related to oxidative stress,... Agent: Genfit

20120129933 - Ceramide dimers and use thereof as pharmaceutical preparation or cosmetic preparation: The invention relates to ceramide dimers which are constructed from two ceramide molecules which are crosslinked to each other via their lipophilic end. The ceramide molecules thereby have at least one hydrophilic group at their hydrophilic end for increasing the hydration shell of the dimer. The ceramide dimers according to... Agent:

20120129934 - Methods for the treatment of senile dementia of the alzheimer's type: The present invention relates to the diagnosis, risk assessment, prevention, and treatment of Senile Dementia of the Alzheimer's Type (SDAT). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum. Subsets of these molecules are significantly altered in subjects with pathologically confirmed deposits of β-amyloid... Agent: Phenomenome Discoveries Inc.

20120129935 - Nutrition with lipids and non-digestible saccharides: The invention relates to a liquid nutrition comprising short chain fatty acyl chains and a non-digestible, fermentable saccharide. The composition is particular suitable for use as an infant nutrition. The composition is also suitable for treatment and/or prevention of gut barrier related disorders.... Agent: N.v. Nutricia

20120129936 - Antimicrobial compositions for use on food products: The present invention relates to antimicrobial compositions, and specifically antimicrobial compositions that are useful at sanitizing food products. The compositions of the present invention include octanoic acid, an acidulant, a coupling agent, an optional buffer, and water. The compositions of the present invention are composed of GRAS or food additive... Agent: Ecolab Usa Inc.

20120129938 - Anti-oomycetes: The present invention relates to the use of compounds of general formula (I) or of a salt thereof as anti-oomycetes and to a method for combating plant pathogens using said compounds.... Agent:

20120129937 - Solubilizer for cosmetic preparations: The present invention relates to a mixture comprising (i) one or a plurality of 1,2-alkane diols with 5 through 8 carbon atoms and (ii) one or a plurality of ammonium-, sodium- or potassium-Ralk-sarcosinates, wherein the structural element Ralk represents alkanoyl, alkenoyl or alkadienoyl with 12 through 22 carbon atoms, and... Agent: Symrise Ag

20120129939 - Polyamine inhibitors for the treatment and prevention of parkinson's disease: Disclosed herein are methods for treating a disease involving α-synucleic aggregation using (1) a compound which reduces the amount of polyamines in an amount effective to reduce α-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce α-synucleic aggregation; or (3) a compound which inhibits... Agent:

20120129940 - Methods of treating autism: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen.... Agent: Seaside Therapeutics, Inc.

20120129941 - Treprostinil treatment for interstitial lung disease and asthma: The present invention describes methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of interstitial lung disease or asthma, or a condition, such as pulmonary fibrosis, associated with interstitial lung disease or a condition associated with asthma. The invention also relates... Agent: United Therapeutics Corporation

20120129942 - Compositions and methods for treating fungal infection of the nail: A stable antifungal composition for topical application on a nail comprising a diol component, an organic acid component, a volatile vehicle, an antifungal agent and a keratolytic agent; the active compound and the keratolytic agent are soluble in the composition in the absence of said volatile vehicle, and wherein at... Agent: Moberg Derma Ab

20120129943 - Method of increasing or maintaining the reproductive performance of sows: The present invention relates to methods and feed compositions for increasing or maintaining the reproductive performance of sows. More particularly, the present invention relates to methods of increasing or maintaining the reproductive performance of sows by administering a biologically active compound during lactation, and food compositions comprising said biologically active... Agent: Pork Crc Ltd

20120129944 - Stabilized composition comprising at least one adrenergic compound: A stabilised composition comprising at least one adrenergic compound and at least one antioxidant selected from the group consisting of a bisulfite, a metabisulfite and a sulfite compound.... Agent: Alk Ag

20120129945 - Inhibitors of cognitive decline: Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods... Agent: Cognition Therapeutics, Inc.

20120129946 - Materials and methods for treating viral infections: The subject invention provides materials and methods for the prevention and/or treatment of viral infections. In a preferred embodiment, a cysteamine compound is administered via pulmonary administration to a subject to treat an influenza virus infection.... Agent:

20120129947 - Amino-alcohol analogues and uses thereof: This invention relates to amino-alcohol analogues and uses thereof in the treatment of diseases and disorders such as cancer, neurodegenerative and metabolic diseases and genetic storage diseases.... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.

20120129948 - Medical implant producing wear particles with benign body response: A substance, which contains anti-inflammatory substances, anti-microbial substances, anti-tumor substances, anti-viral substances, and/or bone stimulating substances, as an additive, can be added to an UHMWPE material for the production of a medical implant for imparting benign body response properties to the medical implant.... Agent: Smith & Nephew Orthopaedics Ag

20120129949 - Use of anthracene derivatives as anti-infectives: s

20120129950 - Antimicrobial compositions: A method for rapid surface sanitization is provided, where the method includes contacting the surface with an effective amount of an antimicrobial composition comprising at least about 50 wt. % of a C1-6 alcohol, based upon the total weight of the antimicrobial composition; and an efficacy-enhancing amount of a C1-10... Agent:

20120129952 - Non-caking salt composition, preparation process and use thereof: The present invention relates to a sodium chloride composition comprising an iron complex of tartaric acid wherein between 55 and 90% by weight of the tartaric acid is meso-tartaric acid. The present invention furthermore relates to a process to prepare such a sodium chloride composition and to the use of... Agent: Akzo Nobel Chemicals International B.v.

20120129951 - Palatable suspending vehicle for pharmaceutical ingredients: The invention relates to a liquid vehicle that can be used to create suspensions and/or solutions of liquid or powdered medications. The vehicle is thixotropic and has improved stability and rheologic characteristics. Vehicles of the invention include an aqueous medium and a suspending agent comprising a polysaccharide having at least... Agent: Gallipot, Inc.

20120129953 - Tingling and salivating compositions: A sensate composition comprises a salivating component, a tingling component and a flavor, the salivating component being formed of at least a mixture of citric, malic and succinic acid, or of their salts, and the tingling component being formed of an ingredient selected from the group consisting of Jambu oleoresin,... Agent: Firmenich Sa

20120129954 - Carboxymethylcellulose polyethylene glycol compositions for medical uses: Compositions comprising carboxypolysaccharides (CPS) including carboxymethyl cellulose (CMC) and polyethylene glycols (PEGs) are provided where the PEG is a PEG-epoxide covalently linked to the CPS. In certain embodiments, the PEG attaches to only one CPS, forming a decorated CPS. In other embodiments, bi-functional PEG molecules are attached to adjacent CPSs,... Agent:

20120129955 - Compositions comprising sulfonated estolides and alkyl ester sulfonates, methods of making them, and compositions and processes employing them: Compositions comprising sulfo-estolides and alkyl ester sulfonates are described. Detergent formulations, such as laundry detergents, softeners, and other materials, containing any of these materials are disclosed, as well as personal care formulations, hard surface cleaner formulations, and automatic dishwasher detergent formulations. Laundry methods employing these formulations are also disclosed. These... Agent:

20120129956 - Moisturizing compositions for lip: A water in oil emulsion lip treatment composition comprising at least one non-polar silicone oil, at least one non-polar organic oil, at least one amphiphilic organic emollient oil, at least one water in oil surfactant; and at least one oil in water surfactant.... Agent:

20120129957 - Analyzing the fmr1 gene: A method of screening a human for risk of malignancies is disclosed. The method may include isolating the human's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele, measuring the number of triple CGG repeats on each of the first and second alleles, wherein the... Agent:

  
05/17/2012 > 241 patent applications in 178 patent subcategories. archived by USPTO category

20120122762 - 186 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences, Inc.

20120122761 - Methods for detecting a polymorphism in the nfkb1 gene promoter: The present invention discloses a functional relationship between a recognized disease condition and a polymorphism in the nucleotide factor kappa B promoter (NFKB1). This relationship provides a platform for methods of altering promoter activity and for determining similar relationships between specific pathologies and identified polymorphisms. A statistically significant risk of... Agent: The Johns Hopkins University

20120122759 - Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography: Methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant are described, which methods comprise the sequential steps of: (a) passing the composition through an ion exchange membrane, where the polypeptide and the membrane have opposite charge, at operating conditions comprised of a buffer... Agent:

20120122760 - Novel lipids for transfection of nucleic acids: Cationic lipid compositions are provided that are useful for efficient delivery of macromolecules, such as nucleic acids, into a wide variety of eukaryotic cell types. Methods for using the compositions also are provided.... Agent:

20120122763 - Novel tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors: The present invention provides novel tetrahydrocarbazole compounds according to formula (I) as ligands of G-protein coupled receptors (GPCR) which are useful in the treatment and/or prophylaxis of physiological and/or pathological conditions in mammals mediated by GPCR or of physiological and/or pathological conditions which can be treated by modulation of these... Agent: Aeterna Zentaris Gmbh

20120122764 - Substituted carbamoylcycloalkyl acetic acid derivatives as nep: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, B, X, m and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of compounds of the invention,... Agent: Novartis Ag

20120122765 - Compounds and related methods for manipulating parp-1-dependent cell death: Apoptosis inducing factor (“AIF”) contains a PAR-binding motif (“PBM”) that binds to Poly(ADP-ribose) (“PAR”). Binding of PAR to AIF via the PBM is required for AIF release from the mitochondria to occur, and that this PAR-related release is a key step in the programmed cell death process known as parthanatos,... Agent:

20120122766 - Novel polypeptide having angiogenesis-inducing activity and antibacterial activity, and use thereof for medical purposes: Novel polypeptides which have an excellent angiogenesis-inducing activity and an excellent antibacterial activity and medical uses thereof are disclosed. The amino acid sequences of the novel polypeptides are shown in any one of SEQ ID NOs:1 to 6. These polypeptides have angiogenesis-inducing and antibacterial activities. Such polypeptides are useful for... Agent: Anges Mg, Inc.

20120122767 - Lactoferrin-based biomaterials for tissue regeneration and drug delivery: The invention provides biomatrix compositions comprising cross-linked lactoferrin, either alone or in combination with other organic or inorganic components. Also provided are methods of making and using the biomatrix compositions. As described herein, cross-linked lactoferrin biomatrix retains the bioactivities of the lactoferrin molecule. The biomatrix composition can act as a... Agent: University Of Connecticut

20120122768 - Alginate oligomers for use in overcoming multidrug resistance in bacteria: The invention provides a method of overcoming resistance to at least one antibiotic in a multidrug resistant bacterium, said method comprising contacting said bacterium with an alginate oligomer together with the antibiotic. The multidrug resistant bacterium may be on an animate or inanimate surface and both medical and non-medical uses... Agent: Algipharma As

20120122769 - Antisense antibacterial compounds and methods: Antibacterial antisense compounds and methods of their use in treating a Mycobacterium tuberculosis infection in a mammalian host are disclosed. The compounds include an antisense oligonucleotide conjugated to a carrier peptide that significantly enhances the antibacterial activity of the oligonucleotide. The antisense oligonucleotides contain 10-20 nucleotide bases and have a... Agent: Avi Biopharma, Inc.

20120122772 - Agent for suppressing elevation of blood gip concentration: An agent for suppressing elevation of blood GIP concentration and an agent for preventing or improving obesity, each of which contains a polyglutamic acid as an active ingredient.... Agent: Kao Corporation

20120122770 - Cell cycle arrest and apoptosis: The HIV-1 accessory gene vpr encodes a conserved 96-amino acid protein that is necessary and sufficient for the HIV-1-induced block of cellular proliferation and induction of apoptosis. Expression of vpr in CD4.sup.+ lymphocytes results in G2 arrest, followed by apoptosis. ATR, as a cellular factor that mediates Vpr-induced cell cycle... Agent:

20120122771 - Structure of the c-terminal region of the insulin receptor a-chain and of the insulin-like growth factor receptor a-chain: The present invention relates generally to structural studies of the insulin binding site of the insulin receptor (IR) and the insulin-like growth factor 1 receptor (IGF-1R). More particularly, the present invention relates to the crystal structure of the low affinity insulin binding site of the IR ectodomain comprising the C-terminal... Agent:

20120122773 - N-substituted-cyclic amino derivative: wherein R1a is optionally substituted C1-6 alkyl, etc.; R1m is hydrogen atom, etc.; G1, G2, G3 and G4 are (i), etc. ((i) G1 is —N(R1b)—, G2 is —CO—, G3 is —C(R1c)(R1d)—, and G4 is oxygen, etc.); R1b is optionally substituted C1-6 alkyl, etc.; R1c and R1d are each independently optionally... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20120122774 - Long-acting formulations of insulins: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.... Agent: Sanofi

20120122775 - Use of ultrarapid acting insulin: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.... Agent: Mannkind Corporation

20120122776 - Dpp-iv inhibitors for treatment of diabetes in pediatric patients: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in paediatric patients.... Agent: Boehringer Ingelheim International Gmbh

20120122777 - Diagnostic agent for ischemic heart disease risk group: The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive... Agent: Daiichi Pure Chemicals Co., Ltd.

20120122778 - Modified tgf-beta superfamily protein: The invention provides modified TGF-β family proteins having altered biological or biochemical properties, and methods for making them. Specific modified protein constructs include TGF-β family member proteins that have N-terminal truncations, “latent” proteins, fusion proteins and heterodimers.... Agent:

20120122779 - Method for site-specific polyvalent display on polymers: The present invention relates to novel complex peptidomimetic products comprising multiple homogeneous or heterogeneous pendant groups that are site-specifically positioned along a linear oligomer or polymer scaffold and methods of making thereof. More specifically, the invention relates to N-substituted glycine peptoid oligomers or peptoids and their use as substrates for... Agent:

20120122780 - Compounds, compositions and methods for modulating uric acid levels: Described herein are compounds useful in the reduction of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.... Agent: Ardea Biosciences Inc.

20120122781 - Peptide ligands of somatostatin receptors: Peptide derivatives, their stereoisomers, mixtures thereof and/or their pharmaceutically acceptable salts, a method of obtaining them, pharmaceutical compositions containing them and the use thereof for the treatment, prevention and/or diagnosis of those conditions, disorders and/or pathologies in which the sstr1, sstr2, sstr3, sstr4 and/or sstr5 somatostatin receptors are expressed.... Agent: Bcn Peptides, S.a.

20120122782 - Complexation of metal ions with polypeptides: Formulations and methods are provided for improving the stability upon exposure to aqueous media of polypeptides present in non-aqueous suspension vehicles. In particular aspects of the invention, formulations are provided that comprise a complex of a metal ion and a polypeptide suspended in a non-aqueous, biocompatible suspension vehicle. Aggregation of... Agent: Durect Corporation

20120122783 - Glucagon antagonists: Glucagon antagonists are provided which comprise amino acid substitutions and/or chemical modifications to glucagon sequence. In one embodiment, the glucagon antagonists comprise a native glucagon peptide that has been modified by the deletion of the first two to five amino acid residues from the N-terminus and (i) an amino acid... Agent: Indiana University Research And Techology Corporation

20120122784 - Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof: The invention relates to novel calcium-sensing receptor (CaSR) modulating substituted cyclopentylene compounds represented in formula I and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to... Agent: Leo Pharma A/s

20120122785 - Combination of a leucine source and an omega- 3 unsaturated fatty acid source for use in the treatment of hypercalcaemia: The present invention relates to a combination of a leucine source and at least one unsaturated fatty acid source for prophylactic or therapeutic treatment of hypercalcaemia. The invention further relates to a combination of a leucine source and at least one unsaturated fatty acid source for reducing or avoiding a... Agent: N.v. Nutricia

20120122786 - Use of polypeptide micromolecule mlif in preparing medicine for preventing and treating myocardial ischemia: Use of polypeptide micromolecule MLIF in preparing medicine for preventing and treating myocardial ischmia, where amino acid sequence of the polypeptide micromolecule MLIF is Met-Gln-Cys-Asn-Ser (SEQ ID NO:1).... Agent: The Second Military Medical University, Pla

20120122788 - E-polylysine conjugates and the use thereof: The present invention relates to ε-polylysine conjugates, in particular conjugates of ε-polylysine with compounds carrying carboxyl groups, and to the preparation and use thereof for targeting of the kidney.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120122787 - Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases: The present invention is directed to, inter alia, methods of treating or ameliorating an effect of a polycystic disease. This method include administering to a patient in need thereof an amount of a modulator of a histone deacetylase (HDAC) path-way, which is sufficient to treat or ameliorate an effect of... Agent:

20120122789 - Methods of reducing myocardial injury following myocardial infarction: The present invention discloses methods of reducing injury resulting from cardiovascular disease, such as myocardial infarction, and/or promoting myocardial repair. The methods include administering an ephrin and pharmaceutical compositions including ephrins to a subject. Kits useful for accomplishing the same are also provided.... Agent:

20120122790 - Methods for the treatment of x-linked hypophosphatemia and related disorders: The disclosure provides methods of treating X-linked hypophosphatemia, related bone demineralization and renal phosphate wasting disorders in a mammalian subject. The methods comprise administering to the subject an effective amount of a polyarginine peptide... Agent:

20120122791 - Substrate for cartilage cultivation using artificial collagen, and method for cartilage regeneration treatment using the substrate: Provided are a substrate for cartilage cultivation, which exhibits high safety and has a growth promoting effect on cartilage cells, and a method for cartilage regeneration treatment. The substrate for cartilage cultivation containing artificial collagen, in particular, an artificial collagen aqueous solution has a growth promoting effect on cartilage cells.... Agent: Jnc Corporation

20120122793 - S-protected cysteine analogs and related compounds: S-protected cysteine analogs and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS).... Agent: Promentis Pharmaceuticals, Inc.

20120122792 - S-t-butyl protected cysteine di-peptide analogs and related compounds: S-t-butyl protected cysteine di-peptide analogs and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS).... Agent: Promentis Pharmaceuticals, Inc.

20120122795 - Accelerated extension of axons: The present disclosure relates to methods and compositions for promoting the extension of a neural cell by increasing the expression of activity of cofilin in the cell. The increase can be local to the end of the neural cell in need of extension and the neural cell can be a... Agent: University Of Southern California

20120122794 - Compound and method for treatment of alzheimer's disease: An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the C-terminal domain of lung surfactant protein C precursor (CTproSP-C, “CTC”) from a mammal; and (ii) proteins comprising an amino acid sequence having at least 70% identity to... Agent: Alphabeta Ab

20120122796 - Cell permeable p53 recombinant protein, polynucleotide encoding the same, and anti-cancer composition containing the same as active ingredient: Disclosed are a cell-permeable p53 recombinant protein in which a macromolecule transduction domain (MTD) is fused to the tumor suppressor p53, a polynucleotide encoding the same, a recombinant expression vector for producing the same, and a pharmaceutical composition of the treatment of cancer, comprising the same. Having high cell permeability,... Agent: Procell Therapeutics Inc.

20120122797 - Peptidic compound and use of same: An object of the present invention is to provide a novel compound having an antitumor/anticancer effect. Specifically, the present invention provides a compound represented by Formula (I), a derivative thereof or a salt of the same. In Formula (I), R1 represents an alkyl group, an alkenyl group, a cycloalkyl group,... Agent: Keio University

20120122798 - Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog: Ovarian cancer is treated with conjugates of an anticancer agent and an Angiopep-2 polypeptide analog (i.e. a polypeptide comprising an ammo acid sequence at least 80% identical to Seq. ID NO:97). Such treatment includes utility in treating metastatic ovarian cancer and in treating patients who have previously exhibited resistance to... Agent: Angiochem Inc.

20120122799 - Cyclic peptide antitumor agents: Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.... Agent: Northwestern University

20120122800 - Long-acting dna dendrimers and methods thereof: This invention provides a unique composition which includes a DNA dendrimer combined with siRNA molecule. Further, methods of preparing a composition which includes a DNA dendrimer combined with a siRNA molecule, methods of protecting a DNA dendrimer siRNA complex against degradation in body fluids, methods of protecting a DNA dendrimer... Agent: Genisphere, LLC Hatfield, Pennsylvania

20120122801 - Mannose-6-phosphate receptor mediated gene transfer into muscle cells: The invention relates to glycoside-compound conjugates for use in antisense strategies and/or gene therapy. The conjugates comprise a glycoside linked to a compound, in which the glycoside is a ligand capable of binding to a mannose-6-phosphate receptor of a muscle cell. For example the cells are muscle cells of a... Agent: Prosensa B.v.

20120122802 - Animal protein-free pharmaceutical compositions: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.... Agent: Allergan, Inc.

20120122803 - Alpha-conotoxin mii analogs: The invention relates to novel conopeptides and/or novel uses of conopeptides. The conopeptides of the invention are analogs of α-Conotoxin MII that are selective for α6-containing nAChRs as described herein.... Agent: University Of Utah Research Foundation

20120122805 - Pesticidal compositions: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.... Agent: Dow Agrosciences LLC

20120122804 - Substituted quinobenzoxazine analogs: e

20120122806 - Method of lowering glycemic index of foods: A method of delaying digestion by an animal or a human of carbohydrates in food, comprising administering an effective amount of one or more flavonoids to the animal or human in conjunction with the food, wherein the flavonoids are selected from luteolin, apigenin, tricin and their pharmaceutically acceptable analogues and... Agent: Queen Bioactives Pty Ltd.

20120122807 - Cardiac glycoside analogs in combination with emodin for cancer therapy: A method and medicine for treating leukemia or other cancer includes administering to a patient diagnosed with leukemia or other cancer a treatment regimen that includes periodic doses of a combination of emodin and digoxin.... Agent: Sirbla Ltd.

20120122808 - Macrolide synthesis process and solid-state forms: Described are methods for making macrolides, and, in particular, a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, among other uses, may be used to make macrolides. Also described... Agent: Intervet International B.v.

20120122809 - Antibacterial aminoglycoside analogs: s

20120122954 - Antisense oligomers targeting pcsk9: The present invention relates to oligomer compounds (oligomers), which target PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for the treatment of certain medical disorders, such as hypercholesterolemia and related disorders.... Agent:

20120122953 - Methods for enhancing utrophin production via inhibition of microrna: This invention provides a method for enhancing utrophin protein production in a cell by inhibiting an utrophin microRNA molecule. Moreover, the invention provides that methods for enhancing utrophin protein production in a muscle cell are used for treating a muscular dystrophy and/or other myopathies.... Agent:

20120122956 - Methods for inhibiting angiogenesis with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin: The present invention relates to methods of inhibiting angiogenesis in mammals. The present invention includes administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to the mammals in need thereof. The present invention also relates to methods of treating a disease associated with angiogenesis in mammals by administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to the... Agent: Enzon Pharmaceuticals, Inc.

20120122960 - Organic compositions to treat beta-enac-related diseases: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.... Agent: Novartis Ag

20120122957 - Regulation of aging by modulation of mitochondrial function: The invention relates to the field of longevity enhancement. More particularly, the invention provides compositions and methods relating to modulation of mitochondrial function. In certain embodiments, the invention provides methods and related compositions for the enhancement of longevity in an animal, comprising inhibition of one or more electron transport chain... Agent: The Salk Institute For Biological Studies

20120122961 - Rnai inhibition of serum amyloid a for treatment of glaucoma: RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.... Agent: Novartis Ag

20120122959 - Targeting micrornas for metabolic disorders: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the... Agent: Eth Zurich

20120122958 - Transcriptional repression leading to parkinson's disease: Parkinson's disease is caused by the preferential loss of substantia nigra dopamine neurons. A Parkin Interacting Substrate, PARIS (ZNF746) is identified. The levels of PARIS are regulated by the ubiquitin proteasome system via binding to and ubiquitination by the E3 ubiquitin ligase, parkin. PARIS is a KRAB and zinc finger... Agent:

20120122955 - Use of lna apob antisense oligomers for the treatment of acute coronary syndromes: The present invention relates to the use of LNA antisense apoB oligonucleotides for the treatment of acute coronary syndrome.... Agent:

20120122963 - Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection... Agent:

20120122962 - Modified small interfering rna molecules and methods of use: The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method... Agent: Novartis Vaccines And Diagnostics, Inc.

20120122810 - Fused pentacyclic polyethers: e

20120122811 - Bicyclic nucleosides and nucleotides as therapeutic agents: The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.... Agent: Biota Scientific Management Pty Ltd

20120122812 - Anti-aging agent: e

20120122813 - Composition containing oligosaccharides for the treatment/prevention of infections: The present invention relates to oligosaccharide mixtures and their use in the treatment and/or prevention of infections, and in particular, for reducing the severity of childhood infection or in the treatment and/or prevention of childhood infection.... Agent: N.v. Nutricia

20120122814 - Composition for prevention or treatment of hypertrophic scars or keloids: e

20120122815 - Composition for treating dry eye and related methods of manufacture and methods of use: The present invention is directed to a composition for treating dry eye comprising, in one embodiment, carboxymethylcellulose and a polyol. Such compositions have been found to alleviate the symptoms of dry eye and remain in the eye for a long period of time.... Agent:

20120122816 - Compositions and methods for organ preservation: The invention relates to reducing, preventing or reversing organ damage, reducing and/or preventing stem cell damage and/or death, enhancing organ preservation and/or survival, or enhancing stem cell preservation and/or survival comprising administering a compound of formula A, a compound of any one of formulae 1-49 or I-III, a lipoxin compound,... Agent: Resolvyx Pharmaceuticals, Inc.

20120122819 - Guanine riboswitch binding compounds and their use as antibiotics: The present invention includes novel compounds and pharmaceutically acceptable formulations of said compounds which exhibit antibiotic activity against microorganisms bearing a guanine riboswitch that controls the expression of the guaA gene, including organisms which are resistant to certain antibiotic families, and which are useful as antibacterial agents for treatment or... Agent: Socpra - Sciences Et Genie S.e.c.

20120122817 - Heterocyclic urea derivatives and methods of use thereof: Compounds of formula (IA) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent: Astrazeneca Ab

20120122818 - Lung-targeted drugs: Methods and compositions are provided for treating lung diseases, including but not limited to infections and small cell and non-small cell lung cancer, by conjugating a drug of interest to glycerol ethers or glycerol phosphate ethers.... Agent: The Regents Of The University Of California

20120122820 - Prodrugs and the use thereof: The present application relates to prodrug derivatives of 2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}thio)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders.... Agent: Bayer Schering Pharma Aktiengesellschaft

20120122821 - Steroid-containing sustained release intraocular implants and related methods: Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may... Agent: Allergan, Inc.

20120122823 - Aqueous drug delivery system: Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and... Agent: Bev-rx. Inc.

20120122822 - Compositions for reducing beta-amyloid-induced neurotoxicity comprising beta-secretase inhibitor: Disclosed are a composition for reducing beta amyloid-induced neurotoxicity by inhibiting β-secretase activity, comprising a dibenzofuran derivative, and a method for preparing the same. Further disclosed is that the combination of the dibenzofuran derivative with a γ-secretase inhibitor or an anti-inflammatory agent shows higher activity with respect to reducing beta... Agent: Phloronol, Inc.

20120122824 - Reduction of side effects from aromatase inhibitors used for treating breast cancer: The present invention is directed generally to pharmaceutical compositions, methods, and kits for improving side effects associated with aromatase inhibitor treatment in a subject diagnosed with breast cancer. More specifically, the present invention provides compositions, methods, and kits comprising an aromatase inhibitor and an androgenic agent.... Agent: Chavah Pty Ltd

20120122826 - Novel quinuclidine derivatives and medicinal compositions containing the same: The invention provides 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide in combination with a steroid, and methods of using it for treatment of respiratory disorders.... Agent:

20120122825 - Use of picoplatin to treat prostate cancer: The invention provides a method of treatment of metastatic hormone-refractory prostate cancer involving substantially as concurrent administration of picoplatin and docetaxel. Prednisone may also be administered. Dosages and dosing regimens are provided.... Agent: Poniard Pharmaceuticals, Inc.

20120122827 - Novel derivatives of cholest-4-en-3-one oxime, pharmaceutical compositions containing them and preparation method: or one of its esters and/or of its addition salts with pharmaceutically acceptable acids, particularly as a cytoprotective drug, preferentially a cardioprotective and/or neuroprotective drug, the compounds of formula I wherein R is R2, R3, R4, R5 or R6 as novel compounds as well as their preparation method and use.... Agent: Trophos

20120122828 - Method for on-demand contraception: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.... Agent: Laboratoire Hra Pharma

20120122829 - Pharmaceutical composition for transdermal or transmucous administration: The present invention relates to a novel pharmaceutical composition for transdermal or transmucous administration of at least one active substance, and comprising especially a fatty acid as a percutaneous absorption promoter, at least one alcoholic vehicle and also a stabilizer capable of stabilizing the fatty acid in the said pharmaceutical... Agent: Besins Healthcare Luxembourg Sarl

20120122830 - Pregnenolone sulfate for the treatment of neurologic disorders: The disclosure relates, in part, to methods of using pregnenolone sulfate (PREGS) to protect against the neurotoxicity of the β-amyloid peptide Aβ1-42. The disclosure also provides methods of using pegnanolone sulfate for treating neurologic disease or dysfunction. The disclosure further provides of using pegnanolone sulfate methods for stimulating or promoting... Agent: King Faisal Specialist Hospital & Research Centre

20120122831 - Method and device for rapid detection of bacterial antibiotic resistance/susceptibility: Described herein is a method and a device for expediting delivery of an agent to a damaged bacterial cell. In one embodiment, the methods and devices are useful for screening candidate antibiotics. In another embodiment, the methods and devices described herein are used to determine susceptibility of bacteria to an... Agent: Trustees Of Boston University

20120122832 - Method of making cefquinome particles: Disclosed is a process for the production of particles of a cefquinome acid addition salt, preferably cefquinome sulfate particles, by precipitation of cefquinome acid addition salt, preferably the sulfate, from a cefquinome betaine solution, wherein acid, preferably sulfuric acid, is added to the betaine solution. According to the invention the... Agent:

20120122833 - Deuterium-enriched meropenem: The present application describes deuterium-enriched meropenem, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20120122834 - Small molecule cd4 mimetics and uses thereof: The invention provides for compounds of formula I: wherein Z is absent or (CRARB)nW; each RA and RB is independently (i) H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, haloalkyl, each of which may be optionally substituted; (ii) OH, ORc, NH2, NHL, NRcRc, SH, S(O)mRc; or (iii) RA... Agent: Johns Hopkins University

20120122835 - Poly (adp-ribose) polymerase (parp) inhibitors: in which R1, R2, R3, R4, R5, R6, R7, X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and... Agent: Takeda Pharmaceutical Company Limited

20120122836 - Polymorphic form of 1-(4--2-ethyl-benzyl)-azetidine-3-carboxylic: This invention relates to a novel crystalline form (Form A) of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this crystalline form, to processes for forming it and to its use in medical treatment.... Agent:

20120122838 - Heterocyclic compounds and uses thereof: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.... Agent:

20120122837 - Inhibitors of fatty acid binding protein: The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance... Agent:

20120122839 - Novel pyrrolidin-2-ones: Compounds of formula (I) or (Ia) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compounds of formula (I) or (Ia) can be used to decrease the side effects from cytotoxic... Agent: Priaxon Ag

20120122841 - Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell has undergone an... Agent: Osi Pharmaceuticals, LLC

20120122840 - Compounds and therapeutic uses thereof: The invention relates to compounds, pharmaceutical compositions, and uses thereof, including therapeutic uses thereof, such as methods useful for treating cancer.... Agent: Myrexis, Inc.

20120122842 - Nampt and rock inhibitors: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.... Agent: Abbott Laboratories

20120122844 - Method of treating contrast-induced nephropathy: s

20120122845 - Method for the production of bioadhesive compact matrices: A method for the preparation of a bioadhesive compact matrix, which comprises the preparation of a uniform mixture of powders comprising one alkylcellulose or one hydroxy alkylcellulose and a non-water-soluble, water-swellable cross-linked polycarboxylic polymer; the preparation of compressed units starting from such powder mixture by direct compression and finally the... Agent:

20120122843 - Compounds and their use for treatment of amyloid beta-related diseases: The present invention relates to novel compounds of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compounds, processes for making said compounds, and their use as medicaments for treatment and/or prevention of Aβ-related diseases.... Agent: Astrazeneca Ab

20120122846 - Furo[3,2-d]pyrimidine compounds: pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative... Agent: Abbott Laboratories

20120122847 - Aurora kinase modulators and method of use: wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase... Agent: Amgen Inc.

20120122848 - (+)-3-hydroxymorphinan derivatives as neuroprotectants: A novel (+)-3-hydroxymorphinan derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating a neurodegenerative disease, are provided.... Agent: Green Cross Corporation

20120122850 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, m, s, t, W, Z, Ar, R1, R2, R3, R6, and R7 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of... Agent: Theravance, Inc.

20120122849 - Pkm2 modulators for use in the treatment of cancer: Compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds in the treatment of cancer.... Agent:

20120122851 - Pharmaceutical preparation and delivery system: The present invention relates to unique delivery systems and the use of an imidazobenzodiazepine derivative, such as flumazenil either alone or in combination with other receptor antagonists in the treatment of disease or medical disorders.... Agent: Palmaya Pty Ltd

20120122852 - Tricyclic n-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use: e

20120122853 - Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals: Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals The invention relates to annelated N-heterocyclic sulfonamides with oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the... Agent: Sanofi-aventis

20120122854 - Carbocyclic fused cyclic amines: n

20120122855 - Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity: The present invention features benzoxazines, benzothiazines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for... Agent: Neuraxon, Inc.

20120122856 - Liquid termiticide compositions of pyrethroids and neonicitinoids: The present invention relates to liquid termiticide compositions comprising a pyrethroid and a neonicotinoid selected from the group consisting of imidacloprid, nithiazine, thiamethoxam, dinotefuran, nitenpyram, thiacloprid and clothianadin, these compositions result in an increase in termite mortality at low application rates and a continuous chemical bather of a termiticide in... Agent: Fmc Corporation

20120122857 - Heterobicyclic carboxamides as inhibitors for kinases: The invention relates to novel compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the... Agent: Novartis Ag

20120122858 - Lactam compounds and their use as pharmaceuticals: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or... Agent: Incyte Corporation

20120122862 - Arginine derivatives with np-i antagonistic activity: The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.... Agent:

20120122861 - Bicyclic amide derivatives for enhancing glutamatergic synaptic responses: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in cognitive abilities related to memory impairment, such... Agent: Cortex Pharmaceuticals, Inc.

20120122859 - Methods of using diaminopyrimidine as p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases: i

20120122860 - Solid forms of sulfonamides and amino acids: Solid forms of phenyl sulfonamide compounds of formula (I) active on protein kinases, including Raf protein kinases, are described, as well as methods of using such solid forms to treat diseases and conditions associated with activity of protein kinases, e.g. Raf protein kinases, including pain, polycystic kidney disease, melanoma and... Agent: Plexxikon, Inc.

20120122864 - Inhibitors of hcv ns5a: Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.... Agent: Presidio Pharmaceuticals, Inc.

20120122863 - Quinazolinedione chymase inhibitors: Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving Chymase.... Agent: Boehringer Ingelheim International Gmbh

20120122865 - Isoindoline compounds and methods of their use: Provided herein are isoindoline compounds, pharmaceutical compositions comprising one or more of such compounds, and methods of their use for treating, preventing, or managing various diseases.... Agent:

20120122866 - Topical pharmaceutical composition including rel-n-[6-[(2r,6s)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide: The present invention relates to pharmaceutical compositions of 2-Methyl-4′-trifluoromethoxy-biphenyl-3-carboxylic acid [6-(cis-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide, to the use of such compositions in therapeutic applications and to methods for manufacturing such compositions.... Agent: Novartis Ag

20120122868 - Apaf-1 inhibitor compounds: Derivatives of 2,5-piperazinedione of formula (I) are apoptotic peptidase activating factor 1 (Apaf-1) inhibitors, therefore they are useful as active pharmaceutical ingredients for the prophylaxis and/or treatment of a pathological and/or physiological condition associated with an increase of apoptosis.... Agent: Laboratorios Salvat, S.a.

20120122867 - Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases: The invention concerns compounds of Formula (I): wherein L1, R1, R2, R3, R4 and X are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of disease, for example cancer.... Agent:

20120122869 - Trizaole compounds that modulate hsp90 activity: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising... Agent: Synta Pharmaceuticals Corp.

20120122870 - Treatment of ischemia-reperfusion injury: Ischemia-reperfusion injury remains a primary cause of morbidity and mortality in individuals who experience disruption of normal blood flow to one or more major organs. For example, there are no clinically proven strategies that prevent acute renal failure following cardiac surgery. The present invention provides a variety of methods for... Agent: Apogee Biotechnology Corporation

20120122871 - Oligomer-containing substituted aromatic triazine compounds: The invention relates to (among other things) oligomer-containing substituted aromatic triazine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.... Agent: Nektar Therapeutics

20120122872 - Treatment or prevention of fungal infections with pdk1 inhibitors: Provided are methods of treating or preventing a fungal infection in a subject. The methods comprise identifying a subject with or at risk of developing a fungal infection and administering to the subject a therapeutically effective amount of an inhibitor or a fungal phosphoinositide-dependent kinase 1 (PDK-1) or a homolog... Agent: University Of Rochester

20120122873 - Amino derivatives of dihydro-1,3,5-triazine used in the treatment of ischemia and/or reperfusion related diseases: The invention relates to amino derivatives of dihydro-1,3,5-triazine, used for the treatment and/or prevention of diseases induced by ischemia and/or reperfusion, notably cardiac and renal complications.... Agent: Poxel

20120122874 - Combination of a sedative and a neurotransmitter modulator, and methods for treating depression: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is... Agent: Sunovion Inc.

20120122877 - Compositions for treating bacterial infections: The present invention is antibiotic compositions having the ability to disrupt a MazEF complex in S. aureus. The compositions also have the ability to inhibit growth of S. aureus and as such are useful as antibiotic compounds.... Agent: Trustees Of Dartmouth College

20120122876 - Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes: The present invention relates to pyridopyrazinone derivatives of formula (I), wherein X, Y, Z1 W, A and R1 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyridopyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies... Agent:

20120122875 - Salts of methyl (r)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylate: The pharmaceutically acceptable salts of methyl (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylate, their preparation methods and their use for preparing anti-diabetic medicaments are disclosed.... Agent: Jiangsu Hengrui Medicine Co., Ltd.

20120122878 - Combination products: The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor.... Agent:

20120122879 - Compounds useful as protein kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20120122880 - Thioxanthene derivatives for the treatment of infectious diseases: The claimed subject matter is directed to certain thioxanthene derivatives and phenothiazine derivatives suitable for use as anti-infective agents, in particular, for the treatment of infectious diseases. The claimed subject matter furthermore relates to compositions including said anti-infective agents.... Agent: Bkg Pharma Aps

20120122881 - Formulation of quinazoline based egfr inhibitors containing a zinc binding moiety: The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a β-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their... Agent: Curis, Inc.

20120122882 - Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors: Substituted pyrrolo-pyrimidine derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a dysregulated protein kinase activity, like... Agent: Nerviano Medical Sciences S.r.l.

20120122883 - New salts: The present invention relates to new crystalline salt forms of flibanserine which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.... Agent: Boehringer Ingelheim International Gmbh

20120122884 - Compounds useful as inhibitors of atr kinase: e

20120122885 - Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use: Compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.... Agent:

20120122886 - Thiadiazole-substituted arylamides as p2x3 and p2x2/3 antagonists: m

20120122887 - Solid state forms of a potent hcv inhibitor: This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:... Agent: Boehringer Ingelheim International Gmbh

20120122888 - Potassium channel modulators: i

20120122891 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing... Agent: Neurocrine Biosciences, Inc.

20120122890 - Potassium channel modulators: e

20120122889 - Small molecule inhibitors of necroptosis: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I)-(VIII) and by Compounds (I)-(I), (13)-(26), (27)-(33), (48)-(57), and (58)-(70). These necrostatins are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of... Agent: President And Fellows Of Harvard College

20120122892 - Chemical compounds: e

20120122894 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20120122893 - Methods of treating cancer: Described are methods and compositions for treating epithelial tumors with a folate-vinca conjugate in combination with at least one other chemotherapeutic agent in which the tumors include ovarian, endometrial or non-small cell lung cancer tumors, including platinum-resistant ovarian tumors and platinum-sensitive ovarian tumors.... Agent:

20120122895 - 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors: The present invention provides 5,6-bicyclic heteroaryl-containing urea compounds of Formula I or II and use of the same for treating conditions mediated by protein kinase such as VEGFR2, c-Met, PDGFRβ c-Kit, CSF1R, or EphA2.... Agent:

20120122896 - 2,1,3-benzoxadiazol derivatives for the inhibition of influenza a and b virus and respiratory syncytial virus replication: A 2,1,3-benzoxadiazole compound as a medicament according to the invention is one of the following compounds: 4-[(4-methoxybenzyl)thio]-7-nitro-2,1,3-benzoxadiazole, 2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)thio]ethyl 4-methoxybenzene-1-sulfonate, 4-[(4-methylphenyl)thio]-7-nitro-2,1,3-benzoxadiazole, 4-[(2,4-dichlorophenyl)thio]-7-nitro-2,1,3-benzoxadiazole, 2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)thio]ethan-1-ol, 4-[(4-methylbenzyl)thio]-7-nitro-2,1,3-benzoxadiazole, 4-[(4-fluorophenyl)thio]-7-nitro-2,1,3-benzoxadiazole, 4-[(3-chlorophenyl)-thio]-7-nitro-2,1,3-benzoxadiazole, 2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)thio]ethyl-4-methoxy-benzoate, 5-[4-(tert-butyl)-1,3-thiazol-2-yl]-2,1,3-benzoxadiazole, N-benzyl-4-nitro-2,1,3-benzoxadiazol-5-amine, 4-nitro-7-(phenylmethylsulfanyl)-2,1,3-benzoxadiazole, 4-nitro-7-(phenylmethylsulfonyl)-2,1,3-benzoxadiazole, 2-(hydroxymethyl)-5-[6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)sulfanyl]purin-9-yl]oxolane-3,4-diole, or 2-[2-amino-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)sulfanyl]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol; or a physiologically tolerable salt, solvate, or physiologically functional derivative thereof. Said compounds are particularly advantageous for... Agent: Pike Pharma Gmbh

20120122897 - Methods of treating patients suffering from movement disorders: Methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof and methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. Also, methods and compositions for treating... Agent: Kyowa Hakko Kirin Co., Ltd.

20120122899 - Piperidinone carboxamide azaindane cgrp receptor antagonists: The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these... Agent: Merck Sharp & Dohme Corp.

20120122900 - Piperidinone carboxamide azaindane cgrp receptor antagonists: The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these... Agent: Merck Sharp & Dohme Corp.

20120122901 - Pyrrolo[2,3-d]pyrimidine compounds: Described herein is pyrrolo{2,3-d}pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing this compounds, and methods for the preparation of these compounds.... Agent: Pfizer Inc.

20120122898 - Solid forms of 3-(4-(aminomethyl)-1-(5-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate: Solid forms of 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate and salts thereof are disclosed. Methods of its use to treat diseases and disorders of the eye are also disclosed.... Agent:

20120122903 - 1-h-quinazoline-2, 4-diones for use in the treatment of neuronal ceroid lipofuscinosis: The invention concerns the use of competitive AMPA receptor antagonists for the treatment, prevention or delay of progression of neuronal ceroid lipofuscinosis.... Agent:

20120122902 - Pyrimidine derivative, preparation method and use thereof: e

20120122904 - Solid forms of (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid: Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid and salts thereof are disclosed. Pharmaceutical dosage forms and methods of their use are also disclosed.... Agent:

20120122905 - Novel gpr 119 agonists: The present invention relates to novel GPR 119 agonists of the general Formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, stereoisomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of the invention, pharmaceutical compositions containing the compounds and to methods for treating... Agent: Cadila Healthcare Limited

20120122906 - Novel sulfonamide derivative and pharmaceutical product containing same: Disclosed is a novel compound which has both angiotensin II receptor antagonist activity and PPARγ activating activity, and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, kidney diseases, arteriosclerosis, inflammatory diseases, type 2 diabetes, diabetic... Agent: Kowa Company, Ltd.

20120122907 - Novel pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors: The present invention relates to novel compounds of Formula (I), wherein M, P, X1, (A)m and (B)n are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other... Agent:

20120122908 - Novel c-4 substituted retinoids: C-4 substituted retinoic acid analogs, synthesis methods of C-4 substituted retinoic acid analogs and methods of using C-4 substituted retinoic acid analogs to treat various cancers and dermatological diseases and conditions. The C-4 substituted retinoic acid analogs include C-4 all-trans retinoic acid (ATRA) and 13-cis retinoic acid (13-CRA) analogs. The... Agent: University Of Maryland

20120122910 - Method of treating cancer using a survivin inhibitor: Disclosed herein are methods of treating cancer by administering to a patient a small molecule inhibitor of Survivin. Also disclosed herein are methods of inhibiting Survivin dimerization in a patient by administering a compound of formula (I), (II), (III), or (IV). Methods of inducing cell cycle arrest in cancer cells,... Agent: The Trustees Of The University Of Pennsylvania

20120122912 - Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis;... Agent:

20120122911 - Piperidinone carboxamide azaindane cgrp receptor antagonists: The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these... Agent: Merck Sharp & Dohme Corp.

20120122909 - Spiro-oxindole compounds and their uses as therapeutic agents: wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions,... Agent: Xenon Pharmaceuticals Inc.

20120122913 - Combination of curcuminoids and mtor inhibitors for the treatment of tauopathies: Methods, uses, compositions, combinations and kits relating to the decrease of Tau protein levels, and prevention and/or treatment of diseases or disorders associated with Tau protein (Tauophathies), such as Alzheimer's disease, using a curcuminoid and a mammalian target rapamycin (mTOR) inhibitor, are described.... Agent: Institut National De La Recherche Scientifque

20120122914 - Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives: The present invention relates to a sustained-release composition containing 2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof as an active ingredient, preparation thereof and the compound. The composition is suitable for oral administration by one time per day, and achieves the peak plasma concentration at 1.0 to 3 hours after oral... Agent: Institute Of Pharmacology And Toxicology Academy Of Military Medical Science P.l.a.china

20120122915 - Crystalline forms of palonosetron hydrochloride: The present invention provides crystalline forms of Palonosetron hydrochloride, processes for their preparation and pharmaceutical compositions containing such crystalline forms of Palonosetron HCl.... Agent:

20120122917 - Method for treatment of hiv and diseases of immune dysregulation: This invention discloses cannabinoid derivatives and pharmaceutical uses thereof.... Agent:

20120122916 - Screening molecules with anti-prion activity: kits, methods and screened molecules: The invention concerns screening molecules with anti-prion activity. More particularly, it concerns kits for screening molecules with anti-prion activity characterized in that they comprise in combination a [PSI+], phenotype yeast, an antibiogram and an agent for purifying prions at sub-efficient doses, said yeast including the ade1-14 allele of the ADE1... Agent: Universite Victor Segalen Bordeaux 2

20120122918 - Antibacterial agents: e

20120122919 - Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist: The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition, which is intended for the treatment of pathologies linked to gastric hyperacidity, comprises a combination of tenatoprazole and one or more histamine H2-receptor antagonists preferably selected from cimetidine, ranitidine, famotidine and nizatidine. The invention is particularly suitable for... Agent: Sidem Pharma

20120122920 - Libraries of n-substituted-n-phenylethylsulfonamides for drug discovery: New compounds are continually being sought for the treatment and prevention of disorders. The invention relates to N-substituted-N-phenylethylsulfonamides libraries which can be used in the search for, and identification of, new lead compounds that could modulate the functional activity of a biological target.... Agent:

20120122922 - Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide: Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein.... Agent: Vertex Pharmaceuticals Incorporated

20120122921 - Process for making modulators of cystic fibrosis transmembrane conductance regulator: a

20120122923 - Dual molecules containing a peroxide derivative, their synthesis and therapeutic uses: The invention concerns dual molecules corresponding to formula (I): in which: A represents a molecular residue with antimalarial activity of formula (IIa) or (IIIa) or a residue facilitating bioavailability; B represents a cycloalkyl group potentially substituted, or B represents a bi- or tricyclic group capable of being substituted, or B... Agent: Centre National De La Recherche Scientifique (c.n.r.s.)

20120122924 - Nampt inhibitors: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.... Agent: Abbott Laboratories

20120122925 - Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm): The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of hypertrophic cardiomyopathy, as well as to a method of treating HCM, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat... Agent: Heart Metabolics Limited

20120122926 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, m, n, q, r, W, Z1, Ar1, Z2, Y, R1, R2, and R3 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods... Agent: Theravance, Inc.

20120122927 - 3 or 4-substituted piperidine compounds: e

20120122928 - Heteroarylpiperidine and -piperazine derivatives as fungicides: in which the symbols A, X, Y, L1, L2, G, Q, p, R1, R2 and R10 are each as defined in the description, and salts, metal complexes and N-oxides of the compounds of the formula (I), and the use thereof for controlling phytopathogenic harmful fungi, and processes for preparing the... Agent: Bayer Cropscience Ag

20120122929 - Heteroarylpiperidine and -piperazine derivatives as fungicides: in which the symbols A, X, Y, L1, L2, G, Q, p, R1, R2 and R10 are each as defined in the description, and salts, metal complexes and N-oxides of the compounds of the formula (I), and the use thereof for controlling phytopathogenic harmful fungi and processes for preparing compounds... Agent: Bayer Cropscience Ag

20120122930 - 1h-benzimidazole-5-carboxamides as anti-inflammatory agents: There are provided compounds of formula (I), wherein R1, R6, R8, Q2, Q3, Q3a, Q4, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family... Agent: Boehringer Ingelheim International Gmbh

20120122931 - Indole derivative or pharmaceutically acceptable salt thereof: [wherein A represents a benzene ring or the like; Y represents a C1-6 alkylene group or the like; RN represents a hydrogen atom or a C1-6 alkyl group; R1 represents a hydrogen atom, a C1-6 alkyl group or the like; R2 represents a phenyl group which may have a substituent,... Agent: Kissei Pharmaceutical Co., Ltd.

20120122932 - Methods and compositions for controlling ectoparasites: A method for inhibiting hatching of an ectoparasite egg, the method comprising exposing the ectoparasite egg to at least one metal chelating agent and/or metalloprotease inhibitor, wherein the metal chelating agent is a compound comprising at least two heteroatoms able to simultaneously coordinate with a metal ion, at least one... Agent: Hatchtech Pty Ltd.

20120122933 - Compounds: The present invention relates to a novel crystalline form of esomeprazole sodium salt. Further, the present invention also relates to the use of the novel crystalline form for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of the novel crystalline form.... Agent:

20120122934 - 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating... Agent:

20120122935 - Compositions and methods for treating necrotizing enterocolitis: The present invention relates to a method for treating or preventing necrotizing enterocolitis (NEC) in a human neonate in need thereof, comprising administering to the neonate a pharmaceutically effective amount of a composition comprising a poly(ADP-ribose) synthetase/polymerase (PARP) inhibitor. Also contemplated herein is an infant food or treatment composition comprising... Agent: Nationwide Children's Hospital, Inc.

20120122936 - Leave-on nonsolid skin conditioning compositions containing 12-[(12-hydroxyoctadecanoyl)oxy] octadecanoic acid: Leave-on non-solid skin conditioning compositions containing 12-[(12-hydroxyoctadecanoyl)oxy]octadecanoic acid. 12[(12-hydroxyoctadecanoyl)oxy]octadecanoic acid can be easily incorporated in combination with lipophilic carriers that are liquid at room temperature. Compositions are able to deliver increased energy production by human fibroblasts. Preferred compositions also contain 12-hydroxy stearic acid and thus are able to deliver a... Agent: Conopco, Inc., D/b/a Unilever

20120122937 - Methods for inhibiting cancer cell proliferation and inducing cancer cell apoptosis: a

20120122938 - Alkoxy compounds for disease treatment: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD)... Agent: Acucela Inc.

20120122939 - Alkylsulfonyl-substituted thiazolide compounds: A new class of alkylsulfonyl-substituted thiazolide compounds is described. These compounds show strong activity against hepatitis virus.... Agent: Romark Laboratories, L.c.

20120122940 - Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas: wherein R1 is a C10-C22 alkyl group, a C10-C22 alkenyl group having 1-6 double bonds, or a C10-C22 alkynyl group having 1-6 triple bonds; R2 and R3 are the same or different and may be chosen from different substituents; and X is a carboxylic acid or a derivative thereof, such... Agent:

20120122942 - 5-oxo-ete receptor antagonist compounds: The present invention relates to novel pharmaceutically-useful compounds which are antagonists of the 5-oxo-ETE receptors, such as the OXE receptor. These compounds have use as therapeutic and/or prophylactic agents for diseases characterized by tissue eosinophilia, such as inflammatory conditions including respiratory diseases. The invention also relates to pharmaceutical compositions, to... Agent:

20120122941 - Cycloalkylamine derivatives: [wherein, Ar which is a partial structure in the general formula (1) represents a phenyl group or a naphthyl group; R1a and R1b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; R2a and R2b are the same or different... Agent:

20120122943 - Melampomagnolide b derivatives as antileukemic and cytotoxic agents: Melampomagnolide B is disclosed as a new antileukemic sesquiterpene. A biotin-conjugated derivative of melampomagnolide B was prepared to elucidate its mechanism of action. Prodrugs of Melampomagnolide B are disclosed.... Agent: University Of Kentucky Research Foundation

20120122944 - Tetrahydronaphthalene derivatives: l

20120122945 - Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol: The present invention relates to novel compounds, ester pro-drugs of [3-(1-1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals in the treatment of conditions mediated by adrenergic receptors.... Agent: Allergan, Inc.

20120122946 - Polymorphisms for predicting disease and treatment outcome: The invention provides compositions and methods for determining the increased risk for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprising determining the type of genomic polymorphism present in a predetermined region of the gene of interest... Agent: University Of Southern California

20120122947 - Spiro-oxindole mdm2 antagonists: Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.... Agent: Ascenta Therapeutics, Inc.

20120122948 - 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors: or a pharmaceutically acceptable salt thereof, with the proviso that the 5-fluorotryptamine is excluded, for the treatment or the prophylaxis of neuroinflammatory diseases or disorders. The invention also relates to a pharmaceutical composition, a method for inhibiting myeloperoxidase enzyme activity, to a method for inhibiting Low density lipoproteins oxidation.... Agent: Universite Libre De Beuxelles

20120122950 - Libraries of 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides for drug discovery: New compounds are continually being sought for the treatment and prevention of disorders. The invention relates to 1-(sulfonyl)-N-phenyl-pyrrolidine 2-carboxamides which can be used in the search for, and identification of, new lead compounds that could modulate the functional activity of a biological target.... Agent:

20120122949 - Ultra-high strength injectable hydrogel and process for producing the same: [Solution to Problem] The present invention is based on a knowledge that high-strength hydrogels can be fabricated by controlling pH of solution, ionic strength in the solution, and buffer concentration in the solution. In addition, the present invention is based on a knowledge that the high-strength hydrogels which have homogeneous... Agent: Next21 K.k.

20120122951 - Skin-whitening agent and cosmetic method for whitening skin: The development of a skin-whitening agent which has a lower molecular weight, can be synthesized through a fewer steps and can be produced at low cost has been demanded. Thus, it is provided by the present invention a skin-whitening agent including one or more compounds selected from the group consisting... Agent: Shiseido Company, Ltd.

20120122952 - 4-hydroxybutyric acid analogs: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially... Agent: Concert Pharmaceuticals Inc.

20120122964 - Bicyclic compound and use thereof for medical purposes: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating... Agent: Ono Pharmaceutical Co., Ltd.

20120122965 - Compositions for skin protection and improvement of skin diseases containing the dibenzo-p-dioxine derivatives: Since the compositions for skin protection and improvement that contain the dibenzo-p-dioxine derivative according to the present invention have excellent functions such as moisturizing and/or wrinkle prevention which are useful in prevention and improvement of various skin diseases, they can be extensively used as cosmetic ingredients or pharmaceutical agents for... Agent: Livechem, Inc.

20120122966 - Use of organic dyes as analgesic agents: An organic dye from the group of crystal violet, gentian violet, malachite green oxalate and rhodamine 6G used as an analgesic agent in the form of a solution with the agent dosage ranging from 0.000001 mg to 10 g per intake. It is preferable to take the agent at least... Agent:

20120122968 - Use of dynamin ring stabilizers: There is provided a method for promoting dynamin ring formation and/or maintenance of dynamin rings in a cell, comprising treating the cell with an effective amount of a dynamin ring stabilizer, or a prodrug or pharmaceutically acceptable salt of the dynamin ring stabilizer. The maintenance or accumulation of dynamin ring... Agent: Children's Medical Research Institute

20120122967 - Compositions and products containing r-equol, and methods for their making: A composition for use in making commercial food and skin products comprising R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering R-equol to a mammal to prevent or treat a disease or... Agent: Children's Hospital Medical Center

20120122969 - Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts: Methods of treating or suppressing Pervasive Developmental Disorders (PDDs) including; Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder (CDD), Rett's Disorder, and PDD-Not Otherwise Specified (PDD-NOS) comprising administering to a subject in need thereof a therapeutically effective amount of a tocotrienol, a tocotrienol ester, a tocotrienol ether, a tocotrienol enriched extract... Agent: Ampere Life Sciences, Inc.

20120122970 - Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (ache): t

20120122971 - New process for preparing hydroxylamines and medicaments:

20120122972 - Novel eicosanoid derivatives: The present invention provides compounds (n-3 PUFA derivatives) of formula (I) that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.... Agent:

20120122973 - Dry processing of retigabine: The invention relates to dry processes for the production of oral dosage forms, especially tablets, containing retigabine and adhesion promoter. In addition, the invention relates to compacted intermediates containing retigabine and an adhesion promoter. Finally, the invention relates to single-dose and multiple-dose containers, preferably sachets and stick-packs, containing the intermediate... Agent: Ratiopharm Gmbh

20120122974 - Hair restorer: The object of the present invention is to provide a hair restorer which exhibits a stimulatory effect on hair restoration against hair loss, hair thinning, split ends, hair graying, etc., with higher stability and safety than those of known hair restorers containing 5-aminolevulinic acids as active components. By using 5-aminolevulinic... Agent: Cosmo Oil Co., Ltd.

20120122975 - 4-cyano-3-benzoylamino-n-phenyl-benzamides for use in pest control: The present invention relates to bis-amide derivatives of formula (I), to processes and intermediates for preparing them, to methods of using them to control insect, acarine, nematode and mollusc pests, and to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising them.... Agent: Syngenta Crop Protection LLC

20120122976 - Phosphate-free pharmaceutical composition for the treatment of glaucoma: The invention relates to a phosphate-free pharmaceutical composition which comprises at least one FP prostanoid receptor agonist and/or at least one prostamide receptor agonist and also citrate salts and/or citric acid.... Agent: Ursapharm Arzneimittel Gmbh

20120122977 - Substituted amino bisphenyl pentanoic acid derivatives as nep inhibitors: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, X, X1, s and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention... Agent: Novartis Ag

20120122978 - Use of ketogenic compounds for treatment of age-associated memory impairment: This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention... Agent: Accera, Inc.

20120122979 - Control of enzymatic peracid generation: A process is provided for producing target concentrations of peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity under conditions where control of reaction pH by selection of... Agent:

20120122980 - Method for making a peroxycarboxylic acid: The present invention relates to apparatus and methods for making a peroxycarboxylic acid. The apparatus includes a reaction catalyst and a guard column for pretreating one or more reagents, which can increase the life, activity, and/or safety of the reaction catalyst. The peroxycarboxylic acid compositions made by the method and... Agent: Ecolab Usa Inc.

20120122981 - Biomarkers related to insulin resistance and methods using the same: Biomarkers relating to glucose disposal rate, insulin resistance, and/or insulin resistance-related disorders are provided. Methods based on the same biomarkers are also provided.... Agent:

20120122983 - Deodorized edible oil or fat with low levels of bound mcpd and process of making by carboxymethyl cellulose and/or resin purification: A process for making a deodorized edible oil or fat having a low level of bound MCPD (monochloro propanediol esters) and/or low level of bound 3-MCPD is described. The process comprises a step of contacting the oil or fat to a carboxymethyl cellulose or an ion exchange resin. The carboxymethyl... Agent: Nestec S.a.

20120122982 - Use of pufas to treat nerve damage: The present invention provides use of compounds which are polyunsaturated fatty acid (PUFA) derivatives of formula (I), in the form of racemates, stereoisomers or mixtures of stereoisomers, or pharmaceutically acceptable salts, or solvates thereof, wherein -AIk- is —(CH2)4—CH(OR2)-[trans]CH═CH-[cis]CH═CH—, —(CH2)4-[cis]CH═CH-[trans]CH═CH—CH(OR2)—, —CH(OR2)-[trans]CH═CH-[cis]CH═CH—CH2-[cis]CH═CH—(CH2)3—, —(CH2)3—CH(OR2)-[trans]CH═CH-[cis]CH═CH—CH2-[cis]CH═CH—, or —(CH2)3-[cis]CH═CH—CH2-[cis]CH═CH-[trans]CH═CH—CH(OR2)—; R1 is a hydrogen atom; or R1... Agent: Equateq Limited

20120122984 - Methods of treating lipomas and liposarcomas: The invention provides methods and compositions for treating lipomas and liposarcomas. The invention also provides methods for reducing white adipose tissue and weight in animals.... Agent: Oragenics, Inc.

20120122985 - Tranexamic acid formulations: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.... Agent:

20120122986 - Methods of treating fragile x syndrome: Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen.... Agent: Seaside Therapeutics, Inc.

20120122987 - Treatment of disorders associated with g protein-coupled receptor 35 (gpr35): Compounds are provided having agonistic activity against G protein-coupled receptor 35 (GPR35). The compounds are useful for providing antinociception, providing neuroprotection in case of stroke or ischemia, or treating gastric inflammation.... Agent: Duke University

20120122988 - 4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.... Agent:

20120122989 - Method of enhancing hair growth: wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is... Agent: Allergan, Inc.

20120122990 - Oleoylethanolamide based functional mesophases: The present invention relates to the field of liquid crystals. Embodiments of the present invention relate to liquid crystals comprising at least one molecule within N-acyl ethanolamide (NAE) family, for example oleoylethanolamide (OEA), compositions comprising them and their possible uses.... Agent: Nestec S.a.

20120122991 - Method for treating cancer by increasing amp-activated kinase activity: The invention relates to modulation of LKB1 or AMP kinase protein activity for treating disorders including diabetes and cancer. The invention also relates to screening for agents that modulate the activity of LKB1 or AMP kinase protein, which are useful in the treatment of diabetes and cancer, as well as... Agent: Beth Israel Deaconess Medical Center, Inc.

20120122992 - Small molecule inhibitors of dusp6 and uses therefor: Compounds that stimulate fibroblast growth factor production, and thus cell growth are provided. Also provided are compositions comprising the compounds and methods of using the compounds. The compounds can be used to treat wounds, to expand cell populations, such as hematopoietic cells, or to grow tissue in vitro, among other... Agent: University Of Pittsburgh-of The Commonwealth Syste

20120122993 - Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-(1r)-, methanesulfonate: A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan mesylate thereof, and less than 50% by weight of hexahydric sugar alcohols.... Agent: Sandoz Ag

20120122994 - Insecticidal compound: An object of the present invention is to provide a new insecticidal compound by paying attention to the insecticidal activity contained in the flower part of marigold, and to provide an insecticide containing the compound as an active ingredient. There are provided an insecticidal compound represented by the following chemical... Agent:

20120122995 - Anti-inflammatory agent and cancer-preventive agent comprising canolol or prodrug thereof and pharmaceutical, cosmetic and food comprising the same: An anti-inflammatory agent or cancer-preventive agent comprising 4-vinyl-2,6-dimethoxyphenol of the formula (1): or a PD thereof.... Agent: Hiroshi Maeda

20120122996 - Azeotrope-like compositions comprising 1-chloro-3,3,3-trifluoropropene: An azeotrope-like mixture consisting essentially of chlorotrifluoropropene and at least one component selected from the group consisting of a C1-C3 alcohol, a C5-C6 hydrocarbon, a halogenated hydrocarbon, methylal, methyl acetone, water, nitromethane, and combinations thereof.... Agent: Honeywell International Inc.

20120122997 - New polysaccharide-based materials: There is provided a plastic or gel material comprising a mixture of: (a) a compound of formula (I) or a mixture of two or more compounds of formula (I), (R−)n(Xn−) (I) or a hydrate thereof, wherein n, R+ and Xn− have meanings given in the description; (b) one or more... Agent:

20120122998 - Liquid low surfactant compositions structured with fibrous polymer and specific low molecular weight water soluble polymers having no flow instability or shear banding: The invention relates to surfactant structured liquids structured with fibrous polymer and which additionally contain specific low molecular weight water soluble polymers to eliminate flow instability.... Agent: Conopco, Inc., D/b/a Unilever

20120122999 - Urethane and urea fluorosurfactants: e

  
05/10/2012 > 194 patent applications in 142 patent subcategories. archived by USPTO category

20120115771 - Carrier: A pharmaceutical composition is provided comprising a vitamin E derivative, an anionic phopholipid-binding protein, an anionic phospholipid and a sterol. Also provided is a method for preparing a composition for delivering a cargo to a subject comprising a) forming liposomes from a vitamin E derivative, an anionic phospholipid-binding protein such... Agent: Ucl Business PLC

20120115772 - Conjugation method: A process for the conjugation of a polymer to a protein, which comprises reacting a polymeric conjugating agent with said protein, in an aqueous medium, in the presence of an amphipathic sugar polymer. The process is particularly useful when conjugating PEG to proteins, particularly to proteins which have previously proved... Agent:

20120115773 - Modified omci as a complement inhibitor: The method of the invention relates to a modified OmCI polypeptide or a polynucleotide encoding a modified OmCI polypeptide which lacks LK/E binding activity and the use of such polypeptides and polynucleotides for the treatment of a disease or condition mediated by complement.... Agent: Natural Environment Research Council

20120115774 - Antimicrobial cationic lipo-beta-peptides: In some aspects, the present invention provides ultrashort lipopeptides which feature β-amino acids or β-peptides and demonstrate antimicrobial activity. Accordingly, some aspects of the present invention provide lipopeptide compositions and methods of making and using the compositions as antimicrobial agents.... Agent: University Of Manitoba

20120115775 - Mutant tat proteins and uses thereof: Disclosed are viral proteins associated with Human Immunodeficiency Virus (HIV) infections and mutants thereof, particularly, mutant Tat proteins capable of modulating multiple steps of the HIV-1 replication cycle. Also provided are methods of using the mutant Tat proteins, and pharmaceutical compositions comprising the same, for prevention and treatment of HIV-1... Agent: The Council Of The Queensland Institute Of Medical Research

20120115776 - Adiponectin-containing eating behavior control agent for oral administration: Disclosed is a technique that facilitates the oral ingestion of adiponectin in a large quantity and enables the expansion of the range of use applications of adiponectin. Specifically disclosed is an appetite control agent for oral administration, which comprises adiponectin as an active ingredient. Particularly, the appetite control agent comprises... Agent: Hokusan Co., Ltd.

20120115778 - Methods of suppressing appetite by the administration of antagonists of the serotonin htr1a or htr2b receptors or inhibitors of tph2: Methods for treating eating disorders associated with excessive weight gain, suppressing appetite, reducing body weight, or treating obesity in an animal by administering one or more antagonists of the serotonin Htr1a or Htr2b receptor, or a Tph2 inhibitor are provided, or combinations thereof.... Agent: The Trustees Of Columbia University In The City Of New York

20120115777 - Use of ultrarapid acting insulin: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.... Agent: Mannkind Corporation

20120115779 - Agent for suppressing elevation of blood triglyceride concentration: An agent for suppressing elevation of a blood triglyceride concentration, comprising a polyglutamic acid as an active ingredient.... Agent: Kao Corporation

20120115780 - Porogen containing calcium phosphate cement compositions: Porogen containing calcium phosphate cement compositions are provided. Aspects of the cement compositions include a dry calcium phosphate reactant component, a setting fluid component and a porogen component. The porogen component includes at least first and second porogens having different pore forming profiles. Aspects of the invention include combining the... Agent:

20120115782 - Compositions and methods for treating or inhibiting liver injury: The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as... Agent: Yale University

20120115781 - Methods for evaluating and implementing prostate disease treatments: Provided is a method for evaluating test agents as candidates for treating prostatic diseases, including benign prostatic hyperplasia and androgen dependent and androgen independent prostate cancer. The method comprises providing a mouse comprising a human prostate primary xenograft, where the xenograft contains blood vessels that include human endothelial cells, initiating... Agent:

20120115783 - Peptidomimetic macrocycles: The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.... Agent: Alleron Therapeutics, Inc

20120115784 - Assessment of cardiac health and thrombotic risk in a patient: The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk... Agent:

20120115785 - Endothelial nitric oxide synthase antagonists and uses thereof for inhibiting oxygen toxicity: Compositions and methods for inhibiting the interaction between eNOS and β-actin are provided for use in inhibiting or reducing lung injury from oxygen toxicity. One embodiment provides a synthetic or recombinant polypeptide having the β-actin binding domain of eNOS, wherein the polypeptide inhibits or reduces eNOS activity in lung endothelial... Agent: Medical College Of Georgia Research Institute, Inc

20120115786 - Agent for reducing risk in onset of disease ascribable to non-dipper circadian rhythm of blood pressure: An agent for reducing risk in onset of diseases ascribable to non-dipping circadian profile of blood pressure is provided. This agent is capable of effectively lowering SBP from night to early morning in individuals with non-dipping circadian profile of blood pressure, in particular, normal individuals with normal SBP and DBP... Agent: Calpis Co., Ltd.

20120115788 - Use of liposomal wnt composition to enhance osseointegration: Methods and compositions are provided for the therapeutic use of Wnt proteins, for enhancing bone growth and regeneration, including repair following injury, osseointegration of implants, and the like. In some embodiments of the invention, the compositions are administered locally, e.g. by injection at the site of an injury. For certain... Agent:

20120115787 - Sclerostin and the inhibition of wnt signaling and bone formation: The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass (HBM). In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293 cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by over-expression of Wnt... Agent:

20120115789 - Methylglyoxal-scavenging compounds and their use for the prevention and treatment of pain and/or hyperalgesia: The present invention relates to compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine- containing protein, preferably an arginine- or lysine-containing cellular protein, such as a sodium ion channel, e.g. the sodium ion channel Na(v)1.8. Preferred scavenger compounds... Agent:

20120115791 - Methods for treating immune mediated neurological diseases: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, Immune complexed IgG to IgG FγR binding, and immune complexed IgG mC1q (membrane C1q) or soluble C1q binding. Such compounds... Agent:

20120115790 - Therapeutic approach to neurodegenerative disorders using a tfp5-peptide: Disclosed herein are isolated peptides, pharmaceutical compositions and methods for use of such for treating subjects with a neurodegenerative disease, such as Alzheimer's. In an example, an isolated polypeptide includes a cyclin dependent kinase 5 (Cdk5) inhibitory domain that has at least 95% sequence identity to the amino acid sequence... Agent: The U.s.a. As Represented By The Secretary, Dept. Of Health & Human Services,

20120115792 - Method for the treatment of infraorbital dark circles using botulinum toxins: Infraorbital dark circles can be treated by administration of a botulinum toxin to a patient. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of an eye of a patient with infraorbital dark circles.... Agent: Allergan, Inc.

20120115793 - Peptidomimetic macrocycles: The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.... Agent: Alleron Therapeutics, Inc

20120115794 - Use of cd44v6 in the treatment of ophthalmic diseases: The present invention relates to the use of peptide compounds for the prevention and/or treatment of ophthalmic diseases. In particular, the present invention relates to a peptide compound comprising an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 2 (KEQWFGNRWHEGYR) or of SEQ ID... Agent: Karlsruher Institut F&#xdc R Technologie

20120115795 - Regulation of sodium channels by plunc proteins: The present invention relates to the ability of PLUNC proteins, such as SPLUNC1 and SPLUNC2, to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by... Agent:

20120115796 - Novel spacer moiety for poly(ehtylene glycol) modified peptide based compounds: e

20120115797 - Peptide compositions that downregulate tlr-4 signaling pathway and methods of producing and using same: Compositions that include isolated peptides that inhibit TLR-4 signaling pathways and inflammation are disclosed. Methods of producing and using the compositions to inhibit TLR-4 signaling and/or inflammation are also disclosed herein.... Agent:

20120115798 - Method for improving the immunity of a companion animal: A method of improving the immunity of a companion animal. The method can include administering to the companion animal a glucose anti-metabolite. The glucose anti-metabolite can be 2-deoxy-D-glucose; 5-thio-D-glucose; 3-O-methylglucose; 1,5-anhydro-D-glucitol; 2,5-anhydro-D-glucitol; 2,5-anhydro-D-mannitol; mannoheptulose; and mixtures and combinations thereof. The companion animal can be a dog or a cat. Improving... Agent:

20120115799 - Pharmaceutical formulations: m

20120115800 - Pigment aggregates: The invention provides a method for in vitro formation of anthocyanic vacuolar inclusion (AVD-like structures, the method comprising the step of combining at least one anthocyanin, and b) at least one lipid. The invention also provides AVI-like structures produced by the method of the invention, compositions comprising such AVI-like structures,... Agent: The New Zealand Institute For Plant And Food Research Limited

20120115801 - Method for obtaining a stable dispersion of benzoyl peroxide: Powder containing benzoyl peroxide is readily wetted by contacting the powder with a liquid containing one or more of a polyol, a polyol, ether, and a low-carbon organic alcohol.... Agent: Dow Pharmaceutical Sciences, Inc.

20120115802 - Method for using ulipristal acetate with cytochrome isozyme modulators: The invention relates to a method of using ulipristal acetate or a metabolite thereof for providing contraception or for treating a patient's condition, comprising providing a patient with ulipristal acetate or a metabolite thereof, and informing the patient or a medical care worker that ulipristal acetate or a metabolite thereof... Agent: Laboratoire Hra Pharma

20120115803 - Treatment of acinetobacter with alginate oligomers and antibiotics: The invention provides a method to improve the efficacy of an antibiotic to inhibit the growth of Acinetobacter, said method comprising using said antibiotic together with an alginate oligomer. The Acinetobacter may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In... Agent: Algipharma As

20120115804 - Compositions and methods for characterizing and treating neoplasia: The invention features compositions and methods for characterizing the methylation status of the Vitamin D Receptor (VDR) in neoplasia (e.g., breast carcinoma), selecting an appropriate therapy, and treating the neoplasia (e.g., breast carcinoma).... Agent: The John Hopkins University

20120115925 - Allelic variants associated with advanced age-related macular degeneration: The invention relates to allelic variants and haplotypes of the Complement Factor H (CFH) gene, the Complement Component 3 (C3) gene, and the Complement Factor D (CFD) gene, associated with either an elevated or a reduced risk that an individual will develop age-related macular degeneration (AMD), methods of diagnosing such... Agent: Massachusetts Eye And Ear Infirmary

20120115935 - Anti-cancer agent, method for inducing apoptosis of cancer cells, and method for screening for anti-cancer agent: Disclosed is an anti-cancer agent which can inhibit the progression of cell cycle in the M phase, unlike taxane anti-cancer agents. The anti-cancer agent comprises a compound capable of inhibiting specifically the expression and/or functions of RBM8A depicted in SEQ ID NO: 1, Magoh depicted in SEQ ID NO: 3... Agent:

20120115926 - Antisense modulation of apolipoprotein b expression: Methods for the rapid and long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated apolipoprotein B are provided.... Agent: Genzyme Corporation

20120115930 - Compositions and their uses directed to hepcidin: Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods... Agent: Isis Pharmaceuticals, Inc.

20120115929 - Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure: The present invention relates to a method for diagnosing and/or prognosing heart failure in a subject the method comprising the step of determining the level of at least one genetic marker in a body fluid sample obtained from said subject, wherein said at least one genetic marker is an mi... Agent:

20120115924 - Micro-rna mediated modulation of colony stimulating factors: The present invention relates to the modulation of immunoregulatory proteins, including cytokines, such as colony stimulatory factors (CSF) via the use of microRNA-155 modulators.... Agent: Santaris Pharma A/s

20120115928 - Mirna and its targets respectively the proteins made based on the targets as a prognostic, diagnostic biomarker and therapeutic agent for cancer: A compound miRNA (miRNA661) (Nr MI0003669 or ENSG00000207574) the sequence of the mature miRNA-661 being 51-ugccugggucucuggccugcgcgu-74 for use as a medicament in the in the treatment and/or the diagnosis of cancer, neuronal disease and infection.... Agent: Universite Du Luxembourg

20120115932 - Modulation of stat 6 expression: Compounds, compositions and methods are provided for modulating the expression of STAT 6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT 6. Methods of using these compounds for modulation of STAT 6 expression and for diagnosis and treatment of disease associated with expression of STAT 6 are provided.... Agent: Isis Pharmaceuticals, Inc.

20120115933 - Organic compositions to treat beta-enac-related diseases: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.... Agent:

20120115934 - Organic compositions to treat beta-enac-related diseases: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.... Agent: Novartis Ag

20120115927 - Pharmaceutical agent for preventing cell death: Disclosed is a pharmaceutical agent for preventing cell death. The occurrence of cell death can be prevented by inhibiting the function of Int6 protein in an affected area. Then, a pharmaceutical agent comprising a substance capable of inhibiting the function of Int6 protein is prepared. The pharmaceutical agent can be... Agent: Tokyo Metropolitan Institute Of Medical Science

20120115931 - Selective inhibitors of cb2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders: The invention relates to a method for treating and/or preventing obesity and/or obesity-related disorders by administering to a subject in need thereof a selective inhibitor of cannabinoid type 2 (CB2) receptor expression.... Agent:

20120115923 - Sirna compositions promoting scar-free wound healing of skin and methods for wound treatment: This invention describes compositions and methods using siRNA to target various genes expressed in cells of injured tissue during scar formation to promote scar-free wound healing.... Agent: Intradigm Corporation

20120115938 - Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance: Disclosed are methods and compositions to genetically modify substantially intact cells having cosmetic function to enhance the cosmetic appearance in mammals so as to enhance and/or maintain a biochemical and/or physiological process that has a positive effect on cosmetic appearance. The methods and compositions may provide cosmetic benefits such as... Agent:

20120115937 - Ghrelin binding nucleic acids: s

20120115936 - Potent anti apob antisense compounds: The present invention relates to oligomer compounds (oligomers), which target APO-B100 mRNA in a cell, leading to reduced expression of APO-B100. Reduction of APO-B100 expression is beneficial for the treatment of certain medical disorders, such as diseases associated with apolipoproteinB activity, such as in non-limiting example, different types of HDL/LDL... Agent:

20120115805 - Use of at least one nucleic acid to influence the natural pigmentation process: A method for influencing the natural pigmentation process of skin or appendages thereof, includes the step of topically contacting the skin or appendages thereof with at least one nucleic acid containing at least 55% guanine nucleotide.... Agent: Henkel Ag & Co. Kgaa

20120115806 - Antitumor combination including cabazitaxel and capecitabine: The invention relates to a method of treatment of metastatic breast cancer in a patient progressing after a previous anthracycline and/or taxane treatment, said method comprising administering to said patient a combination of antitumor agents comprising cabazitaxel and capecitabine, wherein each of said antitumor agents, independently, may be in the... Agent: Sanofi

20120115807 - Combination of alovudine and zidovudine in a molar ratio of 1:100 to 1:350: Co-administration of alovudine and zidovudine at ratios considerably in excess of the prior art completely or substantially abolishes the mitochondrial toxicity of alovudine in mitochondrial DNA depletion experiments. The invention thus provides pharmaceutical compositions comprising alovudine and zidovudine in a molar ratio in the range 1:100 to 1:350 and methods... Agent: Medivir Ab

20120115808 - Pharmacological preparation for topical use containing n-palmitoyl-vanillamide: The present invention relates to topical preparations containing N-palmitoyl-vanillamide having hyperalgesic activity. In particular, the invention relates to N-palmitoyl-vanillamide for use in the treatment of pathologies selected from: post-herpetic neuralgia, neuralgia of trigeminus, occipital neuralgia, dental neuralgia, glottopharyngeal neuralgia, uremic neuralgia, diabetic neuralgia, headache of different origin, neuropathic itch, neurogenic... Agent:

20120115809 - Use of an acylated octasaccharide as an antithrombotic agent: e

20120115810 - Surgical compositions for reducing the incidence of adhesions: A method of preventing or reducing the incidence of post-operative adhesions in or associated with a body cavity, which comprises introducing into the body cavity a composition containing an aqueous solution or suspension or gel formulation containing the polysaccharide dextrin.... Agent:

20120115811 - Phenylanaline amide derivatives useful for treating insulin-related diseases and conditions: Provided herein are compounds of formula I: wherein A, B, X, R1, R2 and subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions.... Agent: Amgen Inc.

20120115812 - Surface coatings for skin: The present invention relates to skin coating compositions and methods and, in particular, to coatings containing an active agent. In some embodiments, the coating may be applied to a skin surface and may be essentially colorless and transparent. In some aspects, the coating comprises a polymer and an active agent,... Agent: Pharmasol Corporation

20120115813 - Boron-containing small molecules: This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.... Agent: Anacor Pharmaceuticals, Inc.

20120115814 - Liquid pharmaceutical form of alkylphosphocholine and method for preparing same: The inventions relates to a liquid pharmaceutical form containing an active ingredient alkylphosphocholines and a co-solvent system. The co-solvent system is mixture from hexylene glycol, propylene glycol, diethylene glycol monoethyl ether and water. The pharmaceutical form having a pH value in the range of 4 to 6, which if it... Agent: Expergen Drug Development Gmbh

20120115815 - Compositions useful especially for treatment or prevention of metabolic syndrome: This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase... Agent: Biotie Therapies Corp.

20120115816 - Compatibilized electrolyte formulations: The invention includes aqueous compatibilized pesticidal formulations and methods of making them. In typical embodiments, formulations comprise a first electrolytic pesticide and a second electrolytic pesticide, and about 30 to about 300 g/L of at least one alkyl polyglycoside. The invention also includes methods of preparing pesticidal formulations to increase... Agent: Syngenta Crop Protection LLC

20120115817 - Phthalimide derivatives of non-steroidal anti-inflammatory compounds and/or tnf-alpha modulators, method for producing same, pharmaceutical compositions containing same and uses thereof for the treatment of inflammatory diseases: The present invention relates to phthalimide derivatives of non-steroidal and/or TNF-α modulating anti-inflammatory compounds as well as the process of obtaining the so-called derivatives, pharmaceutical compositions containing such derivatives and their uses, including use in the treatment of inflammatory diseases, especially those related to chronic inflammatory processes, such as rheumatoid... Agent: Ems S.a.

20120115819 - Pentacycline compounds: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.... Agent:

20120115818 - Synthesis of tetracyclines and intermediates thereto: Efficient method for preparing the enone intermediate (VII) used in the synthesis of tetracyclines derivatives. In particular, the invention provides a synthesis which allows for substituents at positions 4a, 5, 5a, and 12a of the tetracycline ring system.... Agent: President And Felows Of Harvard College

20120115820 - Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility: The present invention relates to a use of a compound having an acid pump antagonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for prevention or treatment of diseases in which abnormal gastrointestinal motility is involved. In addition, the present invention... Agent: Raqualia Pharma Inc.

20120115821 - Composition and method for treating skin conditions: Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described.... Agent: 442 Ventures, LLC

20120115822 - Use of 5h-dibenz/b,f/azepine-5-carboxamide derivatives in the treatment of neuropathic pain and neurological disorders: This invention relates to the use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives in the manufacture of various medicaments for treating neuropathic pain and for treating neurological disorders which involve both motor impairment and neuropathic pain.... Agent: Bial - Portela & C.a., S.a.

20120115823 - Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients: Bismuth-containing compounds include bismuth and a biologically active agent coordinated to the bismuth. The biologically active agent includes at least one heteroatom configured for coordination with the bismuth. Coordination polymers include a polymer matrix that contains a bismuth-containing compound. Methods for modulating a pharmacokinetic property of a biologically active agent... Agent:

20120115824 - Vitamin d receptor agonists and uses thereof: in which R1, R2, R3, R4, R5, R6, X, and a are defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition comprising a compound or salt thereof of Formula (I) and a method of treating a disease which benefits from the modulation of the vitamin... Agent: Vidasym, LLC

20120115827 - 3-aminobenzamide compounds and vanilloid receptor subtype 1 (vr1) inhibitors: The present invention relates to a novel 3-aminobenzamide, compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group... Agent: Japan Tobacco Inc.

20120115825 - Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof: the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as... Agent: Boehringer Ingelheim International Gmbh

20120115828 - Medicinal cream containing miconazole nitrate, hydrocortisone acetate, and a biopolymer, and a process to make it: The present invention is directed to a composition for treating bacterial skin infections & skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, a corticosteroid and an antibacterial active ingredient. It discloses a composition for treating fungal skin infections &... Agent: Apex Laboratories Private Limited

20120115826 - Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.... Agent: Laboratorios Almirall, S.a.

20120115829 - Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection: Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-gauge needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.... Agent: Alcon Research, Ltd.

20120115830 - Assay methods for the determination of fkbpl expression level in the context of breast cancer: Disclosed are methods that employ FKBPL as a marker for a subject's sensitivity to endocrine therapies in the treatment of cancers, and as a predictive marker of cancer progression and disease free survival in relation to hormone responsive cancers.... Agent:

20120115831 - Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders: The present invention relates to the treatment of disorders using anti-progestational agents. More specifically, the present invention relates to the treatment of disorders using low doses of anti-progestational agents. Compared to dosages and lengths of treatment taught by the prior art, the described methods, dosing regimens and medications use effective... Agent:

20120115832 - Tgr5 modulators and methods of use thereof: e

20120115833 - Method of treating hepatocellular carcinoma: A therapeutic method for treating hepatocellular carcinoma is disclosed comprising administering to a patient in need of treatment a ruthenium complex salt.... Agent: Niiki Pharma Inc.

20120115834 - Synergistic combination of flumetsulam or diclosulam with zinc pyrithione: A synergistic antimicrobial composition containing flumetsulam or diclosulam; and zinc pyrithione.... Agent:

20120115835 - Methods for treatment of bacterial infections: The peptidoglycan layer is a vital component of the bacterial cell wall, which comprises 4→3 and 3→3 transpeptide cross-linkages, the formation of which are catalyzed by D,D- and L,D-transpeptidases, respectively. Methods for the treatment of bacterial infections with agents that inhibit L,D-transpeptidases, either alone or in combination with D,D-transpeptidase inhibitors,... Agent: The Johns Hopkins University

20120115836 - Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens: Provided are methods of determining a resistance-adjusted dosage regimen of an anti-infective agent for treatment of an infection of a mammal by a resistant infective organism, wherein an effective dosage regimen of the anti-infective agent is known for treatment of an infection of the mammal by a susceptible strain of... Agent:

20120115839 - Use of selective gaba a alpha 5 negative allosteric modulators for the treatment of central nervous system conditions: The present invention relates to the pharmaceutical use of selective GABA A α5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions related to excessive GABAergic inhibition in the brain.... Agent:

20120115841 - Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists: The present invention relates to bridged spiro[2.4]heptane derivatives of formula (I), wherein W, Y, Z, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds as ALX receptor and/or FPRL2 agonists for the treatment of inflammatory and obstructive airways diseases.... Agent: Actelion Pharmaceuticals Ltd.

20120115840 - Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid: This invention relates to a hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of Compound I,... Agent:

20120115843 - Novel pyrrolidine derivatives: i

20120115844 - Novel triazole compounds i: wherein A, X, Y, Z, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of present invention have affinity and selectivity for the GABA A α5 receptor. Further the present invention is concerned with the manufacture of the compounds... Agent:

20120115842 - Substituted oxindole derivatives, medicaments containing said derivatives and use thereof: The invention relates to novel oxindole derivatives of general formula (I), wherein substituents A, B, X and Y are defined as in claim 1, medicaments containing said derivatives, and the use thereof in the prophylaxis and/or treatment of vasopressin-dependent and/or oxytocin-dependent diseases.... Agent:

20120115845 - Therapeutic agents: e

20120115838 - Ampk-activating heterocycloalkyloxy(hetero)aryl carboxamide, sulfonamide and amine compounds and methods for using the same:

20120115837 - Solid preparation: Provided is a solid preparation comprising (i) a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, (ii) a sugar alcohol, and (iii) a calcium antagonist, which is superior in the dissolution property and stability.... Agent: Takeda Pharmaceutical Company Limited

20120115846 - Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof.: The subject matter of the invention is quinazolinedione derivatives of formula (I), methods for obtaining same and therapeutic uses thereof, such as cancer, diabetes, muscle diseases, bone diseases, cardiovascular diseases, central nervous system diseases, peripheral nervous system diseases, inter alia.... Agent: Sanofi

20120115847 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Bristol-myers Squibb Company

20120115848 - Inhibitors of polo-like kinase: or a salt or solvate thereof, wherein ring A, U1, U2, U3, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention... Agent: Elan Pharmaceuticals, Inc.

20120115849 - Treatment of addiction and impulse-control disorders using pde7 inhibitors: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.... Agent:

20120115851 - Compound inhibiting in vivo phosphorus transport and medicine containing the same: wherein A represents an optionally substituted five- to nine-membered unsaturated carbocyclic moiety or a five- to nine-membered unsaturated heterocyclic moiety, and represents a single bond or a double bond, R5 represents optionally substituted aryl or the like, Z represents —N═CHR6R7 or the like, R6 and R7 represent H, optionally... Agent: Kyowa Hakko Kirin Co., Ltd.

20120115850 - Substituted arylamine compounds and methods of treatment: The invention relates to 5-HT6 receptor antagonists. Novel arylamine compounds and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating obesity, and obesity-related disorders, e.g., cardiovascular disease, digestive disease, respiratory disease, cancer and... Agent:

20120115852 - Heterocyclic compounds as autotaxin inhibitors: Compounds of the formula (I), in which R, R1, R2, X, X1, Y, Y1, Q, E, n1 and n2 have the meanings indicated in claim 1, are autotaxin inhibitors and can be employed for the treatment of tumours.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120115853 - Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use: The present invention relates to compounds defined by formula (I) wherein the groups R1 and R2 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be... Agent: Boehringer Ingelheim International Gmbh

20120115854 - Pharmaceutical composition containing antihypertensive agents: The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases.... Agent:

20120115856 - Agent for treatment or prevention of diseases associated with activity of neurotrophic factors: wherein, R1 represents (1) a C3-6 alkyl group, (2) a C1-6 alkyl group substituted with one or more substituent group(s) selected from those consisting a halogen atom, etc., (3) a C3-10 non-aromatic cyclic hydrocarbon group or a 5- to 6-membered non-aromatic heterocyclic group which respectively is optionally substituted with one... Agent:

20120115855 - Inhibitors of hcv ns5a: Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.... Agent: Presidio Pharmaceuticals, Inc.

20120115859 - 3,4,5-substituted piperidines as renin inhibitors: The application relates to novel substituted piperidines of the general formula (II) in which R1′, R2′, R2″, R4′, X, Z, m and n have the meanings defined in the description, to a process for the preparation thereof and to the use of these compounds as medicines, especially as renin inhibitors.... Agent:

20120115861 - Aminopyridine derivatives for treating tumors and inflammatory diseases: Compounds of the formula (I), in which R1, R2, R3, R4, R7 and Y have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumours and for the treatment of inflammatory diseases.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120115860 - Novel derivatives of aryl--methanone, their method of preparation and their use as medicinal products: The present invention concerns compounds of general formula (1) (I) wherein R1 is: a hydrogen atom, or a halogen, a straight or branched C1-C6 alkyl group or a C1-C3 fluoroalkyl group, a straight or branched C1-C6 alcoxy group, a carbamyl group, N-substituted or not by one or two, straight or... Agent: Pierre Fabre Medicament

20120115857 - Novel polymorphs of efavirenz: The present invention relates to novel amorphous and crystalline forms of efavirenz, processes for their preparation and pharmaceutical compositions containing them. In accordance with the present invention efavirenz crude is dissolved in acetone at 25° C.-30° C., the solution is slowly added to water for 30 minutes at 0° C.-5°... Agent:

20120115858 - Polymorph form ii of tanaproget: Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating... Agent: Wyeth LLC

20120115862 - Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds: n

20120115863 - Compounds for the treatment of cns disorders: The invention relates to novel cycloalkyl- or cycloalkenyl-substituted pyrazolopyrimidinones of formula (I), wherein Ā is selected from the group A1 consisting of a C3-C8-cycloalkyl group or a C4-C8-cycloalkenyl group, whereby the members of C3-C8-cycloalkyl group being selected from the group of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl and cyclooctanyl; and the... Agent: Boehringer Ingelheim International Gmbh

20120115864 - Substituted fused pyrimidine compounds: The present invention discloses substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The compounds of the present invention are useful in the treatment,... Agent:

20120115866 - Kinase inhibitor compounds: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.... Agent: Tyrogenex, Inc.

20120115865 - New salts of an indole derivative and their use in medicine: The present invention relates to new pharmaceutically acceptable salts of 2-hydroxy-3-[5-(morpholin-4-yl-methyl)pyridin-2-yl]1H-indole-5-carbonitrile, processes for their preparations, pharmaceutical formulations containing said salts and to the use of said active salts in therapy, and particularly to GSK3 related disorders.... Agent:

20120115867 - New class of histone deacetylase inhibitors: This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nitrogen, R1, R2 are, independently, hydrogen or C1-C6 alkyl,... Agent: Dac S.r.l.

20120115868 - Novel triazole compounds ii: wherein A, X, Y, u, v, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. The compounds of present invention have affinity and selectivity for the GABA A α5 receptor. Further the present invention is concerned with the manufacture of the compounds of formula... Agent:

20120115869 - Tetrazole derivatives: The present invention relates to compounds of formula (I) for use as pharmaceutical active compounds, as well as pharmaceutical formulations containing the same, for the treatment of allergic diseases.... Agent: Merck Serono S.a.

20120115870 - Control of intraocular pressure using alk5 modulation agents: An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical... Agent: Alcon Research, Ltd.

20120115871 - Method of treatment of depression: The invention comprises a method of treatment of depression or depression-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.... Agent: Supemus Pharmaceuticals, Inc

20120115872 - Combination of a sodium-proton exchanger inhibitor and of a dihydro-1,3,5-triazine amine derivative: The invention relates to a combination of a sodium-proton exchanger inhibitor and of a dihydro-1,3,5-triazine amine derivative which is useful for the treatment and/or prevention of pathologies induced by ischaemia and/or reperfusion, especially cardiac and renal complications.... Agent: Merck Patent Gmbh

20120115873 - Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting parp: The present invention relates to diazabenzo[de]anthracen-3.-onei compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.... Agent: Eisai Inc.

20120115874 - Pyrazine derivatives, process for manufacture and use thereof: and pharmaceutically acceptable salts thereof, wherein the designation of R1, R2, R3 and R4 is provided herein. The invention also provides syntheses for preparation of such compounds. The invention further provides methods of use of these compounds and pharmaceutical compositions containing them for treatment and/or prevention of diseases and for... Agent: Jinan University

20120115875 - Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity: d

20120115876 - N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones:

20120115877 - Facially amphiphilic compounds, compositions, and uses thereof in treating cancer: The present invention discloses compositions of facially amphiphilic compounds and their use in methods for treating or reducing cancers in animals, such as humans.... Agent: Polymedix, Inc.

20120115878 - Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.... Agent:

20120115879 - Method of treatment for mental disorders: The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D4 receptor agonist.... Agent:

20120115880 - Method for treating ocular cancer: Compositions and methods for treating ocular cancer are provided. The composition is a subconjunctival formulation of nutlin-3 and its analogs. The composition provides for methods of treating ocular cancer, including retinoblastoma. The formulation has high penetration into ocular tissue with low toxicity.... Agent: St. Jude Children's Research Hospital

20120115881 - Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same: A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.... Agent: Green Cross Corporation

20120115882 - Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction: A spiro-amino compound of Formula (VI) wherein m is 1 or 2 or 3, n is 1 or 2, R is selected from a 5- or 6-membered aromatic ring and a 5- or 6-membered heteroaromatic ring comprising 1 to 3 heteroatoms selected from S, O and N, such ring being... Agent:

20120115884 - Insecticidal compounds: A compound of formula (I) wherein A, p, R1, R3, R4, R5, and R8 are as defined in claim 1. Furthermore, the present invention relates to intermediates used to prepare compounds of formula (I), to methods of using them to combat and control insect, acarine, nematode and mollusc pests and... Agent: Syngenta Crop Protection LLC

20120115883 - Pyrimidine derivatives which are antagonists of the vitronectin receptor: c

20120115885 - Quinolinone pde2 inhibitors: The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's... Agent:

20120115886 - Fused pyrimidineone compounds as trpv3 modulators: The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating... Agent: Glenmark Pharmaceuticals S.a.

20120115888 - Synergistic combination of flumetsulam or diclosulam with diiodomethyl-p-tolylsulfone: A synergistic antimicrobial composition containing flumetsulam or diclosulam; and diiodomethyl-p-tolylsulfone.... Agent:

20120115887 - Synergistic combination of flumetsulam or diclosulam with isothiazolones: A synergistic antimicrobial composition containing flumetsulam and an isothiazolone biocide chosen from among 4,5-dichloro-2-n-octyl-4-isothiazolin-3-one, 2-n-octyl-4-isothiazolin-3-one and N-n-butyl-1,2-benzisothiazolin-3-one. A synergistic antimicrobial composition containing diclosulam and an isothiazolone biocide chosen from 4,5-dichloro-2-n-octyl-4-isothiazolin-3-one and 2-n-octyl-4-isothiazolin-3-one.... Agent:

20120115889 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20120115890 - Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith: Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9H-purin-2-ylamino]-cyclohexan-1-ol, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed.... Agent:

20120115891 - Method for the induction of a reward response by modulation of dopaminergic systems in the central nervous system: A method of modulating the dopaminergic system of the central nervous system comprising administering to a subject a dopamine precursor and/or a dopamine agonist in an amount effective to induce a reward response in the subject is described, as are related compositions.... Agent: Somalabs Inc.

20120115892 - Administration of nedd8-activating enzyme inhibitor: Disclosed are methods for the treatment of patients with diseases, disorders or conditions responsive to the inhibition of NAE (Nedd8-activating enzyme), e.g., cancer. The methods comprise administering a clinically effective amount of the NAE-inhibitor ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) according to an intermittent dosing regimen in which there is a rest period... Agent: Millennium Pharmaceuticals, Inc.

20120115893 - Substituted bicyclic carboxamide and urea compounds as vanilloid receptor ligands: s

20120115894 - Imidazole derivatives useful as modulators of faah and as faah imaging agents: The present invention is directed to certain Inidazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the... Agent: Merck Sharp & Dohme Corp.

20120115895 - Tricyclic indole-derived spiro derivatives as crth2 modulators: The present invention relates to compounds of formula (I) for use as pharmaceutical active compounds, as well as pharmaceutical formulations containing the same, for the treatment of allergic diseases. The compounds according to Formula (I) are suitable as modulators of CRTH2. The invention provides Spiro derivatives according to Formula (I)... Agent: Merck Serono S.a.

20120115897 - Aryl (ethanoic) propanoic acid ascorbyl ester, preparation method thereof and medicament containing the same: The present invention designs and synthesizes the ascorbyl ester derivatives of the aryl (ethanoic) propanoic acid non-steroidal anti-inflammatory medicaments, such as ibuprofen, ketoprofen and naproxen, and addition salt of the derivatives with pharmaceutical acid or pharmaceutical alkaline. The non-steroidal anti-inflammatory medicament which takes the ibuprofen as the representative is a... Agent: Wuxi Hongrui Bio-pharma-tech Co., Ltd .

20120115896 - Isogenic human cell lines comprising mutated cancer alleles and process using the cell lines: Isogenic human cell lines comprising at least one mutated cancer allele under the control of the cell line endogenous promoter, which corresponds to the wild-type cancer allele promoter are disclosed, as well as an in vitro process for determining sensitivity/resistance of a patient suffering from a tumor to a pharmacological... Agent:

20120115898 - 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof: The invention relates to a compound of formula (I), where: R1 is a phenyl group optionally substituted by one or more halogen atoms; R2 is: a hydrogen atom or a halogen atom or a cyano group; a —C(═O)Y group where Y is a hydrogen atom, or a —NH2 or —OR3... Agent: Sanofi

20120115899 - Naphthyridin-2 (1 h)-one compounds useful as antibacterials: wherein substituents R1, R2 and R5 are as defined, and Ar represents substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, furanyl, imidazolyl and thiophenyl substituted by a hydroxyalkyl substituent and an optional other substituent; compositions containing them, their use in therapy, including their use as antibacterials, for example in the treatment... Agent:

20120115900 - Substituted naphthyridine derivatives and their medical use: The present application discloses novel substituted naphthyridine derivatives of Formula (I) and their use as modulators of the voltage gated Kv7 (KCNQ) potassium ion channels. In other aspects the application discloses the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising these compounds.... Agent: Neurosearch A/s

20120115901 - Porphyrin compounds comprising one or more pyridone moieties: Various porphyrin compounds comprising one or more pyridone moieties, intermediates thereof, compositions thereof, and, methods of making and using thereof.... Agent:

20120115902 - 3h-imidazo [4, 5-b] pyridine- 6 -carboxamides as anti-inflammatory agents: There are provided compounds of formula (I), wherein R1, R6, R8, Q2, Q3, Q3a, Q4, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family... Agent: Boehringer Ingelheim International Gmbh

20120115903 - Substituted heteroaromatic carboxamide and urea compounds as vanilloid receptor ligands: e

20120115904 - Compounds having antiparasitic or anti-infectious activity:

20120115905 - Nitrone, nitroso, and nitroxide spintraps and spin labels and their hydroxylamines: Nitrone, nitroso, and nitroxide spintraps and spin labels and their reduction products are claimed for the prevention and treatment of fibrocystic disease of breast, premenstrual dysphoric syndrome and associated symptomology, prevention and treatment of migraine headache, cyclic vomiting syndrome, rectal hemorrhoids, trigeminal neuralgia, peripheral vascular disease, influenza, peridontitis and gingivitis,... Agent:

20120115906 - Derivatives of 3-alkoxy-4,5-diarylthiophene-2-carboxamide, preparation thereof, and therapeutic use thereof: The invention relates to compounds of the formula (I), where: R1 is: a —NR5R6 group; an unsubstituted or substituted phenyl; R2 is: a (C1-C4)alkyl; an —X—R7 group; R3 and R4 each are independently a substituted phenyl; R5 is a hydrogen atom or a (C1-C4)alkyl; R6 is an unsubstituted or substituted... Agent: Sanofi

20120115907 - Novel compounds as inhibitors of renin: The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical... Agent: Cadila Healthcare Limited

20120115909 - Tazarotene derivatives: The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.... Agent:

20120115908 - Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases: The invention relates to the use of a chemical substance selected from the group consisting of N-′2-hydroxy-3-(1-piperidinyl)-propoxyl 1-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixtures of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compounds in the preparation of a pharmaceutical composition for the treatment... Agent:

20120115910 - Compositions and methods for treating parkinson's disease: This application describes compositions of receptor inhibitors, including typical antipsychotic agents, for example haloperidol, and methods of use for treating clinical signs or symptoms of Parkinson's disease. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in Parkinson's disease as a means... Agent: Clera Inc.

20120115911 - Seed index system for treating agricultural seeds: Seed index system and methods for treating agricultural seeds with one or more seed care products employing a size-adjusted application rate based on the size of the seeds. Such size-adjusted application rates can be determined by a supplier of seed care products and communicated to an applicator who applies the... Agent: Agrilead, Inc.

20120115912 - Rxr agonist compounds and methods: A method of treating a PPARγ and/or RXR related disease or disorder in a subject includes adminstering to the subject an RXR agonist alone or in combination with a PPARγ agonist.... Agent:

20120115913 - Ethanamine compounds and methods of using the same: The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treating depression by administering the ethanamine compound.... Agent:

20120115914 - Treatment methods employing histamine h3 receptor antagonists, including betahistine: Methods of treating depression, binge eating disorder, narcolepsy, excessive daytime sleepiness, substance use disorders, and Prader Willi syndrome, disorders characterized at least in part by hypocortisolemia and decreased activity of the hypothalamic-pituitary-adrenal (HPA) axis, and disorders related to disturbances in circadian rhythm, comprising the step of administering an effective amount... Agent:

20120115915 - N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation: Compositions and methods for inhibiting translation initiation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using N,N′-diarylureas and/or N,N′-diarylthiourea compounds are described.... Agent: President And Fellows Of Harvard College

20120115916 - Oxazole and thiazole derivatives as alx receptor agonists: The invention relates to oxazole and thiazole derivatives of formula (I), wherein A, E, X, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds.... Agent: Actelion Pharmaceuticals Ltd.

20120115917 - Combination therapy for the management of hypertension: The present invention includes a combination comprising: a) mecamylamine; and b) an ACE inhibitor, an AT2 receptor inhibitor, a renin inhibitor, or a combination thereof.... Agent: Targacept, Inc.

20120115918 - Anti-viral compounds: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.... Agent: Abbott Laboratories

20120115919 - Methods of treating and preventing/reducing the likelihood of mesial temporal lobe epilepsy (tle): The invention provides methods of treatment that prevent the onset of Mesial temporal lobe epilepsy (TLE) in a subject, or which reduce the severity of TLE in a subject, by administering a NKCC1 inhibitor to the subject after the subject has suffered from an insult known to precipitate TLE.... Agent:

20120115920 - Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid: The invention provides crystalline salt forms of 4′-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]-imidazol-1-ylmethyl}-3′-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compounds, processes and intermediates for preparing the crystalline compounds, and methods of using the crystalline compounds to treat diseases such as hypertension.... Agent: Theravance, Inc.

20120115921 - Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment: Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.... Agent: Merck Sharp & Dohme Corp.

20120115922 - Smac mimetec: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.... Agent:

20120115939 - Methods for using lipoic acid: The present provides methods for using lipoic acid. In one embodiment, the methods include administering lipoic acid to a female subject in need thereof, wherein at least 10 milligrams lipoic acid per kilogram of body weight is administered. In another embodiment, the methods include administering to a female subject in... Agent: Ndsu Research Foundation

20120115940 - Use of total coumarins of cnidium fruit in preparing medicaments for treating psoriasis: A pharmaceutic composition for treating psoriasis. Ii has an active component and a carrier. The active component has a major active ingredient osthol and a group of minor active ingredients: xanthotoxol, xanthotoxin, isopimpinellin, bergapten, and imperatorine. The major active ingredient osthol accounts for at least 90% by weight of the... Agent:

20120115943 - Composition and method for neuroprotection against excitotoxic injury: The present invention discloses the combined treatment of memantine (N-methyl-D-aspartate receptor antagonist) and tea polyphenol (an antioxidant and anti-inflammatory agent) is more effective (synergistic) in neuroprotection than either memantine or tea polyphenol alone in mouse excitotoxic injury. These findings provide useful information about the potential application of memantine and tea... Agent: National Taiwan University

20120115941 - Compounds affecting glycemic index: Compounds of formula I are disclosed which are useful as glycemic index lowering agents and/or, as α-amylase and/or α-glucosidase inhibitors. Also disclosed are nutritional and/or pharmaceutical compositions and supplements comprising one or more of these compounds. The compounds will be beneficial to patients who require stabilization of their postprandial glucose... Agent: Sacron Innovations Pty Limited

20120115942 - Methods for synthesizing glycinols, glyceollins i and ii and isoflavenes and chromanes using a wittig reaction, and compositions made therewith: Methods for synthesizing glycinols, glyceollins I and II, and isoflavene and chromane compounds using a Wittig reaction, compositions made therewith, and uses thereof are described.... Agent:

20120115944 - Use of carnitine and dihydroquercitin to positively influence the natural pigmentation process: A method for positively influencing the natural pigmentation process of skin or appendages thereof includes topically contacting the skin or appendages thereof with a combination of carnitine and/or a derivative thereof with dihydroquercetin and/or a derivative thereof.... Agent: Henkel Ag & Co., Kgaa

20120115945 - Ferric citrate dosage forms: The disclosure relates to ferric citrate tablets and dosage forms.... Agent: Keryx Biopharmaceuticals Inc.

20120115946 - Formulation: The present invention relates to a hygroscopic matrix based formulation, a process for the preparation thereof and its use in the treatment of diseases.... Agent:

20120115947 - Combination/association of adapalene and benzoyl peroxide for treating acne lesions: Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).... Agent: Galderma Research & Development

20120115948 - Inhibitors of anaphase promoting complex activity: The invention provides an anti-proliferative composition comprising a non-peptide analog of the C-terminal isoleucine-arginine (IR) tail motif of an activator of an anaphase promoting complex (APC). The invention further provides methods of inhibing the ubiquitination activity of the APC by administering compositions of the invention.... Agent: President And Fellows Of Harvard College

20120115949 - Ester mixtures and compositions comprising such ester mixtures: The present invention is directed to a mixture of esters according to the general formula (I), R1—C(=0)-0-R2, wherein R1 is an alkyl moiety with 5 to 11 carbon atoms and wherein R2 is a an alkyl moiety with 8 to 18 carbon atoms and wherein the mixture comprises 10 or... Agent: CognisIPManagement Gmbh

20120115950 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Shire LLC

20120115952 - Method for improving the sensory properties and resistance of food and drink products to micro-organisms: A method for improving the sensory properties and resistance of food and drink products, especially uncured meat products, to various kinds of micro-organisms and in particular food spoilage and food poisoning bacteria includes contacting the food or drink product with a composition comprising alkali metal salts having as anions propionate... Agent:

20120115951 - Protective action of serofendic acid on cardiac muscle: A cardiac myocyte protective agent, comprising a compound represented by the formula (Ia) below, a pharmaceutically acceptable salt thereof, or a solvate thereof:... Agent: Eisai R & D Managment Co., Ltd

20120115953 - Self-neutralizing acid peel for dermatologic use: A dermatologic peel comprising alpha hydroxyl acid and metal hydroxide nanocomplexes as neutralizing agents to continually reduce the activity of the system when the acid and neutralizer components are mixed. For example, a 30% glycolic acid gel mixed with a fluidized magaldrate neutralizer can be applied to the skin and... Agent:

20120115954 - Aqueous retinoid and benzoyl peroxide gel: Embodiments of this invention relate to a composition containing both benzoyl peroxide and a retinoid. Additionally, it relates to the treatment of acne vulgaris by applying an aqueous gel comprising BPO and a retinoid.... Agent: Medicis Pharmaceutical Corporation

20120115955 - Methods for tumor treatment and adipogenesis differentiation: The present invention provides methods and pharmaceutical compositions for treating tumors.... Agent: Centro De Investigacion Principe Felipe

20120115956 - Use of isoleucine n-hexadecanoyl as a \"volumizing\" and/or \"plumping\" agent for human skin: The invention relates to the cosmetic use of isoleucine N-hexadecanoyl of formula (I): CH3—(CH2)14—C(═O)—NH—CH(COOH)—CH(CH3)—CH2—CH3 (I) as a “volumizing” agent and/or as a “plumping” agent for human skin. The invention also relates to a cosmetic treatment method for obtaining a “volumizing” and/or “plumping” effect of the skin of a part of... Agent: Societe D'exploitation De Produits Pour Les Industries Chimques Seppic

20120115957 - Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where... Agent:

20120115958 - Liquid pharmaceutical formulation containing paracetamol: The present invention relates to a sugar-free liquid pharmaceutical formulation comprising an aqueous solution of paracetamol, a solubilizing agent containing polyethylene glycol, a thickening agent containing xanthan gum, and a sweetening system containing sucralose and a mixture of polyols containing glycerol, sorbitol and xylitol in a total amount between approx.... Agent: Aziende Chim. Riun. Ang. Franc. A.c.r.a.f. S.p.a.

20120115959 - Therapeutic compositions and methods: The present invention includes compositions and methods that provide protection in a patient suffering from an eye disease such as age-related macular degeneration. In certain embodiments, the compositions of the present invention are administered during degeneration, and the composition includes an effective amount of an agent that increases choroidal blood... Agent: The Texas A&m University System

20120115960 - Animal feed compositions and feeding methods: This invention relates to animal feed compositions. The invention also provides comprising a compound of this invention and the use of such compositions in methods of increasing and optimizing feed in animals.... Agent:

20120115961 - Metal organic framework compounds: The invention provides novel Zr MOFs, in particular compounds having a surface area of at least 1020 m2/g or if functionalized, having a surface area of at least 500 m2/g.... Agent: Universitetet I Oslo

20120115962 - Cyclodextrin-modified polyamines for delivery of therapeutic molecules: The present invention is directed to drug delivery vehicles comprising one or more cyclodextrin moieties conjugated to a dendritic polyamine for the delivery of small molecule and protein therapeutic molecules and nucleic acid therapeutic molecules, and methods of making and using the delivery vehicles.... Agent: Rutgers, The State University Of New Jersey

20120115963 - Polymer nanoparticles: A process for the preparation of a polymer nanoparticle by a photoinduced emulsion polymerization includes preparing an emulsion comprising at least one surfactant, a dispersed phase and a continuous phase. The dispersed phase comprises at least one polymerizable monomer and the continuous phase comprises water and at least one photoinitiator.... Agent: Eth Zuerich

20120115964 - Xanthan gum and swellable particulate containing composition and uses thereof: This invention relates to a composition comprising at least about 0.2% w/w xanthan gum and at least about 6% w/w of a swellable particulate, and to uses thereof.... Agent: The University Of Nottingham

  
05/03/2012 > 189 patent applications in 141 patent subcategories. archived by USPTO category

20120108492 - Ligand-specific non-antibody compounds that inhibit cr2 activation and methods of use thereof: The present invention describes a novel non-antibody ligand-specific compound that selectively binds to a complement receptor type 2 (CR2) protein, a ligand thereof, or both, wherein the compound competitively inhibits CR2 ligand's binding to a CR2 protein in a standard assay. The present invention also describes compositions and methods of... Agent: The Regents Of The University Of Colorado

20120108493 - Polypeptide fragments comprising endonuclease activity and their use: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide... Agent:

20120108494 - Inhibitors of intracellular urokinase plasminogen activator and methods of use thereof: The present invention provides compositions comprising amiloride amino acid and peptide conjugates. Efficient methods are also provided for administering the compositions for treating cancer and for delivering an amiloride conjugate into cancer cells in a subject in need thereof.... Agent: The Regents Of The University Of California

20120108495 - Method of inhibiting smooth muscle cell proliferation by using reconstituted hdl: A method of inhibiting smooth muscle cell proliferation comprising administering to a subject a pharmaceutical composition including reconstituted HDL as an active ingredient.... Agent: Samsung Life Public Welfare Foundation

20120108497 - Compositions for conferring tolerance to viral disease in social insects, and the use thereof: Compositions and methods for reducing susceptibility to infectious disease in bees using RNA interference technology, and more particularly, prevention and treatment of viral infections in honeybees such as Israel acute paralysis virus (IAPV) by feeding of pathogen-specific dsRNA. Further, multiple-pathogen specific dsRNA is disclosed.... Agent: Beeologics Inc.

20120108496 - Short-chain peptides as parathyroid hormone (pth) receptor agonist: The present invention provides novel short-chain peptides, which primarily act as parathyroid hormone (PTH/PTH-1) receptor agonist. These short-chain peptides exhibit increased stability to proteolytic cleavage. Most of short-chain peptides were found to be stable in rat plasma up to 24 hours (in vitro), showed increased stability against GIT enzymes such... Agent:

20120108498 - Structural and mechanistic basis for novel compound biosynthesis using the 4-electron hexose oxidase: A novel pharmaceutical composition comprising a compound of formula (I) is disclosed. The novel compound can include a pharmaceutically acceptable carrier. The invention further comprises methods for making compounds of formula (I) using Dbv29, and to the use of compound of formula (I) to treat bacterial infections.... Agent: Academia Sinica

20120108499 - Peptoid compounds: The invention relates to new peptoid compounds of formula (I), as well as their use in the treatment of bacterial infections, such as those caused by vancomycin resistant microorganisms, and to compositions thereof.... Agent: University Of Wollongong

20120108500 - Compositions and methods for modulating immunodeficiency virus transcription: The present disclosure provides methods of modulating immunodeficiency virus transcription, involving modulating enzymatic activity and/or levels of a lysine-specific demethylase-1 (LSD1) polypeptide and/or LSD1-mediated demethylation of methylated Tat. The present disclosure also provides method of identifying agents that modulate LSD1-mediated demethylation of a human immunodeficiency virus (HIV) Tat polypeptide.... Agent:

20120108501 - Protease inhibitors: The invention relates to (among other things) protease inhibitors containing both a water-soluble, non-peptidic oligomer and a lipophilic moiety-containing residue. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over protease inhibitor compounds lacking the water-soluble, non-peptidic oligomer and a lipophilic moiety-containing... Agent: Nektar Therapeutics

20120108502 - Novel anti-parasitic compounds: A novel structural class of highly N-methylated linear lipopeptide compounds useful for the treatment of parasitic disease.... Agent: The Regents Of The University Of California Office Of Technology Transfer

20120108503 - Methods for treating type i diabetes with leptin and leptin agonists: The present invention provides for methods of treating type I diabetes by inducing hyperleptinemia in subjects afflicted with type I diabetes. These methods can achieve normoglycemia and suppress hypergluconemia, and alleviate conditions associated with such, even in the absence of or at extremely low levels of adjunct insulin therapy, and... Agent: The Board Of Regents Of The University Of Texas System

20120108504 - Leptin agonist and methods of use: Peptides are provided having leptin receptor agonist activity. The peptides are useful for treating obesity, type II diabetes, appetite control after bariatric surgery, insulin resistance, lipodystrophy and hypothalamic amenorrhea, obesity-related infertility, among other diseases and conditions related to leptin deficiency and/or leptin resistance.... Agent: Temple University-of The Commonwealth System Of Higher Education

20120108505 - Thiophenes as glucagon receptor antagonists, compositions, and methods for their use: The present invention relates to compounds of the general formula (I): wherein R1, R2, R3, R5, s, and Z are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or... Agent: Schering Corporation

20120108506 - Agent for suppressing postprandial elevation of blood insulin concentration: An agent for suppressing postprandial elevation of blood insulin concentration, comprising a polyglutamic acid as an active ingredient.... Agent: Kao Corporation

20120108507 - Methods for in vivo cell reprogramming: The present disclosure provides a new technology platform that converts one type of cells (substrate cells) to another type of cells (product cells).... Agent: Vivoscript, Inc.

20120108508 - Method for promoting secretion of glucagon-like peptide-1 by administering k-casein: The invention relates to a GLP-1 secretagogue and an inhibitor of postprandial rise in blood glucose, containing κ-casein as an active ingredient, and a food or drink for promoting GLP-1 secretion and an inhibitory food or drink of postprandial rise in blood glucose, containing a milk-derived casein protein wherein κ-casein... Agent: Morinaga Milk Industry Co., Ltd.

20120108509 - Artificial scab for use in an airway: Body tissue and structures in an airway may be treated with an artificial scab comprising an inhomogeneous, uncohesive, solid sheet-like body comprising a granular mixture of chitosan and polysaccharide particles. The artificial scab breaks apart into smaller pieces if peeled away from the surgical site or wound, thus reducing the... Agent: Medtronic, Inc.

20120108510 - Methods of improving behavioral therapies: This disclosure provides methods of using compounds that act to increase oxytocin release, including certain melanocortin receptor agonists, for treating or reducing the severity of psychotherapeutic or social disorders such as autism, and in particular the use of these compounds as an adjunct to psychotherapeutic counseling or behavioral therapy.... Agent: Emory University

20120108511 - Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction: The invention provides methods of extracting a biodegradable polyester with a supercritical fluid effective to obtain a purified biodegradable polyester, such as a purified biodegradable poly(lactide-glycolide) (PLG). The supercritical fluid can be carbon dioxide at an elevated pressure, or can be carbon dioxide with one or more cosolvents. Methods for... Agent: Qlt Usa, Inc.

20120108512 - Stable pharmaceutical compositions of peptide derivatized using an oxime linker: The invention relates to stable pharmaceutical compositions comprising a therapeutic peptide derivatized with a property-modifying group, wherein the property-modifying group is conjugated to the peptide by use of a linker comprising an oxime bond.... Agent: Novo Nordisk Health Care Ag

20120108513 - Purification method for divalent cation binding proteins on anion exchange resin: The present invention relates to a method for the purification of divalent cation binding proteins with high purity on an anion exchange resin material, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.... Agent: Baxter International Inc.

20120108514 - Long acting atrial natriuretic peptide (la-anp) and methods for use thereof: Materials and Methods related to making and using natriuretic polypeptides having a mutation that results in an extended carboxy terminus.... Agent: Mayo Foundation For Medical Education And Research

20120108515 - Novel peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation: Novel compounds which may be for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation, bone resorption, or loosening of a prosthetic device.... Agent: Neobiotics Ab

20120108516 - The use of midkine protein and the protein-containing medical device: The applications and medical devices of Midkine in the field of biotechnology are described in this invention. This invention describes the applications of the protein as follow in (a) or (b) in preparing drugs for promoting cartilage growth or treating cartilage diseases, the protein as a growth factor for promoting... Agent:

20120108517 - Agents and methods for denervation: Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery... Agent:

20120108519 - Neo-tryptophan: Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L′, NT71, NT72, NT73, NT74, NT75,... Agent:

20120108518 - Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.... Agent: Nsgene A/s

20120108520 - Antimicrobial compounds and formulations: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial... Agent: Lytix Biopharma As

20120108521 - Immunostimulatory compositions and uses thereof: The present invention provides novel immune-stimulatory polypeptides, and methods for their use and identification.... Agent: Arizona Biomedical Research Commission

20120108522 - Hdac inhibitors and hormone targeted drugs for the treatment of cancer: The present invention relates to the methods of treating endocrine-regulated cancers, including hormone resistant cancers, for example. More specifically, the present invention relates to a method of increasing the sensitivity of hormone resistant cancers to hormonal therapeutic agents. In particular embodiments, the present invention concerns delivery of a histone deacetylase... Agent:

20120108523 - Disease-associated protein: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and... Agent: Novartis Ag

20120108525 - Methods and compositions for the treatment of gastrointestinal disorders: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and... Agent: Ironwood Pharmaceuticals, Inc.

20120108524 - Vaccine comprising amb a 1 peptides for use in the treatment of ragweed allergy: The present invention relates to compositions for preventing or treating allergy to ragweed by tolerisation. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide... Agent: Circassia Limited

20120108526 - Anti-microbial compositions: Antimicrobial compounds from Epicoccum purpurascens (syn. E. negrum) for use against plant and fungi pathogens. An orange yellow metabolite was isolated, the structure elucidated as a small group of compounds Epipyrone A-C and fungicidal activity demonstrated against plant pathogens, for example Botrytis cinerea and Lecanicillium muscarium. Agricultural and pharmaceutical compositions... Agent:

20120108527 - Polymeric topical compositions: The present invention relates to topical antibacterial compositions. The compositions comprise an antibacterial agent such as mupirocin, water, a polymer and a volatile solvent present in an amount of less than about 40%. The invention also relates to methods of treatment by administering the compositions to a patient in need... Agent:

20120108528 - New therapeutic approaches for treating neuroinflammatory conditions: The present invention relates to novel compositions which can be used for the treatment of neuroinflammation, in particular in subjects having a neurodegenerative, autoimmune, infectious, toxic or traumatic disorder. More particularly, the invention relates to combined therapies for treating neuroinflammation. The invention also discloses new methods for treating neuroinflammation pathological... Agent: Pharnext

20120108529 - Protease inhibitors: Compounds useful as protease inhibitors are provided, as are methods of use and preparation of such compounds and compositions containing such compounds. In one embodiment, the compounds are useful for inhibiting HIV protease enzymes, and are therefore useful in slowing the proliferation of HIV.... Agent:

20120108530 - Enhanced neoglycosides through neoglycosylation and methods of use thereof: Using neoglycosylation, the impact of differential glycosylation upon the divergent anticancer and anti-HIV properties of the triterpenoid betulinic acid (BA) was examined. Each member from a library of 37 differentially glycosylated BA variants was tested for anticancer and anti-HIV activities. Enhanced analogs for both desired activities were discovered with the... Agent:

20120108651 - Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment (particularly for reducing the risk of venous thrombosis). For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for... Agent: Celera Corporation

20120108649 - Methods and compositions to protect aquatic invertebrates from disease: Compositions and methods of protecting aquatic invertebrates from disease is shown. In one embodiment, dsRNA or antisense RNA to a nucleic acid molecule of the disease-causing microorganism is prepared and delivered to the animal. In another embodiment, a nucleic acid molecule of the disease-causing microorganism is delivered to the animal.... Agent: Harrisvaccines, Inc.

20120108650 - Micro rna markers and methods related thereto: The present invention provides methods of diagnosis of Alzheimer's disease including assessing the levels of certain microRNAs in a subject and comparing these to levels in subjects not exhibiting the disease. The identified measurements provide input for improved diagnoses of Alzheimer's disease as compared to certain other forms of dementias,... Agent: Emory University

20120108648 - Mitochondrial function-improving agent: It is an object of the present invention to provide a novel mitochondrial function-improving agent and a novel PGC-1α expression inducing agent. The present invention provides a mitochondrial function-improving agent and a PGC-1α expression inducing agent each of which comprises a lysine-specific demethylase-1 (LSD-1) inhibitor.... Agent: National University Corp. Kumamoto University

20120108652 - Oligomers: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce... Agent: Royal Holloway, University Of London

20120108653 - Oligomers: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce... Agent: Royal Holloway, University Of London

20120108646 - Rnai modulation of tgf-beta and therapeutic uses thereof: The present invention concerns methods of treatment using transforming growth factor beta (TGF-beta) modulators. More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling, by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein.... Agent: Alnylam Pharmaceuticals, Inc.

20120108647 - Therapeutic uses of inhibitors of rtp801l: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.... Agent: Quark Pharmaceuticals, Inc.

20120108654 - Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa: Oxidative damage contributes to cone cell death in retinitis pigmentosa and death of rods, cones, and retinal pigmented epithelial (RPE) cells in ocular oxidative stress related diseases including age-related macular degeneration and retinitis pigmentosa. Oral antioxidants may provide modest benefits, but more efficient ways of preventing oxidative damage are needed.... Agent: The Johns Hopkins University

20120108657 - Disease-associated protein: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and... Agent: Novartis Ag

20120108655 - Methods of diagnosing and treating carcinomas: Methods of diagnosing a carcinoma include comparing the expression of miRNAs in a sample with a control and determining ratios of expression of miRNAs. Methods of treatment include administering a nucleic acid encoding a miR-375 gene product. Methods of optimizing treatment in a subject include determining expression of an miR21-gene... Agent: Brown University

20120108656 - Use of microrna-199b-5p in medical and diagnostic field: This invention concerns the use of MicroRNA-199b-5p in medical and diagnostic fields. Particularly, this invention concerns the use of the miR199b-5p in the anti-cancer therapy and as a histophatological and metastasis marker.... Agent:

20120108531 - Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production: Disclosed herein are novel phosphonate nucleosides and thiophosphonate nucleosides comprising a phosphonalkoxy-substituted or phosphonothioalkyl-substituted five-membered, saturated or unsaturated, oxygen-containing or sulfur-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base. The invention further relates to compounds having HIV (Human Immunodeficiency Virus) replication inhibiting properties and to... Agent: K.u.leuven Research & Development

20120108534 - Dihydrothienopyrimidines for the treatment of inflammatory diseases: s

20120108533 - Novel phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents: This invention provides phosphate-modified nucleosides represented by the structural formula: wherein W is O or S, and wherein B, R1; R3 and R2. are s defined herein. These compounds are useful as substrates for DNA/RNA polymerases, and as anti-viral agents in particular against HIV-1.... Agent: Katholieke Universiteit Leuven, K.u.leuven R&d

20120108532 - Pharmaceutical composition for neuroprotective treatment in patients with ictus comprising citicoline and uric acid: A pharmaceutical composition comprised of uric acid and citicoline is for the neuroprotective treatment of patients with ictus.... Agent: Hospital Clinic Provincial De Barcelona

20120108535 - 2-fluorinated riboses and arabinoses and methods of use and synthesis: Disclosed are halogenated 2-deoxy-lactone, 2′-deoxy-nucleosides, and derivatives thereof, for example, a compound of formula (I). Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, and a method of treating a disorder is selected from the group consisting of an... Agent: Cornell University

20120108536 - Pharmaceutical composition and method for inhibiting inflammation: A pharmaceutical composition for inhibiting inflammation, comprising (a) hyaluronic acid, (b) a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and (c) a pharmaceutically acceptable carrier, is provided. Also provided is a method for inhibiting inflammation in a mammal, comprising administrating to the mammal an effective amount of a composition comprising (a) hyaluronic... Agent: China Medical University

20120108537 - Process for preparing a crosslinked gel: A process for preparing a crosslinked gel of at least one polymer or one of its salts, including a) providing an aqueous medium containing at least one polymer, b) forming a homogenous gel from the medium from step a), c) bringing the gel obtained in step b) into contact with... Agent: Teoxane

20120108538 - Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity: This invention relates to methods for identifying, producing or rationally designing sulfated polysaccharide molecules that have antiplasmodial activity. Also provided are sulfated polysaccharide molecules having antiplasmodial activity, as well as methods for treating and preventing diseases including malaria with such molecules.... Agent:

20120108539 - Medicinal anti acne cream and a process to make it: The present invention relates to a composition for treating acne along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and an antiacne active ingredient. It discloses a composition for treating acne along with skin rejuvenation containing a) a biopolymer in the form... Agent: Apex Laboratories Private Limited

20120108540 - Preservatives from chitin derivatives: The invention comprises a process for producing a chitosan derivative, and a product prepared thereby, by activating chitosan or a chitosan precursor chitin in alcohol that contains water from 0% to maximum of about 30% and preparing derivatives by reacting with a reagent to get derivatives that have various uses... Agent: Camlin Fine Sciences Limited

20120108541 - Acylated 1,6-anhydro decasaccharide and its use as an antithrombotic agent: e

20120108544 - Acylated decasaccharides and their use as antithrombotic agents: wherein Ac represents an acetyl group and R represents a group of formula —OH or —OSO3−, in their acid form or in the form of any one of their pharmaceutically acceptable salts, and to their process of preparation. The oligosaccharides of formula (I) are useful as antithrombotic agents.... Agent: Sanofi

20120108543 - Sulfated heptasaccharide and its use as an antithrombotic agent: e

20120108542 - Sulfated octasaccharide and its use as antithrombotic agent:

20120108545 - Trioxane monomers and dimers: Monomeric and dimeric trioxane fluoroaryl amides, 5-carbon-linked, C-10 non-acetal trioxane dimer esters; trioxane silylamides; and trioxane dimer orthoesters and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection;... Agent: The Johns Hopkins University

20120108546 - Synergistic antimicrobial composition: n

20120108547 - Inhibitors of tyrosine kinases and uses thereof: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated... Agent: Pharmacyclics, Inc.

20120108548 - Molecular tweezers for the treatment of amyloid-related diseases: This invention provides novel compositions to inhibit the aggregation of amyloid proteins. In various embodiments the compositions comprise a molecular tweezers that binds lysine and/or arginine and thereby inhibits the aggregation of amyloidogenic proteins.... Agent: Massachusetts Institute Of Technology

20120108549 - Neuroprotective compounds and their use: Apocynin derivative compounds, active pharmaceutical ingredients, dosage forms, and methods of use thereof as neuroprotectants in the brain of mammals.... Agent:

20120108550 - Use of derivatives of polyunsaturated fatty acids as medicaments: Use of polyunsaturated fatty acid derivatives as medicaments or functional foods. The present invention relates to the use of 1,2-fatty acid derivatives in the treatment or prevention of common diseases whose etiology is based on alterations (of any type) of the cell membrane lipids, for example, changes in levels, in... Agent: Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Vk

20120108551 - Ophthalmic compositions: e

20120108552 - Methods of treating acne: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.... Agent: Galderma Laboratories, Inc.

20120108553 - Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries: The present invention is directed to nicotinamide, nicotinamide derivatives and prostaglandin mimetics, alone or in combination with an NSAID, and their use in treating pain, inflammation, and/or gastrointestinal toxicty,... Agent: Cortria Corporation

20120108554 - Process for preparing high purity 1alpha-hydroxy vitamin d2: The present invention relates to a process for purifying Doxercalciferol, a synthetic vitamin D analog, also known as 1α-hydroxy vitamin D2, to the purity greater than 99.5% by crystallization from a mixed solvent of methanol and acetonitrile. Each of the individual impurities can be controlled no more than 0.1% which... Agent: Formosa Laboratories, Inc.

20120108557 - Fluoroquinolone derivatives for ophthalmic applications: The present invention relates to fluoroquinolone derivatives having enhanced ocular penetration characteristics and/or antimicrobial activity, and to compositions comprising such derivatives. The derivatives and compositions are particularly well suited for treating ophthalmic bacterial infections. The present invention more particularly relates to the discovery that a 2-methyl substitution on a diazabicyclo... Agent: Alcon Research, Ltd.

20120108556 - Methods and dosage forms for the treatment of human cancers: Methods for the treatment of human cancers, daily dosage forms for cancer patients, and methods of formulating the dosage forms are provided wherein the daily dosage form contains from about 10-6,000 mg of each of β-sitosterol, isovanillin, and linolenic acid. Preferably, the dosage forms are formulated by first creating an... Agent: Life Plus, LLC

20120108555 - Mixtures or organic compounds for the treatment of airway diseases: A medicament comprising, separately or together, (A) a compound of formula (I) in free or pharmaceutically acceptable salt or solvate form and (B) a corticosteroid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease, the molar ratio of (A) to (B) being from... Agent:

20120108558 - Treatment of hot flashes: 16α,17α-Epoxy-10β-hydroxyestr-4-en-3-one is useful in the treatment of hot flashes by vomeronasal administration.... Agent: Pherin Pharmaceuticals, Inc.

20120108559 - Receptor activator of the rank receptor complex inhibitor: Methods and pharmaceutical compositions utilizing compounds of Formula II: for inhibiting osteoclastogenesis and the activity of osteoclasts in patients.... Agent: The Trustees Of The University Of Pennsylvania

20120108560 - Single phase silicone acrylate formulation: This invention provides a single phase silicone acrylate formulation that resists phase separation and includes (A) at least one of a silicone, an acrylate, and combinations thereof. The single phase silicone acrylate formulation also includes (B) a silicone acrylate hybrid compatibilizing agent including silicone functionality and (meth)acrylate functionality and that... Agent:

20120108561 - Storage-stable, anti-microbial compositions including ceragenin compounds and methods of use: Storage-stable, anti-microbial compositions and products include a carrier and a ceragenin compound suspended in the carrier. Ceragenin compounds suspended in the carrier include a sterol backbone and a number of cationic groups attached to the sterol backbone via hydrolysable linkages. The carrier has a pH of 5.5 or less, which... Agent: Brigham Young University

20120108563 - Methods of treating liposarcoma: Provided herein are methods of treating liposarcoma in a subject, the method comprising administering to the subject a therapeutically effective amount of an Hsp90 inhibitor.... Agent: Infinity Pharmaceuticals, Inc.

20120108562 - Therapeutic compositions and methods: PAD4 inhibitory compositions and methods for their use in treatment of cancer and autoimmune disease are provided according to embodiments of the present invention.... Agent: The Penn State Research Foundation

20120108564 - 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyradine derivatives and use thereof as hiv integrase inhibitor: D

20120108566 - Nicotinamides as jak kinase modulators: The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods... Agent: Portola Pharmaceuticals, Inc.

20120108565 - Pyrrole carboxylic acid derivatives as antibacterial agents: The present invention provides DNA Gyrase and/or Topo IV inhibitors of Formula (I), which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci,... Agent:

20120108568 - Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors: Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer,... Agent: Array Biopharma Inc.

20120108567 - Thiazolyl-dihydro-indazoles: m

20120108569 - 8-aza tetracycline compounds: The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.... Agent:

20120108570 - Pharmacological treatment for sleep apnea: The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.... Agent: The Board Of Trustees Of The University Of Illinois

20120108572 - Novel benzamides, production thereof, and use thereof as medicaments: e

20120108571 - Substituted phenoxy n-alkylated thiazolidinediones as estrogen related receptor-alpha modulators: methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to... Agent:

20120108573 - Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them: wherein A1, A2, R1, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula fare capable of... Agent: Sanofi-aventis Deutschland Gmbh

20120108574 - Substituted benzo-imidazo-pyrido-diazepine compounds: The present invention relates to substituted benzo-imidazo-pyrido-diazepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted benzo-imidazo-pyrido-diazepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.... Agent: Arqule, Inc.

20120108575 - Heterocyclic-substituted piperidine compounds and the uses thereof: The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Heterocyclic-Substituted Piperidine Compound.... Agent: Purdue Pharma L.p.

20120108577 - Compounds for the treatment of multi-drug resistant bacterial infections: The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.... Agent: Astrazeneca Ab

20120108576 - Thiazole compounds and methods of use: wherein the variables Ar1, R2, R3, R4, r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly... Agent: Achillion Pharmaceuticals, Inc.

20120108579 - Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, lo1, lo2, lo5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates... Agent: Boehringer-ingelheim International Gmbh

20120108578 - Inhibitors of 11beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula (I), (Ia1-10), (Ib1-10), (Ic1-10), (Id1-7), (Ie1-5) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of... Agent: Boehringer Ingelheim International Gmbh

20120108580 - Use of fungicidal active substances for controlling mycoses on plants of the palm family: The present invention relates to the use of specific fungicidal active substances, alone or in combination, for controlling mycoses in plants of the palm family and to a method for using said specific fungicidal active substances for controlling said mycoses in the field of plant protection and the protection of... Agent: Bayer Cropscience Ag

20120108581 - Fused piperidine compound and pharmaceutical containing same: (wherein, ring A represents a C10-14 aryl group or 5- to 10-membered heterocyclic group, X represents N—R7, a sulfur atom or an oxygen atom, R1, R2, R2′, R3 and R3′ independently represent a hydrogen atom, C1-6 alkyl group or C3-6 cycloalkyl group, and R4, R5 and R6 independently represent a... Agent: Kowa Company, Ltd

20120108582 - Fused substituted aminopyrrolidine derivative: A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula... Agent: Daiichi Sankyo Company, Limited

20120108584 - 2h or 3h-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof: q

20120108583 - Tricyclic compounds as mpges-1 inhibitors: The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as... Agent: Glenmark Pharmaceuticals S.a.

20120108586 - Arthropod pest control method and composition: Disclosed is a harmful arthropod control composition comprising, as an active ingredient, a fused heterocyclic compound represented by formula (1) [wherein A1 and A2 independently represent a nitrogen atom or the like; R1 and R4 independently represent a halogen atom or the like; R2 and R3 independently represent a halogen... Agent: Sumitomo Chemical Company, Limited

20120108585 - Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Sirtris Pharmaceuticals, Inc.

20120108587 - Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula (I) wherein A1, A2, A3, A4, L, R1, R2, R3, R5 and m are as defined herein. The invention... Agent: Amgen Inc.

20120108589 - Azabicyclo compound and salt thereof: It is intended to provide a novel azabicyclo compound which exhibits both HSP90 inhibitory activity and cell proliferation inhibitory effect. Specifically disclosed is a compound represented by the following general formula (I) or a salt thereof: wherein X1 represents CH or N; any one of X2, X3 and X4 represents... Agent: Taiho Pharmaceutical Co., Ltd.

20120108588 - Novel 3-amido-pyrrolo[3,4-c]pyrazole-5(1h, 4h,6h) carbaldehyde derivatives: wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation,... Agent: Pfizer, Inc.

20120108590 - Melt-extruded solid dispersions containing an apoptosis-inducing agent: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises... Agent: Abbott Laboratories

20120108591 - Alkylsulfinyl-substituted thiazolide compounds: A new class of alkylsulfinyl thiazolides is described. These compounds show strong activity against hepatitis viruses.... Agent: Romark Laboratories, L.c.

20120108592 - Pharmaceutical compositions and methods of use of salicylanilides for treatment of hepatitis viruses: A new class of salicylanilides is described. These compounds show strong activity against hepatitis viruses.... Agent: Romark Laboratories, L.c.

20120108593 - Extreme temperature aqueous decontamination composition: An extreme temperature decontamination composition such as a solution for destroying microorganisms, chemical warfare and bioterrorism agents is utilized that generally does not freeze at low temperatures down to about minus 25° F. and also has no significant evaporation or decomposition at temperatures up to about 120° F. The solution... Agent: American Sterilizer Company

20120108594 - Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein: Novel Form N-1 crystals of the Form N-1 and Form N-4 crystals of the hydrochloride salt and Form N-1 crystals of the methanesulfonic acid salt of the above free base, pharmaceutical compositions containing such novel forms and a method of treating p38 kinase associated conditions, including rheumatoid arthritis are also... Agent: Bristol-myers Squibb Company

20120108595 - Platelet-activating factor receptor antagonists: Cyclohexyl sulfonamide compounds which are platelet-activating factor (PAF) receptor antagonists. Said compounds may be useful, for example, for the treatment of atherosclerosis or other PAF-mediated disorders, including inflammatory, cardiovascular, and immune disorders.... Agent:

20120108596 - Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are prodrugs for ligands, agonists, and partial agonists for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central... Agent: Bristol-myers Squibb Company

20120108597 - Azaquinazolinediones chymase inhibitors: Disclosed are small molecule inhibitors of the formula (I), which are useful in treating various diseases and conditions involving chymase.... Agent: Boehringer Ingelheim International Gmbh

20120108599 - Methods and compositions for the treatment of metabolic disorders: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.... Agent: Biomarin Pharmaceutical Inc.

20120108598 - Sitagliptin synthesis: The present invention relates to novel processes for the preparation of enantiomerically enriched β-amino acid derivatives such as β-amino esters useful for the synthesis of enantiomerically enriched biologically active molecules such as sitagliptin. The key step involves the resolution of the racemate with mandelic acid.... Agent: Mylan India Private Limited

20120108600 - Substituted 4-hydroxypyrimidine-5-carboxamides: The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.... Agent: Merck Sharp & Dohme Corp.

20120108601 - Crystalline pyridazine compound: e

20120108602 - Carbamoyl compounds as dgat1 inhibitors 190:

20120108603 - Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase:

20120108604 - Processes for preparing amine salts of sildenafil-analogues and use thereof: A series of amine salts including a structure of formula (I) and formula (III) have provided. In formula I or formula (III), R1, Ra and RX are as defined in the specification. The amine complex salts disclosed in the present invention are characterized in a pro-drug active form and various... Agent: Kaohsiung Medical University

20120108605 - O-glcnac transferase inhibitors and uses thereof: The present invention provides inhibitors of O-GIcNAc transferase. Typically, the inhibitors are quinolinone-6-sulfonamides. The invention also provides pharmaceutical compositions thereof and methods for using the same in diabetes and complications thereof, neurodegenerative diseases, cancers, autoimmune diseases, and inflammatory diseases.... Agent: President And Fellows Of Harvard College

20120108606 - Carboxamide, sulfonamide and amine compounds and methods for using the same: e

20120108607 - Optically active 3-[(phenylpiperazin-1-yl)alkyl]-3- alkyl-oxindole derivatives having cns activity: The present invention relates to the enantiomers of 5,7-dichloro-3-{4-[4-(4-chlorophenyl)-piperazin-1-yl]butyl}-3-ethyl-1,3-dihydro-2H-indol-2-one of the Formula (II) pharmaceutically acceptable salts thereof, process for the preparation thereof, medicinal products containing said enantiomers and the use thereof and their pharmaceutically acceptable salts in the treatment of the disorders of the central nervous system.... Agent:

20120108608 - Injectable meclizine formulations and methods: Methods of treating or preventing a vertigo, nausea, or vomiting condition comprising injecting a subject with a pharmaceutically acceptable formulation consisting essentially of an effective amount of meclizine or a pharmaceutically acceptable salt thereof, a chemically modified cyclodextrin, and an aqueous carrier medium having a pH between about 2 and... Agent:

20120108610 - 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial: t

20120108609 - Dihydrooxazol-2-amine derivatives: or to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders... Agent:

20120108611 - 5, 6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin ii receptor antagonists: The present invention relates to derivatives of 5,6-bisaryl-2-pyridine-carboxamide, their preparation and their application in therapeutics as antagonists of urotensin II receptors.... Agent: Sanofi-aventis

20120108612 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20120108613 - Compounds and compositions for treating chemical warfare agent-induced injuries: Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.... Agent:

20120108614 - Compounds and compositions for treating chemical warfare agent-induced injuries: Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.... Agent:

20120108615 - Small molecule inhibitors of bacterial motility and a high throughput screening assay for their identification: Certain compounds are provided that can selectively inhibit motile bacteria such as V. cholerae motility. These compounds can indirectly diminish production of cholera toxin and other major virulence required by the cholera bacterium to cause disease.... Agent: Southern Research Institute And Ip

20120108616 - Substituted oxazole derivatives and their use as tyrosine kinase inhibitors: The present invention relates to novel compounds selected from substituted oxazole derivatives of formula (I) that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More... Agent: Centre National De La Recherche Scientifique (cnrs)

20120108617 - Methods and compositions involving (s)-bucindolol: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount... Agent: Arca Biopharma, Inc.

20120108619 - N1/n2-lactam acetyl-coa carboxylase inhibitors: s

20120108618 - Thia-triaza-indacenes: The present invention encompasses compounds of general formula (1) wherein R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.... Agent: Boehringer Ingelheim International Gmbh

20120108620 - Forms of rifaximin and uses thereof: The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods.... Agent: Salix Pharmaceuticals, Ltd.

20120108622 - Pharmaceutical formulation containing gelling agent: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected... Agent: Purdue Pharma L.p.

20120108621 - Pharmaceutical preparation containing oxycodone and naloxone: The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner.... Agent: Purdue Pharma L.p.

20120108623 - Beloxepin and analogs for the treatment of pain: This present disclosure provides methods of treating pain with beloxepin and/or beloxepin analogs.... Agent: Adolor Corporation

20120108624 - Treatment of dyskinesia related disorders: Disclosed herein are methods of treating Parkinsons disease while maintaining a low dyskinesia induction profile and methods of reversing dyskinesias comprising administering a therapeutically effective amount of a compound of the invention. The present invention further relates to uses and pharmaceutical compositions of said compounds in the manufacture of medicaments... Agent:

20120108625 - Novel forms of tiotropium bromide and processes for preparation thereof: This invention relates to novel crystalline forms of tiotropium bromide, processes for preparing them, and their use in pharmaceutical formulations.... Agent: Sicor Inc.

20120108627 - Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation: The present invention relates to imidazo[4,5-c]quinoline derivatives of formula (I), process for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by phosphatidylinositol-3-kinase (PBK) and/or mammalian target of rapamycin (mTOR) and/or tumor necrosis factor-α (TNF-oc) and/or interleukin-6 (IL-6), particularly in the treatment of cancer... Agent:

20120108626 - Multidose package, course and method of treatment for delivering predetermined multiple doses of a pharmaceutical: A multidose package containing an imiquimod formulation suitable for treating topical conditions includes: a) a dispensing aperture for dispensing the formulation from the package; b) a reservoir containing sufficient formulation to provide two or more doses; c) a metered dosage element for measuring a predetermined dose of the formulation, the... Agent: WirraIPPty Ltd

20120108628 - Inhibitors of protein tyrosine kinase activity: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly,... Agent:

20120108629 - New use of neferine: The present invention reveals a new use of neferine. Neferine regulates M8 and V1 subtype of transient receptor potential ion channel (TRPM8 and TRPV1), respectively, in mammalians, including humans, and can be used for preparing medicaments for treating disease related to said ion channel (such as hyperalgesia, Parkinson's disease, painful... Agent: Institute Of Chinese Materia Medica, China Academy

20120108630 - Hedgehog pathway antagonists and methods of use: The present disclosure provides for compounds, pharmaceutical preparations, kits and methods for the inhibition of the Hh pathway and the alleviation of cancer and developmental disorders associated with the Hh pathway.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20120108632 - Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma: The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one prenyltransferase inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma comprising a pharmaceutically... Agent: Alcon Research, Ltd.

20120108631 - Sulfonamides for the modulation of pkm2: The invention relates to sulfonamide compounds and methods for activating PKM2. The compounds and methods are useful in treating or preventing a disease or disorder selected from cancer, cell proliferative disorder, inflammatory disorder, metabolic disorder, and immune system disorder.... Agent:

20120108633 - Injectable composition containing hydroxychloroquine for local administration for treating hemorrhoids: The present invention relates to an injectable composition for local administration for treating hemorrhoids, which contains hydroxychloroquine. Specifically, the composition contains a solution of hydroxychloroquine in physiological saline for injection, together with a local anesthetic and an antioxidant.... Agent:

20120108634 - Farnesyl protein transferase inhibitor combinations with antiestrogen agents: The present invention is concerned with combinations of a farnesyl transferase inhibitor and an antiestrogen agent for inhibiting the growth of tumor cells, useful in the treatment of cancer.... Agent:

20120108635 - Insecticidal arylpyrrolines: The invention relates to novel arylpyrroline compounds of formula (I) which have excellent insecticidal activity and which can thus be used as an insecticide.... Agent: Bayer Cropscience Ag

20120108636 - Allosteric enhancers of th a1 adenosine receptor: wherein W, R1, R5 and R6 have a meaning as defined herein in the specification. The compounds of formula (I) are allosteric enhancers of the A1 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A1 adenosine receptor. Accordingly, the compounds of formula (I)... Agent: King Pharmaceuticals Research And Development, Inc.

20120108637 - Fused bicyclic-substituted amines as histamine-3 receptor ligands: e

20120108638 - Pyridin-4-yl derivatives: The invention relates to pyridine derivatives of Formula (I), wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.... Agent:

20120108639 - Nitrogen-containing aromatic heterocyclyl compound: The present invention provides a compound having excellent regulating action on blood lipid level that is represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein, in one embodiment, A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R1 represents COOH; each R2 represents an alkyl; each... Agent: Daiichi Sankyo Company, Limited

20120108640 - Methods and compositions for the treatment of neuropsychiatric disorders: The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na+—K+-2Cl− (NKCC) cotransporter. In certain embodiments, the Na+—K+-2Cl− co-transporter is NKCC1.... Agent: Neurotherapeutics Pharma, Inc.

20120108641 - Antitumor combination including ave8062 and sorafenib: Combinations comprising AVE8062 and sorafenib are provided which are effective in the treatment of cancers, more particularly of solid tumours.... Agent: Sanofi

20120108642 - Trpv1 antagonists: m

20120108643 - Method of increasing the extent of absorption of tizanidine: An article and method for increasing the extent of tizanidine absorption in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release tablet composition at or around the time food is consumed. The composition may be packaged in a container for distribution.... Agent: King George Holdings Iia S.a.r.l.

20120108644 - Agricultural or horticultural fungicide composition and its use for controlling plant pathogens:

20120108645 - Novel microbiocides: Compounds of formula (I) in which the substituents are as defined in claim 1, are suitable for use as microbiocides.... Agent: Syngenta Crop Protection LLC

20120108658 - Ophthalmic composition: Disclosed is an ophthalmic composition which is characterized by containing (A) a vitamin A, (B) a polyoxyethylene polyoxypropylene glycol, and (C) an oil component that is selected from the group consisting of castor oil, soybean oil, sesame oil, peanut oil, olive oil, almond oil, wheat germ oil, corn oil, rapeseed... Agent:

20120108659 - Methods of treating hypertriglyceridemia: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.... Agent: Amarin Pharma, Inc.

20120108660 - Methods of treating hypertriglyceridemia: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.... Agent: Amarin Pharma, Inc.

20120108661 - Emulsified composition:

20120108662 - Compositions and methods for treating skin disorders: The present application relates to compositions and the treatment of skin disorders, dry skin, protection of skin in inflammatory events and neurological disorders. The present application more particularly discloses the identification of new genes and metabolic pathways involved in skin disorders, which provide novel targets and approaches for treating said... Agent:

20120108663 - Methods of treating hypertriglyceridemia: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.... Agent: Amarin Pharma, Inc.

20120108664 - Transdermal delivery of beneficial substances effected by a hostile biophysical environment: The present invention generally relates to the transdermal delivery of substances In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body.... Agent: Strategic Science & Technologies, LLC

20120108665 - Methods and compositions for treating ophthalmic conditions: We describe methods and compositions for treating ophthalmic conditions associated with angiogenesis, vascular leakage, and/or damage to ganglia.... Agent: Revision Therapeutics, Inc.

20120108666 - Treatment of cell proliferative disorders: The invention relates to compounds and their use in treating cell proliferative disorders, more specifically Syk tyrosine kinase-mediated disorders.... Agent:

20120108667 - Hydroxy ceramides and analogs thereof and their use for preventing or treating cancer: Disclosed herein are compounds, compositions, methods of treatment and synthetic methods for making compounds related to Ceramides and the use of Ceramides.... Agent:

20120108668 - Metabolic profiles: The invention relates to the use of endogenous metabolites to produce a metabolic profile of a disorder or disease in a subject, e.g. an autoimmune disease, in particular rheumatoid arthritis, and the analysis of such metabolic profiles in order to find disturbances in such profiles in a subject which are... Agent:

20120108669 - Method of treating sleep disorders using eplivanserin: Method for treating sleep disorders by using eplivanserin Method of providing eplivanserin. Method of managing the risk to allow an effective and safe use of eplivanserin Method of promoting the use of eplivanserin. Article of manufacture and package.... Agent: Sanofi-aventis

20120108670 - Formoterol tartrate process and polymorph: A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.... Agent: Sunovion Pharmaceuticals Inc.

20120108671 - Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods: The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (−)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, activate GPR120, inhibit inflammation, and treat conditions responsive to PPARγ modulation, conditions... Agent:

20120108672 - Ophthalmic composition and method for prevention of cloudiness/precipitation: An ophthalmic composition characterized by comprising (A) vitamin A, (B) a polyoxyethylene polyoxypropylene glycol, and at least one component selected from (C) trometamol, (D) polyhydric alcohols, (E) a sugar, (F) phosphoric acid and salt thereof and (G) monovalent neutral salts.... Agent:

20120108673 - Process for isolation of lutein and zeaxanthin crystals from plant sources: The present invention provides for a process for isolation of carotenoids crystals comprising drying a plant part to obtain a meal and extracting the meal with alcohol at a temperature in the range of about 50° C. to 75° C. to obtain oleoresin. The oleoresin is enriched with alcohol at... Agent: Katra Phytochem India Private Limited

20120108674 - Injectable hydrogel for the long-term supplementation of glycerol in the skin: An injectable hydrogel, includes, in weight, in a physiologically acceptable carrier fluid: 0.01 to 5% of glycerol and 0.1 to 5% of cross-linked hyaluronic acid, or one of the salts thereof; characterized in that the hyaluronic acid or one of the salts thereof is cross-linked by the formation of covalent... Agent: Anteis S.a.

20120108675 - Process and apparatus for producing hydrocarbons by hydrogenating a terpene feed: The invention relates to a process and an apparatus for producing hydrocarbon components in the presence of a hydrodesulphurization catalyst. The components obtained by the process are suitable for use as fuel composition as such or as an additive in fuel compositions, and in cosmetics or pharmaceutical products.... Agent: Upm-kymmene Corporation

20120108676 - Aerosol-mediated particle synthesis: Disclosed are aerosol-mediated methods for synthesizing particles for biomedical and drug delivery applications. The method is based on the production of particles from sprayed polymeric micro or nano-droplets obtained by, for example, an air-jet nebulization process that is followed by gelation and/or hardening in a crosslinking fluid, non-solvent, precipitating solvent,... Agent: Board Of Regents, The University Of Texas System

20120108677 - Iminic monomers and polymers thereof: Disclosed are biocompatible, bioresorbable polymers comprising a plurality of monomeric repeating units containing an imine group, wherein the inclusion of said imine group is effective to lower the melt viscosity, the solution viscosity, or both, compared to the same polymer without an imine group.... Agent: Rutgers, The State University Of New Jersey

20120108678 - Branched copolymers, compositions and uses: s

20120108679 - Branched copolymers, composition and uses:

20120108680 - Long-chain glycyl polyol type gelator and gel: A gelator made of an aliphatic oxyglycyl polyol that is capable of forming a gel by a small amount of addition in a pH range from acidic to alkaline regions, and a gel having high environmental compatibility, biocompatibility and biodegradability. A gelator including an aliphatic oxyglycyl polyol of Formula (1)... Agent: Nissan Chemical Industries, Ltd.

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141113: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 6.15491 seconds

PATENT INFO